

Management of Hyperglycemia in Type 2 Diabetes, 2015 to a Position Statement of the American Diabetes Assoc Association for the Study of Diabetes

Diabetes Care

38, 140-149

DOI: 10.2337/dc14-2441

Citation Report

#	ARTICLE	IF	CITATIONS
3	The Place of Dpp-4 Inhibitors in the Treatment Algorithm of Diabetes Type 2: A Systematic Review of Cost-Effectiveness Studies. <i>Value in Health</i> , 2014, 17, A347-A348.	0.3	0
4	GLYCEMIC CONTROL AND CARDIOVASCULAR RISK FACTOR MANAGEMENT IN PATIENTS WITH DIABETES WITH AND WITHOUT CORONARY ARTERY DISEASE: INSIGHTS FROM THE DIABETES MELLITUS STATUS IN CANADA (DM-SCAN) SURVEY. <i>Canadian Journal of Cardiology</i> , 2014, 30, S79-S80.	1.7	0
6	Diabetes-related nutrition knowledge and dietary intake among adults with type 2 diabetes. <i>British Journal of Nutrition</i> , 2015, 114, 829-830.	2.3	0
7	Comment on "Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus". <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2015, 34, 435-438.	0.2	0
8	Diabetes Has Gotten Pretty Darn Complicated. <i>Clinical Diabetes</i> , 2015, 33, 114-115.	2.2	0
9	Salutary cardiovascular effects of antidiabetic drugs. <i>Journal of Hypertension</i> , 2015, 33, 2198-2199.	0.5	2
10	Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. <i>Cardiovascular Diabetology</i> , 2015, 14, 154.	6.8	96
11	Type 2 diabetes: recent advances in diagnosis and management. <i>The Prescriber</i> , 2015, 26, 15-21.	0.3	3
12	Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 616-621.	4.4	24
13	Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes. <i>International Journal of Clinical Practice</i> , 2015, 69, 1221-1235.	1.7	17
14	Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. <i>Annals of the New York Academy of Sciences</i> , 2015, 1358, 28-43.	3.8	75
15	The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus. <i>International Journal of Clinical Practice</i> , 2015, 69, 1071-1087.	1.7	29
16	Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option. <i>International Journal of Clinical Practice</i> , 2015, 69, 1427-1437.	1.7	14
17	Potential Place of SGLT2 Inhibitors in Treatment Paradigms for type 2 Diabetes Mellitus. <i>Endocrine Practice</i> , 2015, 21, 1054-1065.	2.1	10
18	Effects of vildagliptin as add-on treatment in patients with type 2 diabetes mellitus: insights from long-term clinical studies in Japan. <i>Journal of Diabetes and Metabolic Disorders</i> , 2015, 15, 21.	1.9	4
19	Informed shared decision-making programme on the prevention of myocardial infarction in type 2 diabetes: a randomised controlled trial. <i>BMJ Open</i> , 2015, 5, e009116-e009116.	1.9	36
21	26th Annual Meeting of The North American Menopause Society September 30–October 3, 2015, Las Vegas, NV. <i>Menopause</i> , 2015, 22, 1361-1401.	2.0	3
22	Clinical Effects of Liraglutide in a Real-World Setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study. <i>Diabetes Therapy</i> , 2015, 6, 173-185.	2.5	23

#	ARTICLE	IF	CITATIONS
23	National Variations in Comorbidities, Glycosylated Hemoglobin Reduction, and Insulin Dosage in Asian Patients with Type 2 Diabetes: The FINE-Asia Registry. <i>Diabetes Therapy</i> , 2015, 6, 519-530.	2.5	15
25	Diabetes in Panama: Epidemiology, Risk Factors, and Clinical Management. <i>Annals of Global Health</i> , 2015, 81, 754-764.	2.0	15
27	My name is Eklavya: Indian guidelines are necessary. <i>Indian Heart Journal</i> , 2015, 67, 625-626.	0.5	1
29	Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. <i>Cardiovascular Diabetology</i> , 2015, 14, 116.	6.8	39
30	Dynamics of heart rate variability in patients with type 2 diabetes mellitus during spinal anaesthesia: prospective observational study. <i>BMC Anesthesiology</i> , 2015, 15, 141.	1.8	2
31	How attractive is the combination of a sodium glucose co-transporter 2 inhibitor with a dipeptidyl peptidase 4 inhibitor in the treatment of type 2 diabetes?. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 613-615.	4.4	4
32	Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis. <i>BMC Endocrine Disorders</i> , 2015, 15, 67.	2.2	19
33	Efficacy and tolerability of vildagliptin as first line treatment in patients with diabetes type 2 in an outpatient setting. <i>Journal of Diabetes and Metabolic Disorders</i> , 2015, 14, 68.	1.9	3
34	Total costs of basal or premixed insulin treatment in 5077 insulin-naïve type 2 diabetes patients: register-based observational study in clinical practice. <i>Clinical Diabetes and Endocrinology</i> , 2015, 1, 17.	2.7	2
35	The Need for a Tool to Assist Health Care Professionals and Patients in Making Medication Treatment Decisions in the Clinical Management of Type 2 Diabetes. <i>Diabetes Spectrum</i> , 2015, 28, 227-229.	1.0	4
36	The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 170-184.	4.7	81
37	Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism. <i>Andrology</i> , 2015, 3, 1094-1103.	3.5	68
38	Development of a self-management education module for those with type 2 diabetes on injectable therapies. <i>Practical Diabetes</i> , 2015, 32, 305-310a.	0.3	1
39	Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in Type 2 diabetes: a network meta-analysis. <i>Diabetic Medicine</i> , 2015, 32, 1530-1540.	2.3	40
40	<scp>NICE</scp> guidelines for Type 2 diabetes: revised but still not fit for purpose. <i>Diabetic Medicine</i> , 2015, 32, 1398-1403.	2.3	8
41	Efficacy and safety of once-a-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 1065-1074.	4.4	61
42	Emerging utility of once-weekly exenatide in patients with type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2015, 8, 505.	2.4	4
43	Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2015, 8, 241.	2.4	28

#	ARTICLE	IF	CITATIONS
44	Pancreatic β -Cell Dysfunction in Type 2 Diabetes: Old Kids on the Block. Diabetes and Metabolism Journal, 2015, 39, 1.	4.7	40
45	Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2015, 8, 483.	2.4	8
46	Effectiveness and tolerability of treatment intensification to basal–bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study. Vascular Health and Risk Management, 2015, 11, 569.	2.3	3
47	The Effects of Glucose-Lowering Therapies on Diabetic Kidney Disease. Current Diabetes Reviews, 2015, 11, 191-200.	1.3	13
48	A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2015, 8, 363.	2.4	16
49	Sulfonylurea: Personalized Medicine for Type 2 Diabetes. Endocrinology and Metabolism, 2015, 30, 467.	3.0	0
50	Diagnosis and Glycemic Control of Type 1 Diabetes. Journal of Korean Diabetes, 2015, 16, 101.	0.3	4
51	Hypoglycemia with New Generation Basal Analog Insulins: A Descriptive Critical Review. Journal of Diabetes & Metabolism, 2015, 06, .	0.2	0
52	Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approach. World Journal of Diabetes, 2015, 6, 1092.	3.5	12
53	Maximizing Patient Safety with Newly Approved Therapies: Focus on SGLT2 Inhibitors. Endocrine Practice, 2015, 21, 1076-1078.	2.1	0
54	A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs in Context, 2015, 4, 1-19.	2.2	253
55	Triple therapy in type 2 diabetes; a systematic review and network meta-analysis. PeerJ, 2015, 3, e1461.	2.0	37
56	SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2015, 8, 543.	2.4	51
57	Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK. Patient Preference and Adherence, 2015, 9, 1611.	1.8	46
58	The role of empagliflozin in the management of type 2 diabetes by patient profile. Therapeutics and Clinical Risk Management, 2015, 11, 739.	2.0	9
59	Continual evolution of type 2 diabetes: an update on pathophysiology and emerging treatment options. Therapeutics and Clinical Risk Management, 2015, 11, 621.	2.0	33
60	Metformin-Associated Lactic Acidosis. Endocrinology and Metabolism, 2015, 30, 45.	3.0	6
61	Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes: A Post Hoc Analysis of the BARI 2D. Journal of Diabetes Research, 2015, 2015, 1-12.	2.3	12

#	ARTICLE	IF	CITATIONS
62	Medicinal Plants Qua Glucagon-Like Peptide-1 Secretagogue via Intestinal Nutrient Sensors. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-9.	1.2	16
63	Diabetes Mellitus 2014. International Journal of Endocrinology, 2015, 2015, 1-4.	1.5	4
64	Type 2 Diabetes Drugs. Home Healthcare Now, 2015, 33, 304-310.	0.2	6
65	Fasting Versus Postprandial Hyperglycemia as a Treatment Target to Lower Elevated Hemoglobin A1C. Endocrine Practice, 2015, 21, 1323-1332.	2.1	7
66	Optimized Human Regular U-500 Insulin Treatment Improves β -Cell Function in Severely Insulin-Resistant Patients with Long-Standing Type 2 Diabetes and High Insulin Requirements. Endocrine Practice, 2015, 21, 1344-1353.	2.1	7
67	Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment. Diabetes Care, 2015, 38, 1161-1172.	8.6	170
68	An alternative combination therapy for type 2 diabetes?. Lancet, The, 2015, 385, 2020-2022.	13.7	1
69	Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. European Heart Journal, 2015, 36, 2288-2296.	2.2	210
70	Minimizing Hypoglycemia and Weight Gain with Intensive Glucose Control: Potential Benefits of a New Combination Therapy (IDegLira). Advances in Therapy, 2015, 32, 391-403.	2.9	6
71	Addition of a Gastrointestinal Microbiome Modulator to Metformin Improves Metformin Tolerance and Fasting Glucose Levels. Journal of Diabetes Science and Technology, 2015, 9, 808-814.	2.2	61
72	The "Evidence" Is In! It Does Get Better!. Diabetes Care, 2015, 38, 3-5.	8.6	7
73	Effectiveness and feasibility of a software tool to help patients communicate with doctors about problems they face with their medication regimen (EMPATHy): study protocol for a randomized controlled trial. Trials, 2015, 16, 145.	1.6	4
74	Pharmacotherapy for type 2 diabetes in very elderly patients: practicing nihilism or pragmatism?. Age and Ageing, 2015, 44, 540-542.	1.6	4
75	Polemics of pioglitazone: an appraisal in 2015. Expert Review of Endocrinology and Metabolism, 2015, 10, 447-458.	2.4	2
76	Therapeutic Options for the Management of Postprandial Glucose in Patients With Type 2 Diabetes on Basal Insulin. Clinical Diabetes, 2015, 33, 175-180.	2.2	21
77	Severe hypoglycaemia during treatment with sulphonylureas in patients with type 2 diabetes in the Capital Region of Denmark. Diabetes Research and Clinical Practice, 2015, 110, 202-207.	2.8	8
78	Initiation of human regular U-500 insulin use is associated with improved glycemic control: a real-world US cohort study. BMJ Open Diabetes Research and Care, 2015, 3, e000074.	2.8	21
79	Dulaglutide, a GLP-1 receptor agonist, for the treatment of type 2 diabetes. Expert Review of Endocrinology and Metabolism, 2015, 10, 581-590.	2.4	0

#	ARTICLE	IF	CITATIONS
81	Insulinoterapia. Medicine, 2015, 11, 5510-5518.	0.0	0
82	Investigation of the relationship between patient empowerment and glycaemic control in patients with type 2 diabetes: a cross-sectional analysis. BMJ Open, 2015, 5, e008422.	1.9	10
83	IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy. Diabetes Therapy, 2015, 6, 573-591.	2.5	26
84	Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?. Diabetes and Metabolism, 2015, 41, 6S21-6S27.	2.9	6
85	Insulinosensibilisateurs (metformine/glitazones) : niveau de preuve et controverse. Medecine Des Maladies Metaboliques, 2015, 9, 759-767.	0.1	0
86	SÃ©curitÃ© cardiovasculaire des incrÃ©tines et des inhibiteurs des co-transporteurs sodium-glucose de type 2 (SGLT2). Revue. Medecine Des Maladies Metaboliques, 2015, 9, 768-775.	0.1	3
87	Effect of the GLP-1 Receptor Agonist Lixisenatide on Counterregulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes. Diabetes Care, 2016, 39, 242-249.	8.6	12
88	Pharmacologic Treatment of Type 2 Diabetes. Annals of Pharmacotherapy, 2015, 49, 540-556.	1.9	69
89	Potential for dipeptidyl peptidase-4 inhibitor and sodium glucose cotransporter 2 inhibitor single-pill combinations. Expert Review of Endocrinology and Metabolism, 2015, 10, 305-317.	2.4	5
90	6. Glycemic Targets. Diabetes Care, 2015, 38, S33-S40.	8.6	214
91	7. Approaches to Glycemic Treatment. Diabetes Care, 2015, 38, S41-S48.	8.6	202
92	Setting the hemoglobin A1c target in type 2 diabetes: a priori, a posteriori, or neither?. Endocrine, 2015, 50, 56-60.	2.3	6
93	Empagliflozin for the treatment of type 2 diabetes mellitus: An overview of safety and efficacy based on Phase 3 trials. Journal of Clinical Pharmacy and Therapeutics, 2015, 40, 1-13.	1.8	13
94	Empagliflozin, an SGLT2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus. Annals of Pharmacotherapy, 2015, 49, 582-598.	1.9	25
95	Once-weekly exenatide as a treatment for Type 2 diabetes. Expert Review of Cardiovascular Therapy, 2015, 13, 611-626.	1.5	0
96	Improved Treatment Satisfaction and Self-reported Health Status after Introduction of Basal-Supported Oral Therapy Using Insulin Glargine in Patients with Type 2 Diabetes: Sub-Analysis of ALOHA2 Study. Diabetes Therapy, 2015, 6, 153-171.	2.5	5
97	Triple fixed drug combinations in type 2 diabetes. Indian Journal of Endocrinology and Metabolism, 2015, 19, 311.	0.4	12
98	In defence of NICE draft type 2 diabetes guidelines. Lancet Diabetes and Endocrinology, 2015, 3, 406.	11.4	0

#	ARTICLE	IF	CITATIONS
100	Hyperglycémie induite par l'analogue de somatostatine pasiréotide au cours de la maladie de Cushing. Medecine Des Maladies Metaboliques, 2015, 9, 261-268.	0.1	0
101	Telephone Intervention to Improve Diabetes Control. American Journal of Preventive Medicine, 2015, 49, 832-841.	3.0	39
102	April 2015 New in Review. Journal of the Academy of Nutrition and Dietetics, 2015, 115, 663-674.	0.8	0
103	Minimizing Hypoglycemia in Diabetes. Diabetes Care, 2015, 38, 1583-1591.	8.6	156
104	Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care, 2015, 38, 1730-1735.	8.6	276
105	Innovative Approaches to Understanding and Addressing Health Disparities in Diabetes Care and Research. Diabetes Care, 2015, 38, 186-188.	8.6	12
106	Type 2 diabetes mellitus treatment patterns in US nursing home residents. Postgraduate Medicine, 2015, 127, 429-437.	2.0	8
107	Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1493-1503.	3.3	13
108	Different binding and recognition modes of GL479, a dual agonist of Peroxisome Proliferator-Activated Receptor α/β . Journal of Structural Biology, 2015, 191, 332-340.	2.8	34
109	Type 1 Diabetes at a Crossroads!. Diabetes Care, 2015, 38, 968-970.	8.6	11
110	Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus. Drugs, 2015, 75, 1141-1152.	10.9	35
111	Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study. Lancet Diabetes and Endocrinology, the, 2015, 3, 605-614.	11.4	122
112	Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy. Journal of Diabetes and Its Complications, 2015, 29, 1266-1271.	2.3	12
113	Severe hypoglycaemia the 'tip of the iceberg': An underestimated risk in both type 1 and type 2 diabetic patients. Diabetes and Metabolism, 2015, 41, 105-106.	2.9	2
114	SGLT2 Inhibitors: The Latest 'New Kids on the Block'. Diabetes Care, 2015, 38, 352-354.	8.6	42
115	To mix or to separate: that is the question. Lancet Diabetes and Endocrinology, the, 2015, 3, 229-231.	11.4	1
116	Are SGLT2 Inhibitors Reasonable Antihypertensive Drugs and Renoprotective?. Current Hypertension Reports, 2015, 17, 551.	3.5	24
118	NICE draft type 2 diabetes guidelines: a cause for concern. Lancet Diabetes and Endocrinology, the, 2015, 3, 403-405.	11.4	9

#	ARTICLE	IF	CITATIONS
119	Where Does Combination Therapy With an SGLT2 Inhibitor Plus a DPP-4 Inhibitor Fit in the Management of Type 2 Diabetes?. Diabetes Care, 2015, 38, 373-375.	8.6	37
120	Pharmacologic Treatment of Type 2 Diabetes. Annals of Pharmacotherapy, 2015, 49, 700-714.	1.9	23
121	Combination Therapy When Metformin Is Not an Option for Type 2 Diabetes. Annals of Pharmacotherapy, 2015, 49, 688-699.	1.9	7
122	Alogliptin benzoate for management of type 2 diabetes. Vascular Health and Risk Management, 2015, 11, 229.	2.3	14
123	Is HbA1c a valid surrogate for macrovascular and microvascular complications in type 2 diabetes?. Diabetes and Metabolism, 2015, 41, 195-201.	2.9	28
124	Combination therapy for patients with uncontrolled type 2 diabetes mellitus: adding empagliflozin to pioglitazone or pioglitazone plus metformin. Expert Opinion on Drug Safety, 2015, 14, 789-793.	2.4	7
125	Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, Obesity and Metabolism, 2015, 17, 630-638.	4.4	51
126	The 2015 Standards for Diabetes Care: Maintaining a Patient-Centered Approach. Annals of Internal Medicine, 2015, 162, 785-786.	3.9	10
127	Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. Clinical Pharmacokinetics, 2015, 54, 691-708.	3.5	141
128	Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin. Current Medical Research and Opinion, 2015, 31, 901-911.	1.9	11
130	Metformin should not be contraindicated in patients with type 2 diabetes and mild to moderate renal impairment. Evidence-Based Medicine, 2015, 20, 115-115.	0.6	2
132	Canagliflozin for the treatment of adults with Type 2 diabetes. Diabetes Management, 2015, 5, 183-201.	0.5	9
133	Number-Based Approach to Insulin Taxonomy. Diabetes Therapy, 2015, 6, 469-479.	2.5	2
134	<i>IL-1B</i>rs1143623 and<i>EEF1A1P11-RPL7P9</i>rs10783050 polymorphisms affect the glucose-lowering efficacy of metformin in Chinese overweight or obese Type 2 diabetes mellitus patients. Pharmacogenomics, 2015, 16, 1621-1629.	1.3	6
135	AFREZZA® (insulin human) Inhalation Powder: A Review in Diabetes Mellitus. Drugs, 2015, 75, 1679-1686.	10.9	28
137	Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials. Current Medical Research and Opinion, 2015, 31, 1993-2000.	1.9	10
138	Dulaglutide: A Review in Type 2 Diabetes. BioDrugs, 2015, 29, 407-418.	4.6	17
139	User's guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgraduate Medicine, 2015, 127, 818-826.	2.0	45

#	ARTICLE	IF	CITATIONS
140	Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial. <i>Clinical Drug Investigation</i> , 2015, 35, 675-684.	2.2	14
141	Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 1295-1303.	2.3	115
142	RSSDI Clinical Practice Recommendations for Management of Type 2 Diabetes Mellitus, 2015. <i>International Journal of Diabetes in Developing Countries</i> , 2015, 35, 1-71.	0.8	11
143	Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy. <i>Postgraduate Medicine</i> , 2015, 127, 827-841.	2.0	10
144	First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2539-2547.	1.8	36
145	Effects of anti-diabetic drugs on bone metabolism. <i>Expert Review of Endocrinology and Metabolism</i> , 2015, 10, 663-675.	2.4	13
146	Better response to the SGLT2 inhibitor dapagliflozin in young adults with type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2553-2559.	1.8	8
147	SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1879-1904.	2.4	58
148	Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naïve Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents. <i>Diabetes Care</i> , 2015, 38, 2274-2281.	8.6	30
149	Racial/ethnic disparities in prevalence and care of patients with type 2 diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2015, 31, 913-923.	1.9	51
150	Response to Comments on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> 2015;38:140â€“149. <i>Diabetes Care</i> , 2015, 38, e128-e129.	8.6	25
151	Status of Diabetes Care: New Challenges, New Concepts, New Measures—Focusing on the Future!. <i>Diabetes Care</i> , 2015, 38, 1177-1180.	8.6	5
152	Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategies. <i>Postgraduate Medicine</i> , 2015, 127, 480-493.	2.0	9
153	Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. <i>Postgraduate Medicine</i> , 2015, 127, 463-479.	2.0	11
154	Shared Decision-Making in Diabetes Care. <i>Current Diabetes Reports</i> , 2015, 15, 112.	4.2	76
155	Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> , 2015, 38, 1567-1582.	8.6	180
157	Glycemic and Cholesterol Control Versus Single-Goal Control in US Veterans with Newly Diagnosed Type 2 Diabetes: A Retrospective Observational Study. <i>Diabetes Therapy</i> , 2015, 6, 339-355.	2.5	2
158	Current management of diabetes mellitus and future directions in care. <i>Postgraduate Medical Journal</i> , 2015, 91, 612-621.	1.8	54

#	ARTICLE	IF	CITATIONS
159	Use of oral combination therapy for type 2 diabetes in primary care: Meeting individualized patient goals. <i>Postgraduate Medicine</i> , 2015, 127, 808-817.	2.0	30
160	Dipeptidyl peptidase-4 inhibitor use in patients with type 2 diabetes and cardiovascular disease or risk factors. <i>Postgraduate Medicine</i> , 2015, 127, 842-854.	2.0	5
161	Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes. <i>The Diabetes Educator</i> , 2015, 41, 19S-31S.	2.5	5
162	Saxagliptin: A Review in Type 2 Diabetes. <i>Drugs</i> , 2015, 75, 1783-1796.	10.9	22
163	Basal Insulin Initiation in Elderly Patients with Type 2 Diabetes in Taiwan: A Comparison with Younger Patients. <i>International Journal of Gerontology</i> , 2015, 9, 142-145.	0.6	2
164	GLP-1 Receptor Agonists. <i>The Diabetes Educator</i> , 2015, 41, 32S-46S.	2.5	11
165	Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins. <i>Diabetology and Metabolic Syndrome</i> , 2015, 7, 63.	2.7	3
166	Sodium glucose co-transporter inhibitors for the management of diabetes mellitus: an opinion paper from the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy. <i>Current Medical Research and Opinion</i> , 2015, 31, 1733-1741.	1.9	3
167	A new angle for glp-1 receptor agonist: the medical economics argument. <i>Journal of Medical Economics</i> , 2015, 18, 1029-1031.	2.1	1
168	Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. <i>Diabetes Research and Clinical Practice</i> , 2015, 110, 75-81.	2.8	58
169	Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1381-1387.	4.1	19
170	Markers of β -Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes. <i>Diabetes Care</i> , 2016, 39, 250-257.	8.6	132
171	Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). <i>Diabetes Care</i> , 2015, 38, 2241-2249.	8.6	184
172	Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. <i>Diabetes Therapy</i> , 2015, 6, 289-302.	2.5	36
173	Primary Care of the Patient with Chronic Kidney Disease. <i>Medical Clinics of North America</i> , 2015, 99, 935-952.	2.5	12
174	GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach. <i>Acta Diabetologica</i> , 2015, 52, 1129-1133.	2.5	15
175	Using the respective contributions of postprandial and basal glucose for tailoring treatments in type 2 diabetes. <i>Diabetes and Metabolism</i> , 2015, 41, 179-182.	2.9	11
176	Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection. <i>Diabetes Care</i> , 2015, 38, 2204-2210.	8.6	61

#	ARTICLE	IF	CITATIONS
177	Landmark studies on the glucagon subfamily of GPCRs: from small molecule modulators to a crystal structure. <i>Acta Pharmacologica Sinica</i> , 2015, 36, 1033-1042.	6.1	14
178	Hypoglycemia and Comorbidities in Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2015, 15, 80.	4.2	13
179	Algorithms for personalized therapy of type 2 diabetes: results of a web-based international survey. <i>BMJ Open Diabetes Research and Care</i> , 2015, 3, e000109.	2.8	7
180	Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1052.	7.4	305
181	Empagliflozin/Linagliptin: A Review in Type 2 Diabetes. <i>Drugs</i> , 2015, 75, 1547-1557.	10.9	13
182	Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2015, 31, 1919-1931.	1.9	18
183	Response to Comment on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> 2015;38:140â€“149. <i>Diabetes Care</i> , 2015, 38, e143-e143.	8.6	10
184	Recognizing and minimizing hypoglycemia: The need for individualized care. <i>Postgraduate Medicine</i> , 2015, 127, 801-807.	2.0	6
185	Ramadan and diabetes: What we see, learn and understand from continuous glucose monitoring. <i>Diabetes and Metabolism</i> , 2015, 41, 456-462.	2.9	9
186	Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). <i>BMJ, The</i> , 2015, 351, h5364.	6.0	53
187	Comment on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> 2015;38:140â€“149. <i>Diabetes Care</i> , 2015, 38, e141-e142.	8.6	5
188	Comment on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> 2015;38:140â€“149. <i>Diabetes Care</i> , 2015, 38, e125-e126.	8.6	3
189	Comment on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> 2015;38:140â€“149. <i>Diabetes Care</i> , 2015, 38, e127-e127.	8.6	5
190	Sodium-glucose co-transporter 2 inhibitors: evidence and place in therapy. <i>Expert Review of Endocrinology and Metabolism</i> , 2015, 10, 645-661.	2.4	2
191	Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease. <i>Advances in Therapy</i> , 2015, 32, 1029-1064.	2.9	30
192	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials. <i>Postgraduate Medicine</i> , 2015, 127, 419-428.	2.0	3
193	Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2819-2833.	1.8	20
194	NICE guidance on type 2 diabetes in adults â€“ what's new?. <i>Independent Nurse</i> , 2016, 2016, 17-22.	0.1	6

#	ARTICLE	IF	CITATIONS
213	Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2016, 9, 25.	2.4	7
214	Glycemic Assessment in a Patient with HB Leiden and Type 2 Diabetes. AACE Clinical Case Reports, 2016, 2, e307-e310.	1.1	3
215	Factors complicating the diabetes management of visitors to Japan: advices from a Japanese National Center for overseas medical staff. Journal of Medical Investigation, 2016, 63, 15-18.	0.5	3
216	Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin. Diabetes and Metabolism Journal, 2016, 40, 230.	4.7	15
217	Reduction of Sulfonylurea with the Initiation of Basal Insulin in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Undergoing Long-Term Sulfonylurea-Based Treatment. Diabetes and Metabolism Journal, 2016, 40, 454.	4.7	5
218	Dipeptidyl Peptidase-4 Inhibitor Switching as an Alternative Add-on Therapy to Current Strategies Recommended by Guidelines: Analysis of a Retrospective Cohort of Type 2 Diabetic Patients. Journal of Diabetes & Metabolism, 2016, 7, .	0.2	6
219	Improving cardiovascular risk in type 2 diabetes: time to get personal. European Heart Journal Quality of Care & Clinical Outcomes, 2016, 2, 233-234.	4.0	3
220	Effectiveness and Safety of Sitagliptin in Patients with Beta-thalassaemia Major and Diabetes Mellitus: A Case Series. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017004.	1.3	5
221	Treatment progression in sulfonylurea and dipeptidyl peptidase-4-inhibitor cohorts of type 2 diabetes patients on metformin. Patient Preference and Adherence, 2016, Volume 10, 1539-1546.	1.8	2
222	Dapagliflozin-Induced Acute-on-Chronic Liver Injury. ACG Case Reports Journal, 2016, 3, e169.	0.4	5
223	Economic Evaluation of Canagliflozin versus Glimepiride and Sitagliptin in Dual Therapy with Metformin for the Treatment of Type 2 Diabetes in Italy. Global & Regional Health Technology Assessment, 2016, 3, GRHTA.5000229.	0.1	2
224	Cardiovascular safety of type 2 diabetes medications: Review of existing literature and clinical implications. Hormones, 2016, 15, 170-185.	1.9	7
225	Efficacy and Safety of Dulaglutide in Hispanic/Latino Patients with Type 2 Diabetes in the Award Clinical Program. Endocrine Practice, 2016, 22, 1406-1414.	2.1	12
226	Rapid Acting Insulin Use and Persistence among Elderly Type 2 Diabetes Patients Adding RAI to Oral Antidiabetes Drug Regimens. Journal of Diabetes Research, 2016, 2016, 1-12.	2.3	3
227	The Impacts of<i>SLC22A1</i>rs594709 and<i>SLC47A1</i>rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients. International Journal of Endocrinology, 2016, 2016, 1-7.	1.5	46
228	Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects. Drug Design, Development and Therapy, 2016, Volume 10, 2525-2534.	4.3	12
229	The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clinical Pharmacology: Advances and Applications, 2016, 8, 61.	1.2	35
230	Advances in the treatment of type 2 diabetes: impact of dulaglutide. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2016, 9, 125.	2.4	9

#	ARTICLE	IF	CITATIONS
231	Repurposing metformin for cancer treatment: current clinical studies. <i>Oncotarget</i> , 2016, 7, 40767-40780.	1.8	252
232	Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 19-29.	1.9	25
233	Options for empagliflozin in combination therapy in type 2 diabetes mellitus. <i>International Journal of General Medicine</i> , 2016, 9, 155.	1.8	13
234	PROGENS-HbA 1c study: safety and effectiveness of premixed recombinant human insulin (Gensulin) Tj ETQq1 1 0.784314 rgBT /Overl	0.9	4
235	Noninsulin Antidiabetic Drugs for Patients with Type 2 Diabetes Mellitus: Are We Respecting Their Contraindications?. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-9.	2.3	14
236	Metformin Treatment and Homocysteine: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Nutrients</i> , 2016, 8, 798.	4.1	40
237	Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0166125.	2.5	188
238	Update on the treatment of type 2 diabetes mellitus. <i>World Journal of Diabetes</i> , 2016, 7, 354.	3.5	407
239	Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 1299-1307.	1.8	448
240	Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjects. <i>Drug Design, Development and Therapy</i> , 2016, 10, 1411.	4.3	3
241	Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents. <i>Pharmacogenomics and Personalized Medicine</i> , 2016, 9, 17.	0.7	16
242	NICE guidance: Translating intentions into practice. <i>British Journal of Health Care Management</i> , 2016, 22, 58-62.	0.2	0
243	Glucagon-like peptide-1 and gastric inhibitory polypeptide. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2016, 23, 23-27.	2.3	11
244	Dose-response relationship between statin therapy and glycaemia in community-based patients with type 2 diabetes: the <sc>F</sc>remantle <sc>D</sc>iabetes <sc>S</sc>tudy. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 1143-1146.	4.4	7
245	Efficacy and safety of linagliptin according to patient baseline characteristics: A pooled analysis of three phase 3 trials. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 886-892.	2.6	7
246	Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an <sc>AWARD</sc>-4 substudy. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 999-1005.	4.4	37
247	Management of diabetes in Indigenous communities: lessons from the Australian Aboriginal population. <i>Internal Medicine Journal</i> , 2016, 46, 1252-1259.	0.8	18
248	Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial. <i>Journal of Diabetes</i> , 2016, 8, 796-808.	1.8	45

#	ARTICLE	IF	CITATIONS
249	Increasing Patient Acceptance and Adherence Toward Insulin. Postgraduate Medicine, 2016, 128, 11-20.	2.0	3
250	Nutritional composition of <i>Stevia rebaudiana</i> , a sweet herb, and its hypoglycaemic and hypolipidaemic effect on patients with non-insulin dependent diabetes mellitus. Journal of the Science of Food and Agriculture, 2016, 96, 4231-4234.	3.5	58
251	Patient engagement impacts glycemic management with vildagliptin and vildagliptin/metformin (single) Tj ETQq0 0.0 rgBT /Overlock 10	1.8	8
252	Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes. Postgraduate Medicine, 2016, 128, 725-730.	2.0	11
253	Assessing Adherence to Insulin Initiation Recommendations at a Suburban Family Medicine Clinic. American Journal of Therapeutics, 2016, 23, e1542-e1546.	0.9	1
254	Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register. Diabetes, Obesity and Metabolism, 2016, 18, 990-998.	4.4	44
255	Making Insulin Accessible: Does Inhaled Insulin Fill an Unmet Need?. Advances in Therapy, 2016, 33, 1267-1278.	2.9	14
256	A Novel Partial PPAR γ Dual Agonist SN159 Improves Insulin Sensitivity. Bulletin of the Korean Chemical Society, 2016, 37, 226-233.	1.9	3
257	Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes. Diabetic Medicine, 2016, 33, 511-514.	2.3	100
258	Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study. Diabetes, Obesity and Metabolism, 2016, 18, 840-843.	4.4	14
259	Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records. Diabetes, Obesity and Metabolism, 2016, 18, 916-924.	4.4	12
260	Benefits/Risks of Sodium-Glucose Co-Transporter 2 Inhibitor Canagliflozin in Women for the Treatment of Type 2 Diabetes. Women's Health, 2016, 12, 379-388.	1.5	16
261	Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective. Journal of Medical Economics, 2016, 19, 1127-1134.	2.1	13
262	Vildagliptin-induced acute lung injury: a case report. Journal of Medical Case Reports, 2016, 10, 225.	0.8	8
263	The combination of dulaglutide and biguanide reduced bodyweight in Japanese patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2016, 18, 1279-1282.	4.4	8
265	Increasing Number of People with Diabetes in Japan: Is This Trend Real?. Internal Medicine, 2016, 55, 1827-1830.	0.7	39
266	Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes. Heart, 2016, 102, 1581-1587.	2.9	29
267	BeAM value: an indicator of the need to initiate and intensify prandial therapy in patients with type 2 diabetes mellitus receiving basal insulin. BMJ Open Diabetes Research and Care, 2016, 4, e000171.	2.8	16

#	ARTICLE	IF	CITATIONS
268	Beneficial effect of farnesoid X receptor activation on metabolism in a diabetic rat model. <i>Molecular Medicine Reports</i> , 2016, 13, 2135-2142.	2.4	18
269	Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial. <i>BMJ Open</i> , 2016, 6, e012185.	1.9	18
271	Impact of Glucose Management Team on Outcomes of Hospitalization in Patients With Type 2 Diabetes Admitted to the Medical Service. <i>Endocrine Practice</i> , 2016, 22, 1401-1405.	2.1	31
272	Most add-on therapies to metformin have similar effects on HbA1c. <i>Evidence-Based Medicine</i> , 2016, 21, 223-223.	0.6	0
273	Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study. <i>BMJ Open</i> , 2016, 6, e010210.	1.9	224
274	Relationship of cardiometabolic parameters in non-smokers, current smokers, and quitters in diabetes: a systematic review and meta-analysis. <i>Cardiovascular Diabetology</i> , 2016, 15, 158.	6.8	58
275	Analytical tools for determination of new oral antidiabetic drugs, glitazones, gliptins, gliflozins and glinides, in bulk materials, pharmaceuticals and biological samples. <i>Open Chemistry</i> , 2016, 14, 215-242.	1.9	13
276	Effectiveness of a Multicomponent Quality Improvement Strategy to Improve Achievement of Diabetes Care Goals. <i>Annals of Internal Medicine</i> , 2016, 165, 399.	3.9	87
278	In type 2 diabetes treated with high-dose insulin, liraglutide reduced HBA_{1c}. <i>Annals of Internal Medicine</i> , 2016, 165, JC40.	3.9	1
280	Pharmacological options for managing type 2 diabetes. <i>NursePrescribing</i> , 2016, 14, 330-338.	0.1	0
281	Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus. <i>Endocrinología Y Nutrición (English Edition)</i> , 2016, 63, 519-526.	0.5	4
284	Lactic acidosis and the relationship with metformin usage. <i>Medicine (United States)</i> , 2016, 95, e4998.	1.0	12
285	Des essais randomisés contrôlés aux études observationnelles. Apports, limites et leçons. Réflexions à propos de l'étude ODYSSEE. <i>Medicine Des Maladies Metaboliques</i> , 2016, 10, 732-740.	0.1	0
286	Under-treatment of type 2 diabetes: Causes and outcomes of clinical inertia. <i>International Journal of Clinical Practice</i> , 2016, 70, 988-995.	1.7	36
287	Prevención primaria de diabetes tipo 2 en Argentina: estudio piloto en la provincia de Buenos Aires. <i>Revista Argentina De Endocrinología Y Metabolismo</i> , 2016, 53, 135-141.	0.0	3
288	Role of Emerging Insulin Technologies in the Initiation and Intensification of Insulin Therapy for Diabetes in Primary Care. <i>Clinical Diabetes</i> , 2016, 34, 34-43.	2.2	6
289	Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program. <i>Current Diabetes Reports</i> , 2016, 16, 44.	4.2	19
290	Capsule Commentary on Min et al., Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes: How to Escalate Therapy for Patients who Fail Sulfonylureas. <i>Journal of General Internal Medicine</i> , 2016, 31, 650-650.	2.6	0

#	ARTICLE	IF	CITATIONS
291	Liraglutide in clinical practice: Glycemic control, and predictors of good response. <i>Medicina Clínica</i> , 2016, 146, 415-416.	0.6	3
292	Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes. <i>Circulation Research</i> , 2016, 118, 1830-1843.	4.5	51
293	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2016, 37, 2315-2381.	2.2	5,370
294	Evidence for Good Cardiovascular Outcomes among Patients with Type 2 Diabetes, and Promising Treatment for Patients with Type 1 Diabetes. <i>Clinical Therapeutics</i> , 2016, 38, 1274-1278.	2.5	1
295	Effect of a macronutrient preload on blood glucose level and pregnancy outcome in gestational diabetes. <i>Journal of Clinical and Translational Endocrinology</i> , 2016, 5, 36-41.	1.4	8
296	Pharmacologic Therapy of Type 2 Diabetes. <i>Medical Clinics of North America</i> , 2016, 100, 647-663.	2.5	17
297	Novel antidiabetic drugs and cardiovascular risk: Primum non nocere. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 759-766.	2.6	18
298	Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial. <i>Diabetes Care</i> , 2016, 39, 1318-1328.	8.6	116
299	Efficacy and safety of a premixed versus a basal-plus insulin regimen as intensification for type 2 diabetes by timing of the main meal. <i>Current Medical Research and Opinion</i> , 2016, 32, 1109-1116.	1.9	3
300	Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1013-1023.	1.9	13
301	NUEVOS FÁRMACOS EN DIABETES MELLITUS. <i>Revista Médica Clínica Las Condes</i> , 2016, 27, 235-256.	0.2	4
302	Pharmacologic Approaches to Weight Management: Recent Gains and Shortfalls in Combating Obesity. <i>Current Atherosclerosis Reports</i> , 2016, 18, 36.	4.8	13
303	Interactive Web-Based Learning. <i>American Journal of Preventive Medicine</i> , 2016, 50, 122-128.	3.0	17
304	EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus. <i>Clinical Therapeutics</i> , 2016, 38, 1288-1298.	2.5	28
305	Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism. <i>Nature Reviews Endocrinology</i> , 2016, 12, 467-484.	9.6	28
306	Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes. <i>Annales D'Endocrinologie</i> , 2016, 77, 557-562.	1.4	15
307	Exenatide Once Weekly: A Review of Pharmacology and Treatment Considerations in Type 2 Diabetes. <i>Clinical Therapeutics</i> , 2016, 38, 582-594.	2.5	16
308	Improving drug prescription in elderly diabetic patients. <i>Revista Espanola De Geriatria Y Gerontologia</i> , 2016, 51, 127-129.	0.7	2

#	ARTICLE	IF	CITATIONS
309	The Effect of Disease Severity on 24-Hour Urine Parameters in Kidney Stone Patients With Type 2 Diabetes. <i>Urology</i> , 2016, 87, 52-59.	1.0	15
310	Trend of antihyperglycaemic therapy and glycaemic control in 184,864 adults with type 1 or 2 diabetes between 2002 and 2014: Analysis of real-life data from the DPV registry from Germany and Austria. <i>Diabetes Research and Clinical Practice</i> , 2016, 115, 31-38.	2.8	38
311	Novel insight into the dangerous connection between diabetes and heart failure. <i>Herz</i> , 2016, 41, 201-207.	1.1	12
312	Glucose-lowering therapy in type 2 diabetes. <i>Herz</i> , 2016, 41, 208-216.	1.1	3
316	Mortality reduction among persons with type 2 diabetes: (α)-Epicatechin as add-on therapy to metformin?. <i>Medical Hypotheses</i> , 2016, 91, 86-89.	1.5	4
317	Onset of Glycemic and Weight Outcomes in Patients Initiating Exenatide Once Weekly: The Relationship of Exenatide Exposure with Efficacy over the First 24 Weeks of Treatment. <i>Diabetes Therapy</i> , 2016, 7, 361-368.	2.5	2
318	Combination of Saxagliptin and Metformin Is Effective as Initial Therapy in New-Onset Type 2 Diabetes Mellitus With Severe Hyperglycemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2528-2535.	3.6	12
319	Combination therapy for the improvement of long-term macrovascular and microvascular outcomes in type 2 diabetes: Rationale and evidence for early initiation. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1177-1185.	2.3	15
320	Personalized intensification of insulin therapy in type 2 diabetes – does a basal-bolus regimen suit all patients?. <i>Current Medical Research and Opinion</i> , 2016, 32, 1425-1434.	1.9	6
321	Proactive and Progressive Approaches in Managing Obesity. <i>Postgraduate Medicine</i> , 2016, 128, 21-30.	2.0	6
323	Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 89, 73-82.	4.0	14
324	lpragliflozin as an Initial Therapy in Drug Naïve Subjects with Type 2 Diabetes. <i>Drug Research</i> , 2016, 66, 345-350.	1.7	4
327	Urinary metabolomic profiling in mice with diet-induced obesity and type 2 diabetes mellitus after treatment with metformin, vildagliptin and their combination. <i>Molecular and Cellular Endocrinology</i> , 2016, 431, 88-100.	3.2	34
328	The current role of thiazolidinediones in diabetes management. <i>Archives of Toxicology</i> , 2016, 90, 1861-1881.	4.2	54
329	Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 91.	1.7	35
330	Small Intestinal Glucose Delivery Affects the Lowering of Blood Glucose by Acute Vildagliptin in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4769-4778.	3.6	14
331	Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 <i>Journal</i> , 2016, 179, 175-183.	2.7	58
332	The effect of local hyperglycemia on skin cells in vitro and on wound healing in euglycemic rats. <i>Journal of Surgical Research</i> , 2016, 206, 418-426.	1.6	23

#	ARTICLE	IF	CITATIONS
333	Diabetes Technologyâ€”Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3922-3937.	3.6	165
334	A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures. BMC Health Services Research, 2016, 16, 356.	2.2	6
335	Real-world Canagliflozin Utilization: Glycemic Control Among Patients With Type 2 Diabetes Mellitusâ€”A Multi-Database Synthesis. Clinical Therapeutics, 2016, 38, 2071-2082.	2.5	7
336	SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan. Expert Opinion on Pharmacotherapy, 2016, 17, 2073-2084.	1.8	18
337	A comparison of the pharmacodynamic profiles of jet-injected regular human insulin versus conventionally administered insulin aspart in healthy volunteers. Diabetes Research and Clinical Practice, 2016, 121, 86-90.	2.8	3
338	Dual oral agent therapy for type 2 diabetes: Why don't our patients stick with it?. Journal of Diabetes and Its Complications, 2016, 30, 1417-1418.	2.3	1
339	Effectiveness of vildagliptin versus other oral antidiabetes drugs as add-on to sulphonylurea monotherapy: Post hoc analysis from the EDGE study. Primary Care Diabetes, 2016, 10, 452-458.	1.8	0
341	Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes. Diabetes Therapy, 2016, 7, 659-678.	2.5	6
342	Treatment discontinuation of oral hypoglycemic agents and healthcare utilization among patients with diabetes. Journal of Diabetes and Its Complications, 2016, 30, 1443-1451.	2.3	12
343	Factors influencing insulin usage among type 2 diabetes mellitus patients: A study in Turkish primary care. European Journal of General Practice, 2016, 22, 255-261.	2.0	6
344	Assessing occurrence of hypoglycemia and its severity from electronic health records of patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2016, 121, 192-203.	2.8	52
345	Efficacy and risk profile of anti-diabetic therapies: Conventional vs traditional drugsâ€”A mechanistic revisit to understand their mode of action. Pharmacological Research, 2016, 113, 636-674.	7.1	53
346	Metformin. Endocrinology and Metabolism Clinics of North America, 2016, 45, 819-843.	3.2	26
347	Drug therapies in type 2 diabetes: an era of personalised medicine. Clinical Medicine, 2016, 16, 441-447.	1.9	5
348	The effects of exenatide twice daily compared to insulin lispro added to basal insulin in Latin American patients with type 2 diabetes: A retrospective analysis of the 4B trial. Diabetes Research and Clinical Practice, 2016, 122, 38-45.	2.8	3
349	Evolving to Personalized Medicine for Type 2 Diabetes. Endocrinology and Metabolism Clinics of North America, 2016, 45, 1011-1020.	3.2	8
350	Eficacia y seguridad de empagliflozina en combinaci3n con otros hipoglucemiantes orales en pacientes con diabetes mellitus tipo 2. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2016, 63, 519-526.	0.8	9
351	Tratamiento de la diabetes mellitus (III). Insulinoterapia. Medicine, 2016, 12, 1026-1034.	0.0	0

#	ARTICLE	IF	CITATIONS
352	Liraglutide in clinical practice: Glycemic control, and predictors of good response. Medicina Clínica (English Edition), 2016, 146, 415-416.	0.2	0
353	Current perspectives on cardiovascular outcome trials in diabetes. Cardiovascular Diabetology, 2016, 15, 139.	6.8	59
354	Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice, 2016, 70, 775-785.	1.7	17
355	Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health. Current Osteoporosis Reports, 2016, 14, 345-350.	3.6	19
356	IDegAsp (insulin degludec + insulin aspart) for the management of type 2 diabetes: current status. Expert Review of Endocrinology and Metabolism, 2016, 11, 103-111.	2.4	4
357	Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia. Postgraduate Medicine, 2016, 128, 747-754.	2.0	6
358	Amyloidogenesis of the amylin analogue pramlintide. Biophysical Chemistry, 2016, 219, 1-8.	2.8	38
359	Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care, 2016, 39, 1972-1980.	8.6	198
360	Pharmacokinetic evaluation of fixed-ratio combination of insulin degludec and liraglutide in the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1225-1232.	3.3	0
361	Similar efficacy and safety of once-a-weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years. Diabetes, Obesity and Metabolism, 2016, 18, 820-828.	4.4	36
362	Challenges of implementing personalized (precision) medicine: a focus on diabetes. Personalized Medicine, 2016, 13, 485-497.	1.5	5
363	Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus. Postgraduate Medicine, 2016, 128, 828-838.	2.0	12
364	Demographic and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Initiating Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Study of UK General Practice. Clinical Therapeutics, 2016, 38, 1825-1832.e15.	2.5	5
365	Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers. Postgraduate Medicine, 2016, 128, 810-821.	2.0	17
366	Effect of Serotonin Transporter 5-HTTLPR Polymorphism on Gastrointestinal Intolerance to Metformin: A GoDARTS Study. Diabetes Care, 2016, 39, 1896-1901.	8.6	41
368	The power of two: an update on fixed-dose combinations for type 2 diabetes. Expert Review of Clinical Pharmacology, 2016, 9, 1453-1462.	3.1	19
369	Targeting hepatic glucose metabolism in the treatment of type 2 diabetes. Nature Reviews Drug Discovery, 2016, 15, 786-804.	46.4	254
370	Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis From the First-in-Human Proof-of-Concept Study. Diabetes Care, 2016, 39, 2254-2261.	8.6	171

#	ARTICLE	IF	CITATIONS
371	Clinical use of the co-formulation of insulin degludec and insulin aspart. International Journal of Clinical Practice, 2016, 70, 657-667.	1.7	14
372	Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonists. Diabetes/Metabolism Research and Reviews, 2016, 32, 497-511.	4.0	19
373	Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes/Metabolism Research and Reviews, 2016, 32, 776-790.	4.0	105
374	NICE: type 2 diabetes in adults, 2015. Practical Diabetes, 2016, 33, 4-5.	0.3	3
375	Omarigliptin for the treatment of type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy, 2016, 17, 1947-1952.	1.8	18
376	Approaches to treatment 2: Comparison of American Association of Clinical Endocrinologists (AACE) and American Diabetes Association (ADA) type 2 diabetes treatment guidelines. Journal of Diabetes, 2016, 8, 4-6.	1.8	15
377	Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes. Journal of Diabetes, 2016, 8, 720-728.	1.8	24
378	Personalized medicine in diabetes: the role of "omics"™ and biomarkers. Diabetic Medicine, 2016, 33, 712-717.	2.3	61
379	Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes, Obesity and Metabolism, 2016, 18, 401-409.	4.4	207
380	Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN : ADD) Tj ETQq1 1 0 4 7 8 4 3 1 4 rg5T /Overd	4.4	14
381	Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2016, 18, 829-833.	4.4	10
382	Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial. Diabetes, Obesity and Metabolism, 2016, 18, 803-811.	4.4	23
383	Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. Diabetes, Obesity and Metabolism, 2016, 18, 812-819.	4.4	49
384	Efficacy of canagliflozin combined with antidiabetic drugs in treating type 2 diabetes mellitus: Meta-analysis of randomized control trials. Journal of Diabetes Investigation, 2016, 7, 359-365.	2.4	6
385	Achieving the composite endpoint of glycated haemoglobin <math>\leq 7.0\%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programme. Diabetes, Obesity and Metabolism, 2016, 18, 49-55.	4.4	16
386	Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2016, 18, 82-91.	4.4	74
387	Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes, Obesity and Metabolism, 2016, 18, 317-332.	4.4	211
388	Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial. Diabetes, Obesity and Metabolism, 2016, 18, 274-280.	4.4	34

#	ARTICLE	IF	CITATIONS
389	Apparent subadditivity of the efficacy of initial combination treatments for type 2 diabetes is largely explained by the impact of baseline HbA1c on efficacy. Diabetes, Obesity and Metabolism, 2016, 18, 348-354.	4.4	10
390	Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial. Diabetes, Obesity and Metabolism, 2016, 18, 528-532.	4.4	22
391	A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8). Diabetes, Obesity and Metabolism, 2016, 18, 475-482.	4.4	72
392	Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment. Diabetes, Obesity and Metabolism, 2016, 18, 615-622.	4.4	27
393	How much is too much? Outcomes in patients using high-dose insulin glargine. International Journal of Clinical Practice, 2016, 70, 56-65.	1.7	31
394	Reductions in Mean 24-Hour Ambulatory Blood Pressure After 6-Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension. Journal of Clinical Hypertension, 2016, 18, 43-52.	2.0	70
395	Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus. Journal of Diabetes Investigation, 2016, 7, 5-16.	2.4	40
396	Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis. Journal of the American Geriatrics Society, 2016, 64, 543-552.	2.6	64
397	Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis. British Journal of Clinical Pharmacology, 2016, 82, 1291-1302.	2.4	39
398	Safety profiling of pioglitazone and telmisartan combination by sub-chronic toxicity study in rat. Regulatory Toxicology and Pharmacology, 2016, 81, 155-161.	2.7	6
400	Beyond Traditional Management: The Use of Medications in the Treatment of Obesity. , 2016, , 231-260.		0
402	Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy. Nutrition and Diabetes, 2016, 6, e217-e217.	3.2	17
403	Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1367-1380.	3.3	4
404	Are patients on basal insulin attaining glycemic targets? Characteristics and goal achievement of patients with type 2 diabetes mellitus treated with basal insulin and physician-perceived barriers to achieving glycemic targets. Diabetes Research and Clinical Practice, 2016, 121, 17-26.	2.8	50
405	A novel option for prandial insulin therapy: inhaled insulin. Postgraduate Medicine, 2016, 128, 839-847.	2.0	4
406	Metformin-associated risk of acute dialysis in patients with type 2 diabetes: a nationwide cohort study. Diabetes, Obesity and Metabolism, 2016, 18, 1283-1287.	4.4	12
407	Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care, 2016, 39, 2026-2035.	8.6	197
408	Predictors of HbA1c levels in patients initiating metformin. Current Medical Research and Opinion, 2016, 32, 2021-2028.	1.9	9

#	ARTICLE	IF	CITATIONS
409	Glycemic Control for Patients With Type 2 Diabetes Mellitus: Our Evolving Faith in the Face of Evidence. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 504-512.	2.2	125
410	Cardiac implications of drugs used to treat type 2 diabetes. <i>British Journal of Cardiac Nursing</i> , 2016, 11, 168-172.	0.1	0
411	Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2016, 68, 733-742.	1.9	31
412	Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 677-686.	4.4	38
413	Intensification of Diabetes Therapy and Time Until A1C Goal Attainment Among Patients With Newly Diagnosed Type 2 Diabetes Who Fail Metformin Monotherapy Within a Large Integrated Health System. <i>Diabetes Care</i> , 2016, 39, 1527-1534.	8.6	62
414	SGLT2 Inhibitors: Benefit/Risk Balance. <i>Current Diabetes Reports</i> , 2016, 16, 92.	4.2	83
415	Basal Insulin Use With GLP-1 Receptor Agonists. <i>Diabetes Spectrum</i> , 2016, 29, 152-160.	1.0	34
416	A Test in Context. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2479-2486.	2.8	23
418	Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments. <i>Annals of Internal Medicine</i> , 2016, 164, 102.	3.9	70
419	Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2016, 164, 740.	3.9	509
420	Alpha-glucosidase inhibitors and hepatotoxicity in type 2 diabetes: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2016, 6, 32649.	3.3	53
421	Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 77-83.	2.4	27
422	Best practice in management of type 2 diabetes. <i>NursePrescribing</i> , 2016, 14, S3-S8.	0.1	0
423	2016 Health Care & Education Presidential Address: If DSME Were a Pill, Would You Prescribe It?. <i>Diabetes Care</i> , 2016, 39, 2101-2107.	8.6	16
424	Efficacy and safety of thrice-weekly insulin degludec in elderly patients with type 2 diabetes assessed by continuous glucose monitoring. <i>Endocrine Journal</i> , 2016, 63, 1099-1106.	1.6	7
425	Do We Need Updated Guidelines on the Use of Insulin Pump Therapy in Type 2 Diabetes? A Review of National and International Practice Guidelines. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 1388-1398.	2.2	3
426	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>Atherosclerosis</i> , 2016, 252, 207-274.	0.8	415
427	Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 1072-1080.	4.4	27

#	ARTICLE	IF	CITATIONS
428	Impact of frailty in older patients with diabetes mellitus: An overview. <i>Endocrinologia Y Nutrición</i> (English Edition), 2016, 63, 291-303.	0.5	6
429	Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting. <i>Pharmacoeconomics</i> , 2016, 34, 953-966.	3.3	25
430	The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1133-1152.	4.1	15
431	Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?. <i>Cardiovascular Diabetology</i> , 2016, 15, 95.	6.8	52
432	The prevalence and treatment patterns of diabetes in the Greek population based on real-world data from the nation-wide prescription database. <i>Diabetes Research and Clinical Practice</i> , 2016, 118, 162-167.	2.8	57
433	One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 1128-1133.	4.4	31
434	Treatment of Type 2 Diabetes: From "Guidelines" to "Position Statements" and Back. <i>Diabetes Care</i> , 2016, 39, S146-S153.	8.6	22
435	Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm. <i>Diabetes Care</i> , 2016, 39, S154-S164.	8.6	36
436	The cost-effectiveness of exenatide twice daily (BID) vs insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes. <i>Journal of Medical Economics</i> , 2016, 19, 1167-1174.	2.1	7
437	Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: <sc>IMAGINE</sc> 2 randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 1055-1064.	4.4	42
438	Pharmacological Approaches in the Treatment and Maintenance of Weight Loss. <i>Diabetes Care</i> , 2016, 39, S260-S267.	8.6	37
439	Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?. <i>Diabetes Care</i> , 2016, 39, S187-S195.	8.6	42
440	Persistence with Insulin Therapy in Patients with Type 2 Diabetes in France: An Insurance Claims Study. <i>Diabetes Therapy</i> , 2016, 7, 537-549.	2.5	28
441	Efficacy and Safety of Multiple Doses of Exenatide Once-Monthly Suspension in Patients With Type 2 Diabetes: A Phase II Randomized Clinical Trial. <i>Diabetes Care</i> , 2016, 39, 1768-1776.	8.6	11
442	Management of postprandial glucose: Recommended targets and treatment with biphasic insulin. <i>Primary Care Diabetes</i> , 2016, 10, 391-397.	1.8	3
444	Glucose: archetypal biomarker in diabetes diagnosis, clinical management and research. <i>Biomarkers in Medicine</i> , 2016, 10, 1153-1166.	1.4	10
445	Should GLP-1 Receptor Agonists Be the First Line of Treatment for Type 2 Diabetes?. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 671-673.	4.4	1
446	Cardiovascular Outcomes of New Medications for Type 2 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 749-758.	4.4	7

#	ARTICLE	IF	CITATIONS
447	Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes. <i>Diabetes Therapy</i> , 2016, 7, 765-776.	2.5	10
448	Case of a woman with acromegaly whose presenting complaint was prolonged postpartum amenorrhea. <i>Journal of Obstetrics and Gynaecology Research</i> , 2016, 42, 1379-1384.	1.3	1
449	Insulin. <i>Endocrinology and Metabolism Clinics of North America</i> , 2016, 45, 845-874.	3.2	11
450	Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease. <i>Diabetes Therapy</i> , 2016, 7, 621-639.	2.5	21
451	Basal-bolus Therapy in Patients with Type 2 Diabetes Mellitus in the UK: Patient Characteristics, Treatment Patterns and the Effect of Switching to Premixed Insulin. <i>Diabetes Therapy</i> , 2016, 7, 793-807.	2.5	4
452	Gal3 Links Inflammation and Insulin Resistance. <i>Cell Metabolism</i> , 2016, 24, 655-656.	16.2	16
453	Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. <i>Annals of Internal Medicine</i> , 2016, 164, 542.	3.9	487
454	The efficacy and safety of liraglutide added to metformin in patients with diabetes: a meta-analysis of randomized controlled trials. <i>Scientific Reports</i> , 2016, 6, 32714.	3.3	13
455	SGLT2i: A novel approach to managing type 2 diabetes. <i>British Journal of Health Care Management</i> , 2016, 22, 450-454.	0.2	0
456	Changes in Characteristics and Treatment Patterns of Patients with Newly Diagnosed Type 2 Diabetes in a Large United States Integrated Health System between 2008 and 2013. <i>Clinical Medicine Insights: Endocrinology and Diabetes</i> , 2016, 9, CMED.s39761.	1.9	12
457	Glycaemic control and antidiabetic treatment trends in primary care centres in patients with type 2 diabetes mellitus during 2007-2013 in Catalonia: a population-based study. <i>BMJ Open</i> , 2016, 6, e012463.	1.9	67
459	Importancia del peso en el control del paciente con diabetes mellitus tipo 2: hacia una visión adipocéntrica del abordaje de la diabetes. <i>Medicina Clínica</i> , 2016, 147, 8-16.	0.6	4
460	Management of chronic kidney disease and diabetes: a case study. <i>Journal of Kidney Care</i> , 2016, 1, 12-17.	0.1	0
461	Use of an electronic health record to identify prevalent and incident cardiovascular disease in type 2 diabetes according to treatment strategy. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000206.	2.8	6
462	Regular Insulin Administered With the V-Go Disposable Insulin Delivery Device in a Clinical Diabetes Setting: A Retrospective Analysis of Efficacy and Cost. <i>Clinical Diabetes</i> , 2016, 34, 201-205.	2.2	3
463	Management of Type 2 Diabetes in the Setting of Morbid Obesity: How Can Weight Gain Be Prevented or Reversed?. <i>Clinical Diabetes</i> , 2016, 34, 115-120.	2.2	2
464	Effects of lifestyle intervention using patient-centered cognitive behavioral therapy among patients with cardio-metabolic syndrome: a randomized, controlled trial. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 227.	1.7	22
466	Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002-2013. <i>Medicine (United States)</i> , 2016, 95, e4018.	1.0	71

#	ARTICLE	IF	CITATIONS
467	Impact of diabetes duration on achieved reductions in glycated haemoglobin, fasting plasma glucose and body weight with liraglutide treatment for up to 28 weeks: a meta-analysis of seven phase III trials. Diabetes, Obesity and Metabolism, 2016, 18, 721-724.	4.4	9
468	CYP2C8 and SLCO1B1 Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes. Diabetes Care, 2016, 39, 1902-1908.	8.6	52
470	Cardiovascular effects of anti-diabetes drugs. Expert Opinion on Drug Safety, 2016, 15, 1239-1257.	2.4	14
473	Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone. Clinical Drug Investigation, 2016, 36, 293-303.	2.2	11
475	Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial. Diabetes Care, 2016, 39, 1501-1509.	8.6	126
476	Safety and efficacy of linagliptin in patients with type 2 diabetes mellitus and coronary artery disease: Analysis of pooled events from 19 clinical trials. Journal of Diabetes and Its Complications, 2016, 30, 1378-1384.	2.3	9
477	Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes. Expert Review of Endocrinology and Metabolism, 2016, 11, 7-19.	2.4	23
478	Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? Yes, They Should Be Relaxed! What's the Fuss?. Diabetes Care, 2016, 39, 1287-1291.	8.6	27
479	Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nature Reviews Endocrinology, 2016, 12, 566-592.	9.6	292
481	Non-Persistence and Non-Adherence of Patients with Type 2 Diabetes Mellitus in Therapy with GLP-1 Receptor Agonists: A Retrospective Analysis. Diabetes Therapy, 2016, 7, 105-124.	2.5	35
482	Filling the Knowledge Gap in Diabetes Management During Ramadan: the Evolving Role of Trial Evidence. Diabetes Therapy, 2016, 7, 221-240.	2.5	6
483	Predictors for achieving target glycemic control in Japanese patients with type 2 diabetes after initiation of basal supported oral therapy using insulin glargine: sub-analysis of the ALOHA2 study, drug use surveillance in Japan. Diabetology International, 2016, 7, 188-198.	1.4	5
484	A higher body mass index attenuates the long-term HbA1c-lowering effects of liraglutide in type 2 diabetes patients treated using sulfonylurea-based therapy. Diabetology International, 2016, 7, 425-431.	1.4	1
486	Early insulin therapy in patients with type 2 diabetes mellitus. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2016, 21, 13-15.	0.2	7
487	Epidemiology of Diabetes—Status of a Pandemic and Issues Around Metabolic Surgery. Diabetes Care, 2016, 39, 878-883.	8.6	46
488	GLP-1 receptor agonist as treatment for cancer as well as diabetes: beyond blood glucose control. Expert Review of Endocrinology and Metabolism, 2016, 11, 1-8.	2.4	5
489	Glucose, cholesterol, and blood pressure: is lower always better for type 2 diabetes?. Endocrine, 2016, 54, 32-37.	2.3	1
490	Baseline ALT levels as a marker of glycemic response to treatment with GLP-1 receptor agonists. Endocrinología Y Nutrición (English Edition), 2016, 63, 164-170.	0.5	5

#	ARTICLE	IF	CITATIONS
491	IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes. Primary Care Diabetes, 2016, 10, 202-209.	1.8	15
492	Linagliptin and pioglitazone combination therapy versus monotherapy with linagliptin or pioglitazone: A randomised, double-blind, parallel-group, multinational clinical trial. Diabetes and Vascular Disease Research, 2016, 13, 286-298.	2.0	5
493	Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial. Diabetology and Metabolic Syndrome, 2016, 8, 15.	2.7	11
494	Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases. Reviews in the Neurosciences, 2016, 27, 689-711.	2.9	27
495	Optimizing management of glycaemia. Best Practice and Research in Clinical Endocrinology and Metabolism, 2016, 30, 397-411.	4.7	10
496	A patient-centric approach to optimise insulin therapy in Asia. Journal of Diabetes and Its Complications, 2016, 30, 973-980.	2.3	1
497	Clinical Update: Cardiovascular Disease in Diabetes Mellitus. Circulation, 2016, 133, 2459-2502.	1.6	766
498	SGLT2 inhibitors in the management of type 2 diabetes. Endocrine, 2016, 53, 364-372.	2.3	64
499	Detecting people at high risk of type 2 diabetes- How do we find them and who should be treated?. Best Practice and Research in Clinical Endocrinology and Metabolism, 2016, 30, 345-355.	4.7	23
500	Optimising the person-centred management of type 2 diabetes. British Journal of Nursing, 2016, 25, 535-538.	0.7	2
501	Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovascular Diabetology, 2016, 15, 37.	6.8	148
502	Precision Medicine in Diabetes: Is It Time?. Diabetes Care, 2016, 39, 1085-1088.	8.6	42
503	Assessing Risks of Glucose Lowering Therapy in Heart Failure: Should We Rely on Post-hoc Analyses?. Current Cardiovascular Risk Reports, 2016, 10, 1.	2.0	0
504	Impact of sub-gastrectomy on glucose regulation in gastric cancer patients with T2DM: a follow-up study. International Journal of Diabetes in Developing Countries, 2016, 36, 89-94.	0.8	2
505	Serum leptin level is associated with glycaemic control in newly diagnosed type 2 diabetes patients: A 1-year cohort study. Diabetes and Metabolism, 2016, 42, 457-461.	2.9	5
506	Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review. Diabetes Therapy, 2016, 7, 411-438.	2.5	66
507	2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology, 2016, 23, NP1-NP96.	1.8	683
508	Do Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A 1c Targets?. Diabetes Care, 2016, 39, e145-e146.	8.6	6

#	ARTICLE	IF	CITATIONS
509	Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in people with Type 2 diabetes. <i>Diabetic Medicine</i> , 2016, 33, 926-933.	2.3	7
510	Effectiveness of insulin therapy in people with Type 2 diabetes in the Hoorn Diabetes Care System. <i>Diabetic Medicine</i> , 2016, 33, 794-802.	2.3	9
511	Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 571-580.	4.4	71
512	Metabolic memory and all-cause death in community-based patients with type 2 diabetes: the Fremantle Diabetes Study. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 598-606.	4.4	19
513	Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 755-765.	4.4	26
514	Treatment intensification for patients with type 2 diabetes and poor glycaemic control. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 892-898.	4.4	41
515	Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes. <i>Diabetes Care</i> , 2016, 39, 353-362.	8.6	105
516	Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52-week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. <i>Diabetologia</i> , 2016, 59, 266-274.	6.3	85
517	Patient/disease features and glycemic targets in type 2 diabetes: Where do we stand?. <i>Acta Diabetologica</i> , 2016, 53, 673-675.	2.5	0
518	Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation. <i>Pharmacogenomics Journal</i> , 2016, 16, 209-219.	2.0	24
519	A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever. <i>Hospital Practice (1995)</i> , 2016, 44, 9-20.	1.0	1
520	Glycemic excursions are positively associated with changes in duration of asymptomatic hypoglycemia after treatment intensification in patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2016, 113, 108-115.	2.8	15
521	Future glucose-lowering drugs for type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 350-359.	11.4	80
522	Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience. <i>Drugs</i> , 2016, 76, 41-74.	10.9	33
523	3. Foundations of Care and Comprehensive Medical Evaluation. <i>Diabetes Care</i> , 2016, 39, S23-S35.	8.6	144
524	Predictors of glycemic control and diabetes-related costs among type 2 diabetes patients initiating therapy with liraglutide in the United States. <i>Journal of Medical Economics</i> , 2016, 19, 403-413.	2.1	10
525	Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation. <i>Diabetes Research and Clinical Practice</i> , 2016, 112, 50-56.	2.8	11
526	Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 105-115.	1.8	10

#	ARTICLE	IF	CITATIONS
527	Metformin inhibits prostate cancer cell proliferation, migration, and tumor growth through upregulation of PEDF expression. <i>Cancer Biology and Therapy</i> , 2016, 17, 507-514.	3.4	47
528	Diabetes Care After Transplant. <i>Medical Clinics of North America</i> , 2016, 100, 535-550.	2.5	39
529	Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes. <i>Postgraduate Medicine</i> , 2016, 128, 409-417.	2.0	34
530	Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin. <i>Diabetes Therapy</i> , 2016, 7, 269-278.	2.5	14
531	Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2016, 17, 91-101.	5.7	22
532	Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study. <i>Annals of Medicine</i> , 2016, 48, 224-234.	3.8	36
534	Avant-propos: ItinÃ©aire des stratÃ©gies thÃ©rapeutiques du diabÃ©te de type 2. <i>Medecine Des Maladies Metaboliques</i> , 2016, 10, 97-100.	0.1	1
535	Metformin Revisited. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 113-114.	4.4	2
536	Cost-effectiveness of continuous subcutaneous insulin infusion in people with type 2 diabetes in the Netherlands. <i>Journal of Medical Economics</i> , 2016, 19, 742-749.	2.1	16
538	Ã©cchec des antidiabÃ©tiques oraux Ã doses maximales tolÃ©rÃ©es : Quels traitements injectables?. <i>Medecine Des Maladies Metaboliques</i> , 2016, 10, 121-130.	0.1	4
540	Conclusion : Comment Ã©quilibrer les buts et besoins thÃ©rapeutiques des soignants et des soignÃ©s ?. <i>Medecine Des Maladies Metaboliques</i> , 2016, 10, 140-146.	0.1	2
541	Efficacy and safety assessment of basal supported oral therapy (BOT) with insulin glargine in a real-life clinical setting, stratified by concomitant orally administered antidiabetic agent (OAD) regimens including dipeptidyl peptidase-4 inhibitor (DPP-4i): subanalysis of the ALOHA2 study, drug-use surveillance in Japan. <i>Diabetology International</i> , 2016, 7, 299-307.	1.4	4
542	La metformine revisitÃ©e et consolidÃ©e en 2016 : un point de vue consensuel de lâ€™Afrique Ã lâ€™Europe. <i>Medecine Des Maladies Metaboliques</i> , 2016, 10, 151-154.	0.1	2
543	Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes. <i>Postgraduate Medicine</i> , 2016, 128, 398-408.	2.0	2
544	The diabetic foot in 2015: an overview. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 169-178.	4.0	88
545	Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. <i>Postgraduate Medicine</i> , 2016, 128, 371-380.	2.0	55
546	The past, present, and future of basal insulins. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 478-496.	4.0	63
547	Clinical and Economic Outcomes Associated With the Timing of Initiation of Basal Insulin in Patients With Type 2 Diabetes Mellitus Previously Treated With Oral Antidiabetes Drugs. <i>Clinical Therapeutics</i> , 2016, 38, 110-121.	2.5	10

#	ARTICLE	IF	CITATIONS
548	Glycaemic control and cardiovascular risk factor management in patients with diabetes with and without coronary artery disease: insights from the diabetes mellitus status in Canada survey. European Heart Journal Quality of Care & Clinical Outcomes, 2016, 2, 277-284.	4.0	14
549	Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes, Obesity and Metabolism, 2016, 18, 203-216.	4.4	322
550	Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes. Journal of General Internal Medicine, 2016, 31, 638-646.	2.6	5
551	Combination therapy of SGLT2 inhibitors with incretin-based therapies for the treatment of type 2 diabetes mellitus: Effects and mechanisms of action. Expert Review of Endocrinology and Metabolism, 2016, 11, 281-296.	2.4	0
552	Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes. Diabetes Therapy, 2016, 7, 45-60.	2.5	116
553	Bariatric Surgery in Obese Patients with Type 1 Diabetes: Effects on Weight Loss and Metabolic Control. Obesity Surgery, 2016, 26, 2370-2378.	2.1	20
554	Dulaglutide (LY-2189265) for the treatment of type 2 diabetes. Expert Review of Clinical Pharmacology, 2016, 9, 385-399.	3.1	20
555	Investigational insulin secretagogues for type 2 diabetes. Expert Opinion on Investigational Drugs, 2016, 25, 405-422.	4.1	37
556	Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ, The, 2016, 352, i610.	6.0	183
557	Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis. European Journal of Clinical Pharmacology, 2016, 72, 655-663.	1.9	23
558	Will delayed release metformin provide better management of diabetes type 2?. Expert Opinion on Pharmacotherapy, 2016, 17, 627-630.	1.8	12
559	Management of Diabetes in Long-term Care and Skilled Nursing Facilities: A Position Statement of the American Diabetes Association. Diabetes Care, 2016, 39, 308-318.	8.6	172
561	Insulin glargine versus insulin degludec in patients failing on oral therapy in type 2 diabetes: A retrospective real world comparative data from India. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2016, 10, 161-165.	3.6	7
562	Comparative effectiveness of sodium-glucose co-transporter 2 inhibitors for controlling hyperglycaemia in patients with type 2 diabetes: protocol for a systematic review and network meta-analysis: Table A1. BMJ Open, 2016, 6, e010252.	1.9	8
563	Insulin Glargine 300ÂU/mL: A Review in Diabetes Mellitus. Drugs, 2016, 76, 363-374.	10.9	29
564	Association Between Severe Hypoglycemia and Cardiovascular Disease Risk in Japanese Patients With Type 2 Diabetes. Journal of the American Heart Association, 2016, 5, e002875.	3.7	51
565	Diabetology and oncology meet in a network model: union is strength. Acta Diabetologica, 2016, 53, 515-524.	2.5	20
566	Impact of frailty in older patients with diabetes mellitus: An overview. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2016, 63, 291-303.	0.8	29

#	ARTICLE	IF	CITATIONS
567	Safety and efficacy of insulin glargine 300â€¦u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis. <i>BMJ Open</i> , 2016, 6, e009421.	1.9	53
568	A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2016, 7, 27-43.	2.5	37
569	Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus White patients with type 2 diabetes mellitus: A pooled analysis. <i>Diabetes Research and Clinical Practice</i> , 2016, 114, 160-172.	2.8	14
570	Shared decision making in endocrinology: present and future directions. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 706-716.	11.4	92
571	Insulin glargine 300 units/mL: A new basal insulin product for diabetes mellitus. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 359-366.	1.0	12
572	Attributes Influencing Insulin Pen Preference Among Caregivers and Patients With Diabetes Who Require Greater Than 20 Units of Mealtime Insulin. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 923-931.	2.2	15
573	Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 898.	7.4	181
574	Premixed insulin regimens for type 2 diabetes. <i>Endocrine</i> , 2016, 51, 387-389.	2.3	2
575	Utilization of a Cloud-Based Diabetes Management Program for Insulin Initiation and Titration Enables Collaborative Decision Making Between Healthcare Providers and Patients. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 59-67.	4.4	111
576	Novel Therapeutic Approaches in Diabetes. <i>Endocrine Development</i> , 2016, 31, 43-56.	1.3	15
577	Practical considerations for the use of sodiumâ€¦glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2016, 32, 1097-1108.	1.9	14
578	Hypoglycemia and diabetes: increased need for awareness. <i>Current Medical Research and Opinion</i> , 2016, 32, 1479-1486.	1.9	18
579	Niveles de ALT y respuesta hipoglucemiante al tratamiento con agonistas del receptor de GLP-1. <i>Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion</i> , 2016, 63, 164-170.	0.8	6
580	Fed and Fasted Single-dose Assessment of Bioequivalence of Dapagliflozin and Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects. <i>Clinical Therapeutics</i> , 2016, 38, 99-109.	2.5	11
581	Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin: rationale and evidences. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 605-616.	3.1	3
582	5. Glycemic Targets. <i>Diabetes Care</i> , 2016, 39, S39-S46.	8.6	222
583	Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 59-64.	2.5	12
584	Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea. <i>Current Medical Research and Opinion</i> , 2016, 32, 807-816.	1.9	32

#	ARTICLE	IF	CITATIONS
585	Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US. <i>Current Medical Research and Opinion</i> , 2016, 32, 669-680.	1.9	38
586	Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 157-166.	3.6	356
587	7. Approaches to Glycemic Treatment. <i>Diabetes Care</i> , 2016, 39, S52-S59.	8.6	226
588	Cardiovascular risk and fitness in veteran football players. <i>Journal of Sports Sciences</i> , 2016, 34, 576-583.	2.0	3
589	Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies. <i>Diabetes Care</i> , 2016, 39, 486-494.	8.6	56
590	Combination therapy for type 2 diabetes: dapagliflozin plus metformin. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 117-126.	1.8	19
591	Effect of canagliflozin on liver function tests in patients with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2016, 42, 25-32.	2.9	107
592	Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 229-240.	3.1	8
593	Explaining psychological insulin resistance in adults with non-insulin-treated type 2 diabetes: The roles of diabetes distress and current medication concerns. Results from Diabetes MILES [®] Australia. <i>Primary Care Diabetes</i> , 2016, 10, 75-82.	1.8	18
594	An overview of new GLP-1 receptor agonists for type 2 diabetes. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 145-158.	4.1	41
595	Metabolic syndrome update. <i>Trends in Cardiovascular Medicine</i> , 2016, 26, 364-373.	4.9	576
596	The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin. <i>Postgraduate Medicine</i> , 2016, 128, 137-144.	2.0	9
597	Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis. <i>Canadian Journal of Diabetes</i> , 2016, 40, 50-57.	0.8	27
598	Canagliflozin treatment of Hispanic and non-Hispanic patients with type 2 diabetes in a US managed care setting. <i>Current Medical Research and Opinion</i> , 2016, 32, 13-22.	1.9	9
599	Therapeutic Concentrations of Metformin: A Systematic Review. <i>Clinical Pharmacokinetics</i> , 2016, 55, 439-459.	3.5	120
600	SGLT2 inhibitors. <i>Biochemical Pharmacology</i> , 2016, 101, 27-39.	4.4	27
601	Once Daily Self-Monitoring of Blood Glucose (SMBG) Improves Glycemic Control in Oral Hypoglycemic Agents (OHA)-Treated Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 378-382.	2.2	8
602	Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. <i>Quality of Life Research</i> , 2016, 25, 1199-1207.	3.1	5

#	ARTICLE	IF	CITATIONS
604	Evaluation and management of diabetic and non-diabetic hypoglycemia in end-stage renal disease. Nephrology Dialysis Transplantation, 2016, 31, 8-15.	0.7	32
605	Effects of diabetes drugs on the skeleton. Bone, 2016, 82, 93-100.	2.9	130
606	Effect of meal composition on postprandial glucagon-like peptide-1, insulin, glucagon, C-peptide, and glucose responses in overweight/obese subjects. European Journal of Nutrition, 2017, 56, 1053-1062.	3.9	17
607	Glycemic excursions are positively associated with HbA1c reduction from baseline after treatment with acarbose in patients with type 2 diabetes on metformin monotherapy. Journal of Diabetes, 2017, 9, 248-255.	1.8	3
608	Impact and Feasibility of Personalized Decision Support for Older Patients with Diabetes: A Pilot Randomized Trial. Medical Decision Making, 2017, 37, 611-617.	2.4	13
609	A comparison of the clinical usefulness of neck circumference and waist circumference in individuals with severe obesity. Endocrine Research, 2017, 42, 6-14.	1.2	44
610	Examining factors associated with excess mortality in older people (age ≥ 70 years) with diabetes: a 10-year cohort study of older people with and without diabetes. Diabetic Medicine, 2017, 34, 387-395.	2.3	15
611	Evolución y grado de control de los factores de riesgo cardiovascular tras 5 años de seguimiento y su relación con la incidencia de arteriopatía periférica: cohorte poblacional ARTPER. Medicina Clínica, 2017, 148, 107-113.	0.6	4
612	Comparison of the diabetes guidelines from the ADA/EASD and the AACE/ACE. Journal of the American Pharmacists Association: JAPhA, 2017, 57, 261-265.	1.5	33
613	Exploring the characteristics of suboptimally controlled patients after 24 weeks of basal insulin treatment: An individualized approach to intensification. Diabetes Research and Clinical Practice, 2017, 123, 209-217.	2.8	7
614	Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden. Applied Health Economics and Health Policy, 2017, 15, 237-248.	2.1	26
616	Special Considerations in Choosing Diabetes Therapy. Physician Assistant Clinics, 2017, 2, 39-52.	0.1	0
617	Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy. Diabetes Research and Clinical Practice, 2017, 124, 57-65.	2.8	33
618	Addition of once daily prandial lixisenatide to basal insulin therapy in patients with type-2 diabetes results in a reduction of HbA1c as an effect of postprandial glucose lowering. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2017, 11, S91-S97.	3.6	4
620	Changes in the management of type 2 diabetic patients in family medicine practices in the Bursa region. Primary Care Diabetes, 2017, 11, 178-183.	1.8	2
621	Attitudes of patients and physicians to insulin therapy in Japan: an analysis of the Global Attitude of Patients and Physicians in Insulin Therapy study. Expert Opinion on Pharmacotherapy, 2017, 18, 5-11.	1.8	14
622	The effects of liraglutide in mice with diet-induced obesity studied by metabolomics. Journal of Endocrinology, 2017, 233, 93-104.	2.6	23
623	Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study. Diabetes Therapy, 2017, 8, 321-334.	2.5	28

#	ARTICLE	IF	CITATIONS
624	A diabetes mellitus guideline gone wrong – the 2017 ACP update. <i>Nature Reviews Endocrinology</i> , 2017, 13, 191-192.	9.6	2
625	Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 387-396.	2.4	16
626	Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2017, 16, 18.	6.8	43
627	Basal insulin treatment intensification in patients with type 2 diabetes mellitus: A comprehensive systematic review of current options. <i>Diabetes and Metabolism</i> , 2017, 43, 110-124.	2.9	9
628	Efficacy and safety of fixed-dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: A phase 3 trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 754-758.	4.4	16
629	Sitagliptin: A Review in Type 2 Diabetes. <i>Drugs</i> , 2017, 77, 209-224.	10.9	83
630	Exenatide: pharmacokinetics, clinical use, and future directions. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 555-571.	1.8	58
631	Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 251-260.	11.4	363
632	Metformin: New Preparations and Nonglycemic Benefits. <i>Current Diabetes Reports</i> , 2017, 17, 5.	4.2	67
633	Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 391-402.	11.4	56
634	Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes. <i>Postgraduate Medicine</i> , 2017, 129, 231-241.	2.0	7
635	Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 831-841.	4.4	75
636	Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 858-865.	4.4	58
637	Evaluation of a Premixed Insulin Analog Suspension in Japanese People with Type 2 Diabetes and the Clinical Importance of Improved Injection Techniques: A Cross-Sectional Pilot Study. <i>Diabetes Therapy</i> , 2017, 8, 445-449.	2.5	1
639	Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials. <i>Diabetes Research and Clinical Practice</i> , 2017, 126, 230-239.	2.8	22
640	No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 970-978.	4.4	17
641	Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: THE DURATION-NEO randomized clinical study. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 979-988.	4.4	38
642	Delays in treatment intensification with oral antidiabetic drugs and risk of microvascular and macrovascular events in patients with poor glycaemic control: An individual patient simulation study. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1006-1013.	4.4	12

#	ARTICLE	IF	CITATIONS
643	Adaptación española de las guías europeas de 2016 sobre prevención de la enfermedad cardiovascular en la práctica clínica. Clínica E Investigación En Arteriosclerosis, 2017, 29, 69-85.	0.8	7
644	The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy. Advances in Therapy, 2017, 34, 638-657.	2.9	3
645	Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus. Diabetes Therapy, 2017, 8, 275-291.	2.5	26
646	Consensus recommendations on exploring effective solutions for the rising cost of diabetes. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2017, 11, 141-147.	3.6	9
647	Evaluating drug cost per responder and number needed to treat associated with lixisenatide on top of glargine when compared to rapid-acting insulin intensification regimens on top of glargine, in patients with type 2 diabetes in the UK, Italy, and Spain. Journal of Medical Economics, 2017, 20, 633-639.	2.1	8
648	The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes. Current Medical Research and Opinion, 2017, 33, 1045-1055.	1.9	9
649	A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges. Diabetes Technology and Therapeutics, 2017, 19, 255-264.	4.4	24
650	Hydrothermal Duodenal Mucosal Resurfacing. Gastrointestinal Endoscopy Clinics of North America, 2017, 27, 299-311.	1.4	34
651	Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: <sc>A</sc> retrospective cohort study. Diabetes, Obesity and Metabolism, 2017, 19, 1097-1105.	4.4	2
652	Predictors of insulin uptake among adults with type 2 diabetes in the Stepping Up Study. Diabetes Research and Clinical Practice, 2017, 133, 204-210.	2.8	8
653	Combining the <sc>G</sc>-protein-coupled receptor 40 agonist faspiglitam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: <sc>A</sc> randomized, 12-week trial. Diabetes, Obesity and Metabolism, 2017, 19, 1127-1134.	4.4	10
654	Review of insulin-associated hypoglycemia and its impact on the management of diabetes in Southeast Asian countries. Journal of Diabetes Investigation, 2017, 8, 635-645.	2.4	14
655	Management of Type 2 Diabetes in 2017. JAMA - Journal of the American Medical Association, 2017, 317, 1015.	7.4	118
656	Antidiabetic effect of SN158 through PPAR α/β dual activation in ob / ob mice. Chemico-Biological Interactions, 2017, 268, 24-30.	4.0	8
657	Rapid Discovery of Potent and Selective Glycosidase-Inhibiting De Novo Peptides. Cell Chemical Biology, 2017, 24, 381-390.	5.2	46
658	Insulin glargine 300 units/mL: a guide for healthcare professionals involved in the management of diabetes. Current Medical Research and Opinion, 2017, 33, 785-793.	1.9	3
659	Association of DPP-4 activity with BMD, body composition, and incident hip fracture: the Cardiovascular Health Study. Osteoporosis International, 2017, 28, 1631-1640.	3.1	12
660	Change in HbA1c associated with treatment intensification among patients with type 2 diabetes and poor glycemic control. Current Medical Research and Opinion, 2017, 33, 853-858.	1.9	15

#	ARTICLE	IF	CITATIONS
661	Bile acid sequestrants for glycemic control in patients with type 2 diabetes: A systematic review with meta-analysis of randomized controlled trials. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 918-927.	2.3	72
662	Retrospective Study on the Impact of Adherence in Achieving Glycemic Goals in Type 2 Diabetes Mellitus Patients Receiving Canagliflozin. <i>Advances in Therapy</i> , 2017, 34, 937-953.	2.9	13
663	Dulaglutide for the treatment of type 2 diabetes. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 485-496.	3.1	30
664	Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 953-961.	4.4	87
665	Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial. <i>Diabetes Care</i> , 2017, 40, 485-493.	8.6	26
666	Association of dipeptidyl peptidase 4 inhibitors with risk of metastases in patients with type 2 diabetes and breast, prostate or digestive system cancer. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 687-692.	2.3	19
667	Therapeutics for Equine Endocrine Disorders. <i>Veterinary Clinics of North America Equine Practice</i> , 2017, 33, 127-139.	0.7	24
668	Persistence with rapid-acting insulin and its association with A1C level and severe hypoglycemia among elderly patients with type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2017, 33, 1309-1316.	1.9	6
669	“Knowing what Matters in diabetes: Healthier below 7 th ™: results of the campaign’s first 10 years (part 2), participants without known diabetes history. <i>Cardiovascular Endocrinology</i> , 2017, 6, 48-54.	0.8	3
671	Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States. <i>Current Medical Research and Opinion</i> , 2017, 33, 1317-1328.	1.9	21
672	Translating U-500R Randomized Clinical Trial Evidence to the Practice Setting: A Diabetes Educator/Expert Prescriber Team Approach. <i>The Diabetes Educator</i> , 2017, 43, 311-323.	2.5	4
673	Use of GLP-1 receptor agonists for type 2 diabetes treatment intensification after basal insulin failure. <i>Diabetes and Metabolism</i> , 2017, 43, 2S34-2S38.	2.9	0
674	Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1587-1593.	4.4	24
675	Evaluating new HbA1c methods for adoption by the IFCC and NGSP reference networks using international quality targets. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 1426-1434.	2.3	26
676	Hypoglycemic and Hypolipidemic Effects of Leucine, Zinc, and Chromium, Alone and in Combination, in Rats with Type 2 Diabetes. <i>Biological Trace Element Research</i> , 2017, 180, 246-254.	3.5	25
677	Implantable batteryless device for on-demand and pulsatile insulin administration. <i>Nature Communications</i> , 2017, 8, 15032.	12.8	37
678	Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease. <i>Diabetes</i> , 2017, 66, 2310-2315.	0.6	20
679	Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1391-1401.	3.5	34

#	ARTICLE	IF	CITATIONS
680	Diabetes Mellitus Treatment Deintensification. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	2.2	3
681	Real-world Clinical Outcomes Among Patients With Type 2 Diabetes Receiving Canagliflozin at a Specialty Diabetes Clinic: Subgroup Analysis by Baseline HbA 1c and Age. <i>Clinical Therapeutics</i> , 2017, 39, 1123-1131.	2.5	11
682	Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial. <i>Diabetes Care</i> , 2017, 40, 951-957.	8.6	102
683	LX2761, a Sodium/Glucose Cotransporter 1 Inhibitor Restricted to the Intestine, Improves Glycemic Control in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 362, 85-97.	2.5	25
684	GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries. <i>Diabetes Therapy</i> , 2017, 8, 115-128.	2.5	30
685	Risks of Metformin in Type 2 Diabetes and Chronic Kidney Disease: Lessons Learned from Taiwanese Data. <i>Nephron</i> , 2017, 135, 147-153.	1.8	23
686	Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 315-322.	4.4	3
687	Gaps and barriers in the control of blood glucose in people with type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2017, 14, 172-183.	2.0	102
688	A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1645-1654.	4.4	24
689	Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 843-851.	1.8	19
690	Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1546-1554.	4.4	8
691	Diabetes type 2 management: what are the differences between DPP-4 inhibitors and how do you choose?. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 839-841.	1.8	12
692	Impact on Diabetes Self-Management and Glycemic Control of a New Color-Based SMBG Meter. <i>Journal of Diabetes Science and Technology</i> , 2017, 11, 1218-1225.	2.2	16
693	Increased healthcare utilization costs following initiation of insulin treatment in type 2 diabetes: A long-term follow-up in clinical practice. <i>Primary Care Diabetes</i> , 2017, 11, 184-192.	1.8	6
694	Prescription of oral antidiabetic drugs in Tyrol – Data from the Tyrol diabetes registry 2012–2015. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 46-51.	1.9	9
695	Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial. <i>Diabetes Care</i> , 2017, 40, 201-209.	8.6	92
696	Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 282-302.	1.3	183
697	Which Patients Will Benefit from a Switch in Therapy from Premixed Insulin to Insulin Glargine plus Oral Antidiabetic Drugs? Further Analysis of the Lantus Registry Study. <i>Diabetes Therapy</i> , 2017, 8, 887-898.	2.5	2

#	ARTICLE	IF	CITATIONS
699	Features of glycemic variations in drug naïve type 2 diabetic patients with different HbA1c values. Scientific Reports, 2017, 7, 1583.	3.3	11
701	Cardiovascular events associated with secondâ€line antiâ€diabetes treatments: analysis of realâ€world Korean data. Diabetic Medicine, 2017, 34, 1235-1243.	2.3	11
702	Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus. International Journal of Clinical Practice, 2017, 71, e12948.	1.7	20
703	Academy of Nutrition and Dietetics Nutrition Practice Guideline for Type 1 and Type 2 Diabetes in Adults: Systematic Review of Evidence for Medical Nutrition Therapy Effectiveness and Recommendations for Integration into the Nutrition Care Process. Journal of the Academy of Nutrition and Dietetics, 2017, 117, 1659-1679.	0.8	206
705	Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide. Clinical Therapeutics, 2017, 39, 1347-1359.	2.5	17
706	Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3621-3634.	3.6	136
707	Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized <scp>MARLINA</scp>â€<scp>T2D</scp> trial. Diabetes, Obesity and Metabolism, 2017, 19, 1610-1619.	4.4	119
708	Review of basalâ€plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. Diabetic Medicine, 2017, 34, 1193-1204.	2.3	15
709	The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100ÂU/mL. Cardiovascular Diabetology, 2017, 16, 66.	6.8	9
710	The Role of SGLT-2 Inhibitors as Part of Optimal Medical Therapy in Improving Cardiovascular Outcomes in Patients with Diabetes and Coronary Artery Disease. Cardiovascular Drugs and Therapy, 2017, 31, 311-318.	2.6	12
711	Assessing Psychological Insulin Resistance in Type 2 Diabetes: a Critical Comparison of Measures. Current Diabetes Reports, 2017, 17, 46.	4.2	11
713	A behavioral sensing system that promotes positive lifestyle changes and improves metabolic control among adults with type 2 diabetes. , 2017, , .		4
714	Long-Standing Problem of Î²-Blockerâ€Elicited Hypoglycemia in Diabetes Mellitus. Hypertension, 2017, 70, 42-43.	2.7	14
715	Is diabetes self-management education still the Cinderella of diabetes care?. Patient Education and Counseling, 2017, 100, 1957-1960.	2.2	14
716	Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies. American Journal of Medicine, 2017, 130, S4-S17.	1.5	83
717	â€Treatment-resistantâ€™ type 2 diabetes: Which definition for clinical practice?. Diabetes and Metabolism, 2017, 43, 295-297.	2.9	4
718	Effect of anti-diabetic drugs on bone metabolism: Evidence from preclinical and clinical studies. Pharmacological Reports, 2017, 69, 1328-1340.	3.3	49
719	A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion, 2017, 33, 1853-1860.	1.9	10

#	ARTICLE	IF	CITATIONS
720	Synthesis and pharmacological evaluation of glycine amide derivatives as novel vascular adhesion protein-1 inhibitors without CYP3A4 and CYP2C19 inhibition. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 4110-4122.	3.0	8
721	Practical Recommendations for Transitioning Patients with Type 2 Diabetes from Hospital to Home. <i>Current Diabetes Reports</i> , 2017, 17, 52.	4.2	27
722	Dulce Digital: An mHealth SMS-Based Intervention Improves Glycemic Control in Hispanics With Type 2 Diabetes. <i>Diabetes Care</i> , 2017, 40, 1349-1355.	8.6	118
723	Metformin: clinical topics and new mechanisms of action. <i>Diabetology International</i> , 2017, 8, 4-6.	1.4	8
724	Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors. <i>BMC Endocrine Disorders</i> , 2017, 17, 32.	2.2	4
725	Mining the Genome for Therapeutic Targets. <i>Diabetes</i> , 2017, 66, 1770-1778.	0.6	14
726	Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies. <i>American Journal of Cardiology</i> , 2017, 120, S4-S16.	1.6	60
727	Extending Metformin Use in Diabetic Kidney Disease: A Pharmacokinetic Study in Stage 4 Diabetic Nephropathy. <i>Kidney International Reports</i> , 2017, 2, 705-712.	0.8	21
729	Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 341-354.	11.4	307
730	Diabetes medication pharmacology. <i>BJA Education</i> , 2017, 17, 198-207.	1.4	9
731	Considerations on glycaemic control in older and/or frail individuals with diabetes and advanced kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 591-597.	0.7	6
732	Evidence-based recommendations for insulin intensification strategies after basal insulin in type 2 diabetes. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2017, 11, S507-S521.	3.6	3
733	Evolution and degree of control of cardiovascular risk factors after 5 years of follow-up and their relationship with the incidence of peripheral arterial disease: ARTPER cohort. <i>Medicina Clínica (English Edition)</i> , 2017, 148, 107-113.	0.2	2
734	SGLT2 inhibitor/DPP-4 inhibitor combination therapy – complementary mechanisms of action for management of type 2 diabetes mellitus. <i>Postgraduate Medicine</i> , 2017, 129, 409-420.	2.0	30
735	Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naïve patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 355-366.	11.4	288
736	Effectiveness of chronic care models for the management of type 2 diabetes mellitus in Europe: a systematic review and meta-analysis. <i>BMJ Open</i> , 2017, 7, e013076.	1.9	45
737	Renal function preservation with pioglitazone or with basal insulin as an add-on therapy for patients with type 2 diabetes mellitus. <i>Acta Diabetologica</i> , 2017, 54, 561-568.	2.5	10
738	Mobile health (m-Health) for diabetes management. <i>British Journal of Health Care Management</i> , 2017, 23, 102-108.	0.2	6

#	ARTICLE	IF	CITATIONS
739	Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates. <i>Current Medical Research and Opinion</i> , 2017, 33, 1155-1163.	1.9	4
740	Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 545-549.	1.8	4
741	Factors associated with improved glycemic control following continuous subcutaneous insulin infusion therapy in patients with type 2 diabetes uncontrolled with bolus+basal insulin regimens: a analysis from the OpT2mise randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1490-1494.	4.4	8
742	Insulin initiation for type 2 diabetes mellitus in primary care. <i>Nature Reviews Endocrinology</i> , 2017, 13, 317-318.	9.6	0
743	The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study. <i>Diabetes and Vascular Disease Research</i> , 2017, 14, 295-303.	2.0	12
744	Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data. <i>Cardiovascular Diabetology</i> , 2017, 16, 40.	6.8	19
745	Cardiovascular Outcome Trials of the Incretin-Based Therapies: What Do We Know So Far?. <i>Endocrine Practice</i> , 2017, 23, 89-99.	2.1	10
746	Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom. <i>Diabetes Therapy</i> , 2017, 8, 335-353.	2.5	25
747	Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: a randomized, 18-week, open-label, phase 3 trial (onset 3). <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1389-1396.	4.4	40
748	Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK. <i>Diabetes Therapy</i> , 2017, 8, 513-530.	2.5	18
749	The use of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and hypertension: a focus on African-American populations. <i>Postgraduate Medicine</i> , 2017, 129, 421-429.	2.0	2
750	Improving glycaemic control in type 2 diabetes: stimulate insulin secretion or provide beta-cell rest?. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1205-1213.	4.4	54
752	Pharmacologic Therapy for Type 2 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes. <i>Annals of Internal Medicine</i> , 2017, 166, 572.	3.9	92
753	Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?. <i>Current Diabetes Reports</i> , 2017, 17, 21.	4.2	33
754	Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis. <i>Postgraduate Medicine</i> , 2017, 129, 436-445.	2.0	23
755	Cardiovascular inflammation is reduced with methotrexate in diabetes. <i>Molecular and Cellular Biochemistry</i> , 2017, 432, 159-167.	3.1	14
756	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>International Journal of Behavioral Medicine</i> , 2017, 24, 321-419.	1.7	84
757	A Large Difference in Dose Timing of Basal Insulin Introduces Risk of Hypoglycemia and Overweight: A Cross-Sectional Study. <i>Diabetes Therapy</i> , 2017, 8, 385-399.	2.5	6

#	ARTICLE	IF	CITATIONS
758	Diabetes Self-Management Education and Medical Nutrition Therapy Improve Patient Outcomes: A Pilot Study Documenting the Efficacy of Registered Dietitian Nutritionist Interventions through Retrospective Chart Review. Journal of the Academy of Nutrition and Dietetics, 2017, 117, 1254-1264.	0.8	29
759	Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care, 2017, 40, 614-624.	8.6	97
760	Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials. Scientific Reports, 2017, 7, 44865.	3.3	28
761	Exenatide Add-on to Continuous Subcutaneous Insulin Infusion Therapy Reduces Bolus Insulin Doses in Patients with Type 2 Diabetes: A Randomized, Controlled, Open-Label Trial. Diabetes Therapy, 2017, 8, 177-187.	2.5	14
762	Efficacy and safety of linagliptin/metformin single-pill combination as initial therapy in drug-naïve Asian patients with type 2 diabetes. Diabetes Research and Clinical Practice, 2017, 124, 48-56.	2.8	13
763	Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia. Diabetes Research and Clinical Practice, 2017, 123, 199-208.	2.8	44
765	Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes. Diabetes Care, 2017, 40, 832-838.	8.6	262
766	The economic impact of insulin-related hypoglycemia in Denmark: an analysis using the Local Impact of Hypoglycemia Tool. Journal of Medical Economics, 2017, 20, 363-370.	2.1	8
767	Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease. Annals of Internal Medicine, 2017, 166, 191.	3.9	215
768	Nutrition Therapy for the Prevention and Treatment of Prediabetes and Diabetes. , 2017, , 151-171.		0
769	Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide. Clinical Pharmacokinetics, 2017, 56, 719-731.	3.5	18
770	Behaviours, thoughts and perceptions around mealtime insulin usage and wastage among people with type 1 and type 2 diabetes mellitus: A cross-sectional survey study. Diabetes Research and Clinical Practice, 2017, 126, 30-42.	2.8	9
771	8. Pharmacologic Approaches to Glycemic Treatment. Diabetes Care, 2017, 40, S64-S74.	8.6	365
772	4. Lifestyle Management. Diabetes Care, 2017, 40, S33-S43.	8.6	253
773	Resolving the KgA1c paradox in the management of type 2 diabetes mellitus. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2017, 11, S159-S168.	3.6	0
774	The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial. Diabetes Therapy, 2017, 8, 101-114.	2.5	103
775	Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes, 2017, 66, 241-255.	0.6	454
776	Factors associated with reaching or not reaching target HbA1c after initiation of basal or premixed insulin in patients with type 2 diabetes. Diabetes and Metabolism, 2017, 43, 69-78.	2.9	8

#	ARTICLE	IF	CITATIONS
777	6. Glycemic Targets. Diabetes Care, 2017, 40, S48-S56.	8.6	305
778	Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase <sc>II</sc> and <sc>III</sc> studies. Diabetes, Obesity and Metabolism, 2017, 19, 429-435.	4.4	12
779	Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes. Clinical Diabetes, 2017, 35, 141-153.	2.2	1
780	Cost-Effectiveness of IDegLira Versus Insulin Intensification Regimens for the Treatment of Adults with Type 2 Diabetes in the Czech Republic. Diabetes Therapy, 2017, 8, 1331-1347.	2.5	10
781	Noninsulin Diabetes Medications. Nursing Clinics of North America, 2017, 52, 523-537.	1.5	7
783	Long-Term Effectiveness of Liraglutide in Association with Patientsâ€™ Baseline Characteristics in Real-Life Setting in Croatia: An Observational, Retrospective, Multicenter Study. Diabetes Therapy, 2017, 8, 1297-1308.	2.5	13
784	Pratique de lâ€™autosurveillance glycÃ©mique en France : donnÃ©es dâ€™une enquÃªte nationale. Medecine Des Maladies Metaboliques, 2017, 11, 458-467.	0.1	1
785	Incretins and Their Endocrine and Metabolic Functions. Endocrine Development, 2017, 32, 38-48.	1.3	5
786	Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes. Expert Review of Clinical Pharmacology, 2017, 10, 1303-1316.	3.1	6
787	Sitagliptin 100â€‰mg vs glimepiride 1â€‰3â€‰mg as an add-on to insulin and metformin in type 2 diabetes (SWIM). Endocrine Connections, 2017, 6, 748-757.	1.9	2
789	Synthesis and structure activity relationships of carbamimidoylcarbamate derivatives as novel vascular adhesion protein-1 inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 6024-6038.	3.0	3
790	Caring for older people with diabetes in primary care. International Diabetes Nursing, 2017, 14, 16-19.	0.1	0
791	Impact of improving postprandial glycemic control with intensifying insulin therapy in type 2 diabetes. Postgraduate Medicine, 2017, 129, 791-800.	2.0	6
792	Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c â‰¥10.0%: Two pooled analyses including 20 randomised controlled trials. International Journal of Clinical Practice, 2017, 71, e13029.	1.7	4
793	Predicting severe hypoglycaemia â€“ a step forward. Nature Reviews Endocrinology, 2017, 13, 692-693.	9.6	0
794	The effect of care intervention for obese patients with type II diabetes. Medicine (United States), 2017, 96, e7524.	1.0	13
795	Comparing Clinical Outcomes and Costs for Different Treatment Intensification Approaches in Patients with Type 2 Diabetes Uncontrolled On Basal Insulin: Adding Glucagon-Like Peptide 1 Receptor Agonists Versus Adding Rapid-Acting Insulin or Increasing Basal Insulin Dose. Endocrine Practice, 2017, 23, 1316-1324.	2.1	7
796	Lactate Levels with Chronic Metformin Use: A Narrative Review. Clinical Drug Investigation, 2017, 37, 991-1007.	2.2	16

#	ARTICLE	IF	CITATIONS
797	Safety evaluation of trelagliptin in the treatment of Japanese type 2 diabetes mellitus patients. Expert Opinion on Drug Safety, 2017, 16, 1313-1322.	2.4	10
798	Canagliflozin: A Review in Type 2 Diabetes. Drugs, 2017, 77, 1577-1592.	10.9	32
799	Rationale and design of the DARWIN-T2D (Dapagliflozin Real World evldeNce in Type 2 Diabetes). Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 1089-1097.	2.6	26
800	Hypoglycemia awareness among insulin-treated patients with diabetes in Malaysia: A cohort subanalysis of the HAT study. Diabetes Research and Clinical Practice, 2017, 133, 40-49.	2.8	15
801	Relation Between Different Measures of Glycemic Exposure and Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes Mellitus: An Observational Cohort Study. Diabetes Therapy, 2017, 8, 1097-1109.	2.5	34
802	Bolstering your armamentarium with SGLT2 inhibitors. Nurse Practitioner, 2017, 42, 28-34.	0.3	2
803	Improved Glycemic Control Achieved by Switching to Insulin Degludec in Insulin-Treated Patients with Type 2 Diabetes in a Real-World Setting: a Non-interventional, Retrospective Cohort Study. Diabetes Therapy, 2017, 8, 1047-1055.	2.5	7
804	Treatment of Diabetes and Obesity by Rationally Designed Peptide Agonists Functioning at Multiple Metabolic Receptors. Endocrine Development, 2017, 32, 165-182.	1.3	12
805	Antihyperglycemic Medications: A Claims-Based Estimate of First-line Therapy Use Prior to Initialization of Second-line Medications. Diabetes Care, 2017, 40, 1500-1505.	8.6	8
806	A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes. Expert Opinion on Drug Safety, 2017, 16, 1399-1405.	2.4	7
807	Marine collagen peptides reduce endothelial cell injury in diabetic rats by inhibiting apoptosis and the expression of coupling factor 6 and microparticles. Molecular Medicine Reports, 2017, 16, 3947-3957.	2.4	12
808	Incidence, Demographics, and Clinical Characteristics of Diabetes of the Exocrine Pancreas (Type 3c): A Retrospective Cohort Study. Diabetes Care, 2017, 40, 1486-1493.	8.6	198
809	Diabetes Management After Stroke. , 2017, , 271-283.		1
810	SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia, 2017, 60, 1862-1872.	6.3	134
811	Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGLarLixi, for the Management of Type 2 Diabetes. Diabetes Therapy, 2017, 8, 739-752.	2.5	29
813	Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm. Diabetes Care, 2017, 40, 1121-1127.	8.6	43
814	Is It Time to Change the Type 2 Diabetes Treatment Paradigm? No! Metformin Should Remain the Foundation Therapy for Type 2 Diabetes. Diabetes Care, 2017, 40, 1128-1132.	8.6	32
815	Complex interplay between metformin, AKI and lactic acidosis. Nature Reviews Nephrology, 2017, 13, 521-522.	9.6	16

#	ARTICLE	IF	CITATIONS
816	Initiating insulin: How to help people with type 2 diabetes start and continue insulin successfully. International Journal of Clinical Practice, 2017, 71, e12973.	1.7	29
817	Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes. Expert Opinion on Investigational Drugs, 2017, 26, 1083-1089.	4.1	23
818	Individualising treatment and care of patients with diabetes. The Prescriber, 2017, 28, 23-25.	0.3	2
819	Individualisation du traitement de l'hyperglycémie du diabète de type 2 : choix selon la classe thérapeutique, ou selon la molécule. Medecine Des Maladies Metaboliques, 2017, 11, 2S2-2S14.	0.1	0
820	L'électrostimulation musculaire : une alternative à l'activité physique conventionnelle pour les patients atteints de diabète de type 2 ?. Medecine Des Maladies Metaboliques, 2017, 11, 168-171.	0.1	0
822	Incidence and Trends in Hypoglycemia Hospitalization in Adults With Type 1 and Type 2 Diabetes in England, 1998-2013: A Retrospective Cohort Study. Diabetes Care, 2017, 40, 1651-1660.	8.6	49
823	The Use of Decomposition Methods in Real-World Treatment Benefits Evaluation for Patients with Type 2 Diabetes Initiating Different Injectable Therapies: Findings from the INITIATOR Study. Value in Health, 2017, 20, 1252-1259.	0.3	7
825	iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents. Current Medical Research and Opinion, 2017, 33, 2187-2194.	1.9	3
827	Short-term intensive insulin therapy could be the preferred option for new onset <sc>T</sc>ype 2 diabetes mellitus patients with <sc>HbA1c</sc> > 9%. Journal of Diabetes, 2017, 9, 890-893.	1.8	12
828	Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence. Obesity Science and Practice, 2017, 3, 342-351.	1.9	22
829	Experience of Home Telehealth Technology in Older Patients With Diabetes. CIN - Computers Informatics Nursing, 2017, 35, 530-537.	0.5	23
830	Hypoglycemia After Initiation of Basal Insulin in Patients with Type 2 Diabetes in the United States: Implications for Treatment Discontinuation and Healthcare Costs and Utilization. Advances in Therapy, 2017, 34, 2083-2092.	2.9	31
831	Treatment patterns and clinical characteristics of patients with type 2 diabetes mellitus according to body mass index: findings from an electronic medical records database. BMJ Open Diabetes Research and Care, 2017, 5, e000382.	2.8	20
832	A novel free fatty acid receptor 1 (<sc>GPR</sc>40/<sc>FFAR</sc>1) agonist, <sc>MR</sc>1704, enhances glucose-dependent insulin secretion and improves glucose homeostasis in rats. Pharmacology Research and Perspectives, 2017, 5, e00340.	2.4	13
833	New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin. Current Diabetes Reports, 2017, 17, 91.	4.2	13
834	Dipeptidyl peptidase-4 inhibitors and risk of arthralgia: A systematic review and meta-analysis. Diabetes and Metabolism, 2017, 43, 493-500.	2.9	28
835	Minimizing Glycemic Fluctuations in Patients with Type 2 Diabetes: Approaches and Importance. Diabetes Technology and Therapeutics, 2017, 19, 498-506.	4.4	48
836	Examining factors associated with nonadherence and identifying providers caring for nonadherent subgroups. Journal of Pharmaceutical Health Services Research, 2017, 8, 247-253.	0.6	7

#	ARTICLE	IF	CITATIONS
837	Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control. Diabetes Care, 2017, 40, 1425-1432.	8.6	213
838	Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes. Diabetes Care, 2017, 40, 1469-1478.	8.6	112
839	Risk Factors for Nocturnal Hypoglycemia in Insulin-treated Patients With Type 2 Diabetes: A Secondary Analysis of Observational Data Derived From an Integrated Clinical Trial Database. Clinical Therapeutics, 2017, 39, 1790-1798.e7.	2.5	16
840	Self-reported hypoglycemia in insulin-treated patients with diabetes: Results from an international survey on 7289 patients from nine countries. Diabetes Research and Clinical Practice, 2017, 134, 17-28.	2.8	40
841	A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data. Journal of Diabetes and Its Complications, 2017, 31, 1719-1727.	2.3	55
842	Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes. Current Geriatrics Reports, 2017, 6, 175-186.	1.1	20
843	Towards a personalized assessment of pancreatic function in diabetes. Expert Review of Precision Medicine and Drug Development, 2017, 2, 275-285.	0.7	0
844	Insulin Degludec 200 Units/mL Is Associated With Lower Injection Frequency and Improved Patient-Reported Outcomes Compared With Insulin Glargine 100 Units/mL in Patients With Type 2 Diabetes Requiring High-Dose Insulin. Clinical Diabetes, 2017, 35, 90-95.	2.2	18
845	Characteristics Associated with the Choice of First Injectable Therapy Among US Patients With Type 2 Diabetes. Clinical Therapeutics, 2017, 39, 2399-2408.	2.5	15
846	Individualized Glycemic Goals and an Expanded Classification of Severe Hypoglycemia in Diabetes. Diabetes Care, 2017, 40, 1641-1643.	8.6	26
847	Patient Preferences for Attributes of Type 2 Diabetes Mellitus Medications in Germany and Spain: An Online Discrete-Choice Experiment Survey. Diabetes Therapy, 2017, 8, 1365-1378.	2.5	32
848	Optimizing Glycemic Control Through Titration of Insulin Glargine 100 U/mL: A Review of Current and Future Approaches with a Focus on Asian Populations. Diabetes Therapy, 2017, 8, 1197-1214.	2.5	7
849	Use of 50/50 Premixed Insulin Analogs in Type 2 Diabetes: Systematic Review and Clinical Recommendations. Diabetes Therapy, 2017, 8, 1265-1296.	2.5	5
850	Factors Associated with Type 2 Diabetes Mellitus Treatment Choice Across Four European Countries. Clinical Therapeutics, 2017, 39, 2296-2310.e14.	2.5	15
851	Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9). Clinical Therapeutics, 2017, 39, 2284-2295.	2.5	11
853	Care of older people with diabetes. Nursing Standard (Royal College of Nursing (Great Britain): 1987), 2017, 32, 50-63.	0.1	3
854	Practical Approaches to Diagnosing, Treating and Preventing Hypoglycemia in Diabetes. Diabetes Therapy, 2017, 8, 1427-1435.	2.5	14
855	Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice, 2017, 131, 49-60.	2.8	26

#	ARTICLE	IF	CITATIONS
856	Pleiotropic effects of metformin to rescue statin-induced muscle injury and insulin resistance: A proposed mechanism and potential clinical implications. <i>Medical Hypotheses</i> , 2017, 107, 39-44.	1.5	10
857	Visit-to-Visit Variations in Fasting Plasma Glucose and HbA1c Associated With an Increased Risk of Alzheimer Disease: Taiwan Diabetes Study. <i>Diabetes Care</i> , 2017, 40, 1210-1217.	8.6	60
858	A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes. <i>Advances in Therapy</i> , 2017, 34, 1791-1814.	2.9	21
860	An RCT Investigating Patient-Driven Versus Physician-Driven Titration of BIAsp 30 in Patients with Type 2 Diabetes Uncontrolled Using NPH Insulin. <i>Diabetes Therapy</i> , 2017, 8, 767-780.	2.5	5
861	Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014. <i>Diabetes Therapy</i> , 2017, 8, 863-873.	2.5	170
862	The Economic Burden of Insulin-Related Hypoglycemia in Spain. <i>Diabetes Therapy</i> , 2017, 8, 899-913.	2.5	20
863	Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes. <i>Postgraduate Medicine</i> , 2017, 129, 686-697.	2.0	39
865	Effectiveness of shared goal setting and decision making to achieve treatment targets in type 2 diabetes patients: A cluster-randomized trial (<scp>OPTIMAL</scp>). <i>Health Expectations</i> , 2017, 20, 1172-1180.	2.6	19
866	iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes. <i>Annals of Pharmacotherapy</i> , 2017, 51, 990-999.	1.9	10
867	Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients. <i>Cardiovascular Diabetology</i> , 2017, 16, 24.	6.8	41
868	Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. <i>Cardiovascular Diabetology</i> , 2017, 16, 42.	6.8	80
869	Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 123.	2.4	7
870	Change in life expectancy with type 2 diabetes: a study using claims data from lower Saxony, Germany. <i>Population Health Metrics</i> , 2017, 15, 5.	2.7	29
871	Cardioprotective potential of N-acetyl cysteine against hyperglycaemia-induced oxidative damage: a protocol for a systematic review. <i>Systematic Reviews</i> , 2017, 6, 96.	5.3	21
872	Assessing the Therapeutic Utility of Professional Continuous Glucose Monitoring in Type 2 Diabetes Across Various Therapies: A Retrospective Evaluation. <i>Advances in Therapy</i> , 2017, 34, 1918-1927.	2.9	21
873	Differential Treatment Response to Insulin Intensification Therapy: A Post Hoc Analysis of a Randomized Trial Comparing Premixed and Basal-Bolus Insulin Regimens. <i>Diabetes Therapy</i> , 2017, 8, 915-928.	2.5	5
874	Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes. <i>Drugs</i> , 2017, 77, 1353-1362.	10.9	11
875	Impact of Metformin Use on Lactate Kinetics in Patients with Severe Sepsis and Septic Shock. <i>Shock</i> , 2017, 47, 582-587.	2.1	34

#	ARTICLE	IF	CITATIONS
876	Integrated Diabetes Care. , 2017, , .		9
877	Hypoglycemia in patients with type 2 diabetes newly initiated on basal insulin in the US in a community setting: impact on treatment discontinuation and hospitalization. Current Medical Research and Opinion, 2017, 33, 209-214.	1.9	12
878	Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM). Pharmacoeconomics, 2017, 35, 375-396.	3.3	24
879	Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus. Diabetes Therapy, 2017, 8, 33-53.	2.5	14
880	Essentials of SGLT2 Inhibitors in Diabetes. , 2017, , .		1
881	Non-insulin anti-diabetic drugs: An update on pharmacological interactions. Pharmacological Research, 2017, 115, 14-24.	7.1	19
882	Place of sodium-glucose cotransporter-2 inhibitors in East Asian subjects with type 2 diabetes mellitus: Insights into the management of Asian phenotype. Journal of Diabetes and Its Complications, 2017, 31, 494-503.	2.3	22
883	Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview. Advances in Therapy, 2017, 34, 41-59.	2.9	20
884	Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective. Clinical Therapeutics, 2017, 39, 1012-1025.	2.5	15
885	The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies. European Journal of Health Economics, 2017, 18, 937-965.	2.8	13
886	Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients. Diabetes, Obesity and Metabolism, 2017, 19, 108-117.	4.4	32
887	Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials. Diabetes, Obesity and Metabolism, 2017, 19, 266-274.	4.4	37
888	Management of newly treated diabetes in Medicare beneficiaries with and without heart failure. Clinical Cardiology, 2017, 40, 38-45.	1.8	13
889	Predictors of outcomes in patients with type 2 diabetes in the lixisenatide <sc>GetGoal</sc> clinical trials. Diabetes, Obesity and Metabolism, 2017, 19, 275-283.	4.4	13
890	Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 211-223.	3.3	16
891	Effect of Metformin Use on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2017, 15, 221-229.	1.9	18
892	Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. Diabetes/Metabolism Research and Reviews, 2017, 33, e2818.	4.0	50
893	Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors. Annals of Medicine, 2017, 49, 51-62.	3.8	17

#	ARTICLE	IF	CITATIONS
894	Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations. <i>Journal of Diabetes Investigation</i> , 2017, 8, 19-28.	2.4	22
895	Controversy of oral hypoglycemic agents in type 2 diabetes mellitus: Novel move towards combination therapies. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2017, 11, S5-S13.	3.6	28
896	Titration of basal insulin or immediate addition of rapid acting insulin in patients not at target using basal insulin supported oral antidiabetic treatment – A prospective observational study in 2202 patients. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2017, 11, 51-57.	3.6	3
897	Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 142-147.	4.4	56
898	Following the LEADER – why this and other recent trials signal a major paradigm shift in the management of type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 517-519.	2.3	9
899	Mechanisms of diabetes mellitus-induced bone fragility. <i>Nature Reviews Endocrinology</i> , 2017, 13, 208-219.	9.6	678
900	Glycemic control and safety in Chinese patients with type 2 diabetes mellitus who switched from premixed insulin to insulin glargine plus oral antidiabetics: a large, prospective, observational study. <i>Diabetes/Metabolism Research and Reviews</i> , 2017, 33, e2863.	4.0	7
901	Clinical inertia to insulin initiation and intensification in the UK: A focused literature review. <i>Primary Care Diabetes</i> , 2017, 11, 3-12.	1.8	170
902	Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: <scp>a</scp> systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 228-238.	4.4	75
903	Targeting postprandial blood sugar over fasting blood sugar: A clinic based comparative study. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2017, 11, 133-136.	3.6	3
904	Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300ÂU/mL. <i>Clinical Pharmacokinetics</i> , 2017, 56, 449-458.	3.5	12
905	Metformin, beyond an insulin sensitizer, targeting heart and pancreatic Î² cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 1984-1990.	3.8	67
906	Center-based patient care enhances survival of elderly patients suffering from peripheral arterial disease. <i>Annals of Medicine</i> , 2017, 49, 291-298.	3.8	26
907	Could metformin be used in patients with diabetes and advanced chronic kidney disease?. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 156-161.	4.4	5
908	Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabetes: the real world experience. <i>Endocrine</i> , 2017, 55, 173-178.	2.3	31
909	A Shared Decision-Making System for Diabetes Medication Choice Utilizing Electronic Health Record Data. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2017, 21, 1280-1287.	6.3	33
910	A meta-analysis comparing clinical effects of short- or long-acting <scp>GLP</scp>-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 216-227.	4.4	123
911	A real-world study of treatment patterns and outcomes in <scp>US</scp> managed-care patients with type 2 Diabetes initiating injectable therapies. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 375-386.	4.4	18

#	ARTICLE	IF	CITATIONS
912	Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice. <i>European Journal of Pharmacology</i> , 2017, 794, 37-44.	3.5	86
913	Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 143-155.	2.2	33
914	Vildagliptin and caloric restriction for cardioprotection in pre-diabetic rats. <i>Journal of Endocrinology</i> , 2017, 232, 189-204.	2.6	13
915	A Proposal for an Out-of-Range Glycemic Population Health Safety Measure for Older Adults With Diabetes. <i>Diabetes Care</i> , 2017, 40, 518-525.	8.6	17
916	Hypoglycemia in Frail Elderly Patients With Type 2 Diabetes Mellitus Treated With Sulfonylurea. <i>Journal of Diabetes Science and Technology</i> , 2017, 11, 438-439.	2.2	5
917	A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin. <i>Diabetes/Metabolism Research and Reviews</i> , 2017, 33, e2858.	4.0	34
918	Lessons in Care: Insights Into Recent Changes in the American Diabetes Association's Clinical Practice Recommendations. <i>Clinical Diabetes</i> , 2017, 35, 96-99.	2.2	1
919	Inhibition of C1-Ten PTPase activity reduces insulin resistance through IRS-1 and AMPK pathways. <i>Scientific Reports</i> , 2017, 7, 17777.	3.3	11
920	Diabetes and older people: ensuring individualised practice. <i>Nursing and Residential Care</i> , 2017, 19, 390-392.	0.1	1
921	Personalizing Type 2 Diabetes Management: Use of a Patient-Centered Approach to Individualizing A1C Goals and Pharmacological Regimens. <i>Clinical Diabetes</i> , 2017, 35, 321-328.	2.2	4
922	If DSME Were a Pill, Would You Prescribe It?. <i>Diabetes Spectrum</i> , 2017, 30, 51-57.	1.0	1
926	Deprescribing in Older Nursing Home Patients: Focus on Innovative Composite Measures for Dosage Deintensification. <i>Innovation in Aging</i> , 2017, 1, igx031.	0.1	8
927	Stroke: the key risk factors. <i>British Journal of Cardiac Nursing</i> , 2017, 12, 552-559.	0.1	2
928	Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2017, 357, j2499.	2.3	52
929	Provider Decisions and Patient Outcomes After Premature Metformin Discontinuation. <i>Diabetes Spectrum</i> , 2017, 30, 17-22.	1.0	3
930	A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes. <i>Journal of Clinical Medicine Research</i> , 2017, 9, 567-572.	1.2	8
931	Effects of glucose-lowering agents on ischemic stroke. <i>World Journal of Diabetes</i> , 2017, 8, 270.	3.5	4
932	American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on Testing for Autonomic And Somatic Nerve Dysfunction. <i>Endocrine Practice</i> , 2017, 23, 1472-1478.	2.1	18

#	ARTICLE	IF	CITATIONS
934	Working with patients to promote self-management. British Journal of Health Care Management, 2017, 23, 308-312.	0.2	0
935	Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2017, Volume 10, 273-284.	2.4	25
936	Effects of Intensive Control of Glycemia on Clinical Kidney Outcomes in Type 2 Diabetes Patients Compared with Standard Control: A Meta-Analysis. Frontiers in Pharmacology, 2017, 8, 845.	3.5	10
937	Comparison of the efficacy and safety of 10-mg empagliflozin every day versus every other day in Japanese patients with Type 2 Diabetes Mellitus: a pilot trial. Journal of Medical Investigation, 2017, 64, 50-57.	0.5	2
938	Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2017, Volume 10, 123-139.	2.4	81
939	Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy. Core Evidence, 2017, Volume 12, 1-10.	4.7	5
940	Insulin Therapy for Adult Patients with Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association, 2017. Diabetes and Metabolism Journal, 2017, 41, 367.	4.7	11
941	Indexing Natural Products for Their Potential Anti-Diabetic Activity: Filtering and Mapping Discriminative Physicochemical Properties. Molecules, 2017, 22, 1563.	3.8	18
942	Cinnamic Acid and Its Derivatives: Mechanisms for Prevention and Management of Diabetes and Its Complications. Nutrients, 2017, 9, 163.	4.1	191
943	Hypoglycemia and Dementia. Endocrinology and Metabolism, 2017, 32, 195.	3.0	13
944	Isolated Compounds from Natural Products with Potential Antidiabetic Activity - A Systematic Review. Current Diabetes Reviews, 2018, 14, 36-106.	1.3	51
945	Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management. Frontiers in Endocrinology, 2017, 8, 6.	3.5	814
946	Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial. Diabetes and Metabolism Journal, 2017, 41, 135.	4.7	14
947	Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials. Current Diabetes Reviews, 2017, 13, 405-423.	1.3	135
948	A Novel Index Using Soluble CD36 Is Associated with the Prevalence of Type 2 Diabetes Mellitus: Comparison Study with Triglyceride-Glucose Index. Endocrinology and Metabolism, 2017, 32, 375.	3.0	13
949	Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus. Diabetes and Metabolism Journal, 2017, 41, 69.	4.7	12
950	Clinical Decision Support System for Diabetes Based on Ontology Reasoning and TOPSIS Analysis. Journal of Healthcare Engineering, 2017, 2017, 1-14.	1.9	29
951	Effectiveness of Vildagliptin in Clinical Practice: Pooled Analysis of Three Korean Observational Studies (the VICTORY Study). Journal of Diabetes Research, 2017, 2017, 1-8.	2.3	2

#	ARTICLE	IF	CITATIONS
952	Diabetes Mellitus Treatment. , 2017, , 288-293.		8
953	Comparative Liquid Chromatographic Study for Concurrent Determination of Canagliflozin and Metformin in Combined Tablets. Journal of Analytical Methods in Chemistry, 2017, 2017, 1-9.	1.6	10
954	AN INTERNATIONAL POSITION STATEMENT ON THE MANAGEMENT OF FRAILTY IN DIABETES MELLITUS: SUMMARY OF RECOMMENDATIONS 2017. Journal of Frailty & Aging,the, 2018, 7, 1-11.	1.3	71
955	Personalized Care and the Role of Insulin as a Vehicle to Optimizing Treatments in Diabetes Care. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 1160-1168.	0.9	4
956	Economic Impact of Treatment Duration and Persistence with Basal Insulin in Previously Insulin-Naive Users. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 327-336.	0.9	3
957	Determinants of Long-Term Durable Glycemic Control in New-Onset Type 2 Diabetes Mellitus. Diabetes and Metabolism Journal, 2017, 41, 284.	4.7	12
958	Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2017, Volume 10, 317-332.	2.4	11
959	Risk factors for unstable blood glucose level: integrative review of the risk factors related to the nursing diagnosis. Revista Latino-Americana De Enfermagem, 2017, 25, e2893.	1.0	9
960	Aspalathin Protects the Heart against Hyperglycemia-Induced Oxidative Damage by Up-Regulating Nrf2 Expression. Molecules, 2017, 22, 129.	3.8	64
962	Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2017, Volume 10, 47-55.	2.4	12
963	Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2017, Volume 10, 79-87.	2.4	24
964	Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. Archives of Endocrinology and Metabolism, 2017, 61, 188-192.	0.6	19
965	Drug-class-specific changes in the volume and cost of antidiabetic medications in Poland between 2012 and 2015. PLoS ONE, 2017, 12, e0178764.	2.5	7
966	Exploring differences in the use of the statin choice decision aid and diabetes medication choice decision aid in primary care. BMC Medical Informatics and Decision Making, 2017, 17, 118.	3.0	15
967	The impact of cardiovascular co-morbidities and duration of diabetes on the association between microvascular function and glycaemic control. Cardiovascular Diabetology, 2017, 16, 114.	6.8	27
969	Insulin lispro 25/75 and insulin lispro 50/50 as starter insulin in Japanese patients with type 2 diabetes: subanalysis of the CLASSIFY randomized trial. Endocrine Journal, 2017, 64, 705-717.	1.6	1
970	Insulin therapy for adult patients with type 2 diabetes mellitus: a position statement of the Korean Diabetes Association, 2017. Korean Journal of Internal Medicine, 2017, 32, 967-973.	1.7	5
971	Semaglutide"the "new kid on the block"in the field of glucagon-like peptide-1 receptor agonists?. Annals of Translational Medicine, 2017, 5, 475-475.	1.7	8

#	ARTICLE	IF	CITATIONS
972	Diabetes mellitus and stroke: A clinical update. World Journal of Diabetes, 2017, 8, 235.	3.5	105
973	Efficacy and Safety of Insulin Glargine 300 U/mL in North Americans and Non-North Americans with Type 2 Diabetes: A Patient-Level Meta- Analysis of the EDITION 1, 2 and 3 Studies. Journal of Diabetes & Metabolism, 2017, 09, .	0.2	0
974	Highlights From the American Diabetes Association's 2017 Standards of Medical Care in Diabetes for Osteopathic Physicians. Journal of Osteopathic Medicine, 2017, 117, 457-472.	0.8	2
975	Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2017, Volume 10, 111-122.	2.4	23
976	Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 749-762.	1.9	11
977	Association between Metformin Use and Risk of Lactic Acidosis or Elevated Lactate Concentration in Type 2 Diabetes. Yonsei Medical Journal, 2017, 58, 312.	2.2	14
978	Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale. Drug Design, Development and Therapy, 2017, Volume11, 923-937.	4.3	4
979	Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. Drug Design, Development and Therapy, 2017, Volume 11, 2905-2919.	4.3	67
980	Coronary Artery Bypass Grafting in Patients with Diabetes Mellitus: A Cardiologist's View. , 2017, , .		1
981	Comparative Effectiveness of Rapid-Acting Insulins in Adults with Diabetes. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 291-298.	0.9	4
982	Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association. Diabetes and Metabolism Journal, 2017, 41, 337.	4.7	49
983	Monotherapy in Patients with Type 2 Diabetes Mellitus. Diabetes and Metabolism Journal, 2017, 41, 349.	4.7	13
984	GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nature Reviews Nephrology, 2017, 13, 605-628.	9.6	233
985	DPPH Radical Scavenging and Postprandial Hyperglycemia Inhibition Activities and Flavonoid Composition Analysis of Hawk Tea by UPLC-DAD and UPLC-Q/TOF MSE. Molecules, 2017, 22, 1622.	3.8	19
986	Comparative Study on Adding Pioglitazone or Sitagliptin to Patients with Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin. Open Access Macedonian Journal of Medical Sciences, 2017, 5, 955-962.	0.2	6
987	Managing problems with medications for type 2 diabetes. Practice Nursing, 2017, 28, 148-153.	0.1	0
988	Type 2 diabetes mellitus treatment habits in a specialized care setting: the START-DIAB study. Mediterranean Journal of Nutrition and Metabolism, 2017, 10, 165-179.	0.5	2
989	The Role of Diet in the Prevention and Treatment of Diabetes. , 2017, , 691-707.		0

#	ARTICLE	IF	CITATIONS
990	Quality of diabetes mellitus therapy in patients with chronic kidney disease in the real world. Italian Journal of Medicine, 2017, 11, 48.	0.3	0
991	Novel Pure Component Contribution Algorithm (PCCA) and UHPLC Methods for Separation and Quantification of Amlodipine, Valsartan, and Hydrochlorothiazide in Ternary Mixture. Journal of AOAC INTERNATIONAL, 2017, 100, 692-699.	1.5	4
992	Place des inhibiteurs des SGLT2 dans le traitement du patient diabétique de type 2. Medecine Des Maladies Metaboliques, 2018, 12, 22-30.	0.1	9
993	Treatment of type 2 diabetes mellitus in elderly patients. Revista Clínica Española, 2018, 218, 74-88.	0.5	17
994	Higher mortality rate in patients with heart failure who are taking commonly prescribed antidiabetic medications and achieve recommended levels of glycaemic control. Diabetes, Obesity and Metabolism, 2018, 20, 1766-1769.	4.4	4
995	Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?. Clinical Diabetes, 2018, 36, 138-147.	2.2	10
996	RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017. International Journal of Diabetes in Developing Countries, 2018, 38, 1-115.	0.8	85
997	EADSG Guidelines: Insulin Therapy in Diabetes. Diabetes Therapy, 2018, 9, 449-492.	2.5	103
998	Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology, 2018, 6, 370-381.	11.4	185
999	Physical activity and exercise on diabetic foot related outcomes: A systematic review. Diabetes Research and Clinical Practice, 2018, 139, 81-90.	2.8	56
1000	Real-world evaluation of HbA1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin: an analysis of electronic medical records from a network of hospitals in Florida. Current Medical Research and Opinion, 2018, 34, 1099-1115.	1.9	4
1001	The safety of gliptins : updated data in 2018. Expert Opinion on Drug Safety, 2018, 17, 387-405.	2.4	101
1002	Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period. Current Medical Research and Opinion, 2018, 34, 981-994.	1.9	16
1003	Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study. Diabetes, Obesity and Metabolism, 2018, 20, 1602-1614.	4.4	54
1004	Work-loss years among people diagnosed with diabetes: a reappraisal from a life course perspective. Acta Diabetologica, 2018, 55, 485-491.	2.5	13
1005	Clinical Benefit of Basal Insulin Analogue Treatment in Persons with Type 2 Diabetes Inadequately Controlled on Prior Insulin Therapy: A Prospective, Noninterventional, Multicenter Study. Diabetes Therapy, 2018, 9, 651-662.	2.5	4
1006	Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know. Clinical Diabetes, 2018, 36, 174-182.	2.2	6
1007	Pharmacological management of diabetes in severe mental illness: a comprehensive clinical review of efficacy, safety and tolerability. Expert Review of Clinical Pharmacology, 2018, 11, 411-424.	3.1	12

#	ARTICLE	IF	CITATIONS
1008	Impact of metformin on gastric adenocarcinoma survival: A Belgian population based study. Cancer Epidemiology, 2018, 53, 149-155.	1.9	14
1009	Changes in metformin use and other antihyperglycemic therapies after insulin initiation in patients with type 2 diabetes. Diabetes Research and Clinical Practice, 2018, 139, 221-229.	2.8	6
1010	Study design and baseline characteristics of inpatients with diabetes mellitus in a tertiary hospital in China: A database study based on electronic medical records. Journal of Evidence-Based Medicine, 2018, 11, 152-157.	2.4	20
1011	Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification. Diabetic Medicine, 2018, 35, 694-706.	2.3	2
1012	Why prescribe exercise as therapy in type 2 diabetes? We have a pill for that!. Diabetes/Metabolism Research and Reviews, 2018, 34, e2999.	4.0	20
1013	The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin. Clinical Science, 2018, 132, 489-507.	4.3	75
1014	Pharmacokinetics of metformin in patients with gastrointestinal intolerance. Diabetes, Obesity and Metabolism, 2018, 20, 1593-1601.	4.4	32
1015	Development of an Injectable Slow-Release Metformin Formulation and Evaluation of Its Potential Antitumor Effects. Scientific Reports, 2018, 8, 3929.	3.3	24
1016	Identification des obèses au traitement par exenatide ou liraglutide : résultats de deux études en vie réelle. Médecine Des Maladies Métaboliques, 2018, 12, 62-68.	0.1	0
1017	Do sulphonylureas still have a place in clinical practice?. Lancet Diabetes and Endocrinology, 2018, 6, 821-832.	11.4	83
1019	Quantitative determination of metformin, saxagliptin and 5-hydroxy saxagliptin simultaneously by hydrophilic interaction liquid chromatography - electrospray ionization mass spectrometry and its application to a bioequivalence study with a single-pill combination in human. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1081-1082, 109-117.	2.3	11
1020	Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers. Postgraduate Medicine, 2018, 130, 381-393.	2.0	24
1021	Consequences of non-medical switch among patients with type 2 diabetes. Current Medical Research and Opinion, 2018, 34, 1475-1481.	1.9	4
1022	Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes. Medicine (United States), 2018, 97, 10784314.	1.0	4
1023	Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?. Cardiovascular Drugs and Therapy, 2018, 32, 213-222.	2.6	40
1024	The role of KATP channels in cerebral ischemic stroke and diabetes. Acta Pharmacologica Sinica, 2018, 39, 683-694.	6.1	55
1025	Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis. PharmacoEconomics - Open, 2018, 2, 209-219.	1.8	28
1026	Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes. Digestive Diseases, 2018, 36, 322-324.	1.9	17

#	ARTICLE	IF	CITATIONS
1027	Treatment of type 2 diabetes: future approaches. British Medical Bulletin, 2018, 126, 123-137.	6.9	29
1028	Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment. Journal of Clinical Pharmacology, 2018, 58, 1314-1323.	2.0	60
1029	Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?. Diabetes, Obesity and Metabolism, 2018, 20, 1937-1943.	4.4	3
1030	Is the management of diabetes different in dialysis patients?. Seminars in Dialysis, 2018, 31, 367-376.	1.3	6
1031	Consensus on insulin treatment in type 2 diabetes. Endocrinología y Nutrición (English Ed), 2018, 65, 1-8.	0.2	0
1032	SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 2018, 20, 1972-1976.	4.4	31
1033	Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the <scp>DURATION</scp>-8 randomized controlled trial. Diabetes, Obesity and Metabolism, 2018, 20, 1520-1525.	4.4	23
1034	Japanese Clinical Practice Guideline for Diabetes 2016. Journal of Diabetes Investigation, 2018, 9, 657-697.	2.4	158
1035	Development of a Physiologically Based Pharmacokinetic Model for Sinoglatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics. Clinical Pharmacokinetics, 2018, 57, 1307-1323.	3.5	10
1036	Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. Diabetes, Obesity and Metabolism, 2018, 20, 2000-2003.	4.4	42
1037	Type 2 diabetes mellitus in older people: a brief statement of key principles of modern day management including the assessment of frailty. A national collaborative stakeholder initiative. Diabetic Medicine, 2018, 35, 838-845.	2.3	84
1038	Effects on the glucagon response to hypoglycaemia during <scp>DPP</scp>-4 inhibition in elderly subjects with type 2 diabetes: <scp>A</scp>-randomized, placebo-controlled study. Diabetes, Obesity and Metabolism, 2018, 20, 1911-1920.	4.4	5
1039	Insulin Treatment. Endocrinology, 2018, , 1-24.	0.1	0
1040	Metformin for non-small cell lung cancer patients: Opportunities and pitfalls. Critical Reviews in Oncology/Hematology, 2018, 125, 41-47.	4.4	32
1041	Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important?. Diabetes Research and Clinical Practice, 2018, 142, 19-25.	2.8	16
1042	Coronary artery disease severity modifies associations between glycemic control and both mortality and myocardial infarction. Journal of Diabetes and Its Complications, 2018, 32, 480-487.	2.3	6
1043	The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 1585-1592.	4.4	11
1044	Relation between HbA1c and incident cardiovascular disease over a period of 6 years in the Hong Kong population. Diabetes and Metabolism, 2018, 44, 415-423.	2.9	5

#	ARTICLE	IF	CITATIONS
1045	Impact of the severity of hypoglycemia on health - Related quality of life, productivity, resource use, and costs among US patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2018, 32, 451-457.	2.3	19
1046	Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano. Revista Clinica Espanola, 2018, 218, 74-88.	0.6	39
1047	Impact of type 2 Diabetes and Metformin use on Vitamin B12 Associated Biomarkers - an Observational Study. Experimental and Clinical Endocrinology and Diabetes, 2018, 126, 394-400.	1.2	2
1049	Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes. Expert Opinion on Biological Therapy, 2018, 18, 343-351.	3.1	12
1050	Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. Diabetes Care, 2018, 41, 705-712.	8.6	67
1051	Two-year trial of intermittent insulin therapy vs metformin for the preservation of β -cell function after initial short-term intensive insulin induction in early type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 1399-1407.	4.4	20
1052	Impact of Canagliflozin Treatment on Health-Related Quality of Life among People with Type 2 Diabetes Mellitus: A Pooled Analysis of Patient-Reported Outcomes from Randomized Controlled Trials. Patient, 2018, 11, 341-352.	2.7	9
1053	Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study. Diabetes Therapy, 2018, 9, 253-268.	2.5	68
1054	Real-world clinical responses in patients with type 2 diabetes mellitus adding exenatide BID (EBID) or mealtime insulin to basal insulin: a retrospective study using electronic medical record data. Current Medical Research and Opinion, 2018, 34, 1045-1051.	1.9	1
1055	Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment. Diabetes Therapy, 2018, 9, 521-543.	2.5	55
1056	Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus. Endocrinology and Metabolism Clinics of North America, 2018, 47, 81-96.	3.2	54
1057	Personalizing Glucose-Lowering Therapy in Patients with Type 2 Diabetes and Cardiovascular Disease. Endocrinology and Metabolism Clinics of North America, 2018, 47, 137-152.	3.2	7
1058	Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients. European Radiology, 2018, 28, 2856-2869.	4.5	192
1059	Cost-Effectiveness Analysis of Canagliflozin 300mg Versus Dapagliflozin 10mg Added to Metformin in Patients with Type 2 Diabetes in the United States. Diabetes Therapy, 2018, 9, 565-581.	2.5	13
1060	Smart Care Based on Telemonitoring and Telemedicine for Type 2 Diabetes Care: Multi-Center Randomized Controlled Trial. Telemedicine Journal and E-Health, 2018, 24, 604-613.	2.8	37
1061	New Diabetes Medications Raise New Perioperative Concerns for the Anesthesiologist. Anesthesia and Analgesia, 2018, 126, 390-392.	2.2	5
1062	No Impact of Pre-existing Cardiovascular Disease on Prescribing Patterns of Sulphonylureas in Denmark - A Registry-based Nationwide Study. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 606-611.	2.5	2
1063	Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2018, 20, 68-76.	4.4	32

#	ARTICLE	IF	CITATIONS
1064	What have we learnt from “cereal world” data, observational studies and meta-analyses. Diabetes, Obesity and Metabolism, 2018, 20, 47-58.	4.4	35
1065	Temporal changes in glycaemic thresholds for treatment intensification in type 2 diabetes in an urban Australian setting: the Fremantle Diabetes Study. Internal Medicine Journal, 2018, 48, 1215-1221.	0.8	0
1066	Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment. Current Medical Research and Opinion, 2018, 34, 995-1003.	1.9	41
1067	Metformin-induced anticancer activities: recent insights. Biological Chemistry, 2018, 399, 321-335.	2.5	51
1068	Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs. International Journal of Cardiology, 2018, 254, 291-296.	1.7	27
1069	Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: A European analysis of over 60 million glucose tests. Diabetes Research and Clinical Practice, 2018, 137, 37-46.	2.8	181
1071	Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A “post-hoc” analysis of a phase 3 randomized clinical trial. Journal of Diabetes Investigation, 2018, 9, 840-849.	2.4	6
1072	Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study. Advances in Therapy, 2018, 35, 243-253.	2.9	19
1073	Normalizing fibromyalgia as a chronic illness. Postgraduate Medicine, 2018, 130, 9-18.	2.0	27
1074	Switching basal insulins in type 2 diabetes: practical recommendations for health care providers. Postgraduate Medicine, 2018, 130, 229-238.	2.0	6
1075	Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial. Diabetes, Obesity and Metabolism, 2018, 20, 1202-1212.	4.4	81
1076	Association of hypoglycaemia severity with clinical, patient-reported and economic outcomes in US patients with type 2 diabetes using basal insulin. Diabetes, Obesity and Metabolism, 2018, 20, 1156-1165.	4.4	13
1077	Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study. Advances in Therapy, 2018, 35, 43-55.	2.9	20
1078	Characteristics of Elderly Patients Initiating Sitagliptin or Non-DPP-4-Inhibitor Oral Antihyperglycemic Agents: Analysis of a Cross-Sectional US Claims Database. Diabetes Therapy, 2018, 9, 309-315.	2.5	7
1079	Investigation of in vitro genotoxic effects of an anti-diabetic drug sitagliptin. Food and Chemical Toxicology, 2018, 112, 235-241.	3.6	14
1080	Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: A meta-analysis. Diabetes Research and Clinical Practice, 2018, 137, 137-148.	2.8	114
1081	Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. Diabetes Care, 2018, 41, 596-603.	8.6	59
1082	When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy. Diabetes/Metabolism Research and Reviews, 2018, 34, e2981.	4.0	23

#	ARTICLE	IF	CITATIONS
1083	Changes in patient characteristics, glucose lowering treatment, glycemic control and complications in type 2 diabetes in general practices (Disease Analyzer, Germany: 2008-2016). Postgraduate Medicine, 2018, 130, 244-250.	2.0	9
1084	Rationale and Design for the J-DISCOVER Study: DISCOVERing the Treatment Reality of Type 2 Diabetes in a Real-World Setting in Japan—A Protocol. Diabetes Therapy, 2018, 9, 165-175.	2.5	23
1085	Effects of nutrition therapy on HbA1c and cardiovascular disease risk factors in overweight and obese patients with type 2 diabetes. Nutrition Journal, 2018, 17, 42.	3.4	34
1086	Factors Influencing the Prescribing Preferences of Physicians for Drug-Naive Patients with Type 2 Diabetes Mellitus in the Real-World Setting in Japan: Insight from a Web Survey. Diabetes Therapy, 2018, 9, 1185-1199.	2.5	15
1087	Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1 trials. Diabetes, Obesity and Metabolism, 2018, 20, 2291-2297.	4.4	38
1088	Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia. Diabetes Therapy, 2018, 9, 1201-1216.	2.5	8
1090	The Economic Burden of Insulin-Related Hypoglycemia in Adults with Diabetes: An Analysis from the Perspective of the Italian Healthcare System. Diabetes Therapy, 2018, 9, 1037-1047.	2.5	10
1091	Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3). BMJ Open Diabetes Research and Care, 2018, 6, e000464.	2.8	18
1092	A qualitative study exploring patients' experiences regarding insulin pump use. Saudi Pharmaceutical Journal, 2018, 26, 487-495.	2.7	12
1093	Treatment with Oral Drugs. Endocrinology, 2018, , 1-44.	0.1	0
1095	A review of the new GLP-1 receptor agonist/basal insulin fixed-ratio combination products. Therapeutic Advances in Endocrinology and Metabolism, 2018, 9, 69-79.	3.2	23
1096	Bioequivalence of Dapagliflozin/Metformin Extended-release Fixed-combination Drug Product and Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Russian Subjects. Clinical Therapeutics, 2018, 40, 550-561.e3.	2.5	12
1097	A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects. Advances in Therapy, 2018, 35, 531-544.	2.9	12
1098	Similar Efficacy and Safety of Basaglar® and Lantus® in Patients with Type 2 Diabetes in Age Groups (<65 Years, 65-75 Years): A Post Hoc Analysis from the ELEMENT-2 Study. Diabetes Therapy, 2018, 9, 827-837.	2.5	5
1099	Comparison of non-insulin antidiabetic agents as an add-on drug to insulin therapy in type 2 diabetes: a network meta-analysis. Scientific Reports, 2018, 8, 4095.	3.3	14
1100	Glycaemic control and treatment of type 2 diabetes in adults aged 75 years or older. International Journal of Clinical Practice, 2018, 72, e13075.	1.7	13
1101	Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study. Diabetes Therapy, 2018, 9, 789-801.	2.5	28
1102	Dipeptidyl peptidase-4 inhibitors as preferable oral hypoglycemic agents in terms of treatment satisfaction: Results from a multicenter, 12-week, open label, randomized controlled study in Japan (PREFERENCE 4 study). Journal of Diabetes Investigation, 2018, 9, 137-145.	2.4	16

#	ARTICLE	IF	CITATIONS
1103	Different insulin concentrations in resuspended vs. unsuspended NPH insulin: Practical aspects of subcutaneous injection in patients with diabetes. <i>Diabetes and Metabolism</i> , 2018, 44, 368-372.	2.9	4
1104	Insights Into the Current Management of Older Adults With Type 2 Diabetes in the Ontario Primary Care Setting. <i>Canadian Journal of Diabetes</i> , 2018, 42, 23-30.	0.8	16
1105	Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy: <scp>R</scp>eview of current strategies. <i>Journal of Diabetes</i> , 2018, 10, 94-111.	1.8	18
1106	Severe hypoglycaemia among patients with type 2 diabetes requiring emergency hospital admission: <scp>T</scp>he <scp>H</scp>ypoglycaemia <scp>I</scp>n <scp>P</scp>ortugal <scp>O</scp>bservational <scp>S</scp>tudyâ€“<scp>E</scp>mergency <scp>R</scp>oom (<scp>HIPOS</scp>â€“<scp>ER</scp>). <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 50-59.	4.4	17
1107	Therapeutic inertia in patients treated with two or more antidiabetics in primary care: <scp>F</scp>actors predicting intensification of treatment. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 103-112.	4.4	65
1108	Clinical risk factors predicting genital fungal infections with sodiumâ€“glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit. <i>Primary Care Diabetes</i> , 2018, 12, 45-50.	1.8	34
1109	Our First 825 T2DM Patients on 14-Day Factory-Calibrated Glucose Monitoring System: Clinical Utility and Challenges. <i>Journal of Diabetes Science and Technology</i> , 2018, 12, 230-231.	2.2	5
1110	Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the <scp>DUAL V</scp> randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 200-205.	4.4	14
1111	Therapeutic application of <scp>GPR119</scp> ligands in metabolic disorders. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 257-269.	4.4	48
1112	The Real-Life Effectiveness and Care Patterns of Type 2 Diabetes Management in Greece. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2018, 126, 53-60.	1.2	12
1113	Glycaemic outcomes of anIndividualized treatMent aPproach for oldERvulnerable patients:Arandomized, controlled stUdy in type 2 diabetesMellitus (IMPERIUM). <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 148-156.	4.4	13
1114	Diabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 335-338.	4.5	22
1115	Treatment satisfaction with ITCA 650, a novel drugâ€“device delivering continuous exenatide, versus twiceâ€“daily injections of exenatide in type 2 diabetics using metformin. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 638-645.	4.4	6
1116	Effectiveness of certified diabetes educators following pre-approved protocols to redesign diabetes care delivery in primary care: Results of the REMEDIES 4D trial. <i>Contemporary Clinical Trials</i> , 2018, 64, 201-209.	1.8	14
1117	Registered nursesâ€™ knowledge of medical care for older adults with diabetes in long-term care facilities in Taiwan. <i>Collegian</i> , 2018, 25, 271-275.	1.3	1
1118	HbA 1C variability and hypoglycemia hospitalization in adults with type 1 and type 2 diabetes: A nested case-control study. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 203-209.	2.3	17
1119	Identifying insulin treatment responders with a composite measure: beyond Hba1c <â€“7% in patients with type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2018, 34, 329-336.	1.9	3
1120	Effects of dosage and dosing frequency on the efficacy and safety of highâ€“dose metformin in Japanese patients with type 2 diabetes mellitus. <i>Journal of Diabetes Investigation</i> , 2018, 9, 587-593.	2.4	31

#	ARTICLE	IF	CITATIONS
1121	Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 508-519.	4.4	39
1122	Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes. <i>Metabolism: Clinical and Experimental</i> , 2018, 78, 141-154.	3.4	47
1123	Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2018, 34, 313-318.	1.9	7
1124	Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study. <i>American Heart Journal</i> , 2018, 196, 18-27.	2.7	15
1125	Clinical considerations for use of insulin degludec/insulin aspart in Japanese patients. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 77-85.	3.1	0
1126	Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: <i>Post hoc</i> analysis of a randomized, 52-week, open-label, parallel-group trial. <i>Journal of Diabetes Investigation</i> , 2018, 9, 831-839.	2.4	4
1127	Real-world comparison of treatment patterns and effectiveness of albiglutide and liraglutide. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 89-100.	1.4	2
1128	Biphasic insulin aspart ³⁰ reduces glycemic variability to a greater degree than insulin detemir: A randomized controlled trial of once-daily insulin regimens using continuous glucose monitoring. <i>Journal of Diabetes Investigation</i> , 2018, 9, 573-578.	2.4	3
1129	Better glycaemic control and less hypoglycaemia with insulin glargine 300 <i>U/mL</i> vs glargine 100 <i>U/mL</i> : 1-year patient-level meta-analysis of the <i>EDITION</i> clinical studies in people with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 541-548.	4.4	69
1130	Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 497-507.	4.4	33
1131	Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy. <i>Current Medical Research and Opinion</i> , 2018, 34, 1-10.	1.9	10
1132	Associations of Residential Socioeconomic, Food, and Built Environments With Glycemic Control in Persons With Diabetes in New York City From 2007-2013. <i>American Journal of Epidemiology</i> , 2018, 187, 736-745.	3.4	42
1133	Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: Subgroup analysis of a randomized clinical trial. <i>Journal of Diabetes Investigation</i> , 2018, 9, 579-586.	2.4	11
1134	Initiation of Basal Insulin Analog Treatment for Type 2 Diabetes and Reasons Behind Patients'™ Treatment Persistence Behavior: Real-World Data from Germany. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2018, 126, 287-297.	1.2	4
1135	Postprandial glucose and healthcare resource use: a cross-sectional survey of adults with diabetes treated with basal-bolus insulin. <i>Journal of Medical Economics</i> , 2018, 21, 66-73.	2.1	10
1136	Pharmacotherapy of type 2 diabetes: An update. <i>Metabolism: Clinical and Experimental</i> , 2018, 78, 13-42.	3.4	144
1137	Incidence rate and patient characteristics of severe hypoglycemia in treated type 2 diabetes mellitus patients in Japan: Retrospective Diagnosis Procedure Combination database analysis. <i>Journal of Diabetes Investigation</i> , 2018, 9, 925-936.	2.4	23
1138	Spanish consensus on treat to target for osteoporosis. <i>Osteoporosis International</i> , 2018, 29, 489-499.	3.1	13

#	ARTICLE	IF	CITATIONS
1139	Does insulin therapy matter? Determinants of diabetes care outcomes. Primary Care Diabetes, 2018, 12, 224-230.	1.8	3
1140	Concordance with prescribing information dosage recommendations for dipeptidyl-peptidase-4 inhibitors among type 2 diabetes mellitus patients with moderate to severe chronic kidney disease. Current Medical Research and Opinion, 2018, 34, 1021-1027.	1.9	5
1141	Control of cardiovascular disease risk factors among patients with type II diabetes in a primary-care setting in Beijing. Journal of the American Society of Hypertension, 2018, 12, 128-134.	2.3	2
1142	An Indirect Comparison of Changes in the Impact of Weight on Quality of Life Among Subjects with Type 2 Diabetes Treated with Antihyperglycemic Agents in Dual Therapy with Metformin. Diabetes Therapy, 2018, 9, 125-140.	2.5	0
1143	Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care, 2018, 41, 258-266.	8.6	350
1144	Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial. Diabetes Care, 2018, 41, 333-340.	8.6	41
1145	The nutritional supplement FFD-002 attenuates streptozotocin-induced diabetes and decelerates diabetes-related tissue injury. Journal of Food Biochemistry, 2018, 42, e12486.	2.9	1
1146	An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin. Journal of Medical Economics, 2018, 21, 340-347.	2.1	24
1147	4. Lifestyle Management: Standards of Medical Care in Diabetesâ€”2018. Diabetes Care, 2018, 41, S38-S50.	8.6	493
1148	6. Glycemic Targets: Standards of Medical Care in Diabetesâ€”2018. Diabetes Care, 2018, 41, S55-S64.	8.6	701
1149	8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetesâ€”2018. Diabetes Care, 2018, 41, S73-S85.	8.6	668
1150	Leukocyte telomere length correlates with glucose control in adults with recently diagnosed type 2 diabetes. Diabetes Research and Clinical Practice, 2018, 135, 30-36.	2.8	23
1151	Primary care physician perspectives on basal insulin initiation and maintenance in patients with type 2 diabetes mellitus. Primary Care Diabetes, 2018, 12, 155-162.	1.8	10
1152	Insulin Glargine 300 U/ML is Associated with Less Weight Gain while Maintaining Glycemic Control and Low Risk of Hypoglycemia Compared with Insulin Glargine 100 U/ML in an Aging Population with Type 2 Diabetes. Endocrine Practice, 2018, 24, 143-149.	2.1	12
1153	Comparison of medication adherence and persistence in type 2 diabetes: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 2018, 20, 1040-1043.	4.4	101
1154	Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind, placebo-controlled trial. Diabetes, Obesity and Metabolism, 2018, 20, 1044-1049.	4.4	9
1155	Baseline factors associated with better response to insulin lispro low mixture or insulin glargine: A post hoc analysis of the DURABLE study. Diabetes Research and Clinical Practice, 2018, 135, 134-142.	2.8	0
1156	Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database. Diabetes, Obesity and Metabolism, 2018, 20, 831-839.	4.4	14

#	ARTICLE	IF	CITATIONS
1157	Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2018, 9, 27-36.	2.5	5
1158	Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (<scp>CVD&REAL Nordic</scp>) when compared with dipeptidyl peptidase-4 inhibitor therapy: <scp>A</scp> multinational observational study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 344-351.	4.4	164
1159	Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New. <i>Canadian Journal of Diabetes</i> , 2018, 42, 325-334.	0.8	11
1160	Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future. <i>Critical Reviews in Toxicology</i> , 2018, 48, 52-108.	3.9	69
1161	Effect of once-weekly dulaglutide on glycated haemoglobin (<scp>HbA1c</scp>) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline <scp>HbA1c</scp>. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 409-418.	4.4	56
1162	Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in <scp>J</scp>apanese people with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 378-388.	4.4	82
1163	Regarding Insulin Initiation in Type 2 Diabetes Mellitus and the Risk for Hypoglycemia. <i>Canadian Journal of Diabetes</i> , 2018, 42, 221.	0.8	1
1164	Postoperative Euglycaemic Diabetic Ketoacidosis Associated with Sodium"Glucose Cotransporter-2 Inhibitors (Gliflozins): A Report of Two Cases and Review of the Literature. <i>Anaesthesia and Intensive Care</i> , 2018, 46, 215-219.	0.7	25
1165	Biochemical Markers Present in a Population Susceptible to Suffering From Metabolic Syndrome. <i>Global Journal of Health Science</i> , 2018, 10, 85.	0.2	0
1166	Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes. <i>Medicine (United States)</i> , 2018, 97, e12633.	1.0	16
1167	Analysis of new therapeutic strategies for diabetes mellitus based on traditional Chinese medicine "xiao"-formulae. <i>Journal of Traditional Chinese Medical Sciences</i> , 2018, 5, 361-369.	0.2	1
1168	Keeping up-to-date with diabetes care and education. <i>Nursing</i> , 2018, 48, 22-29.	0.3	2
1169	Impact of pharmacotherapeutic education on medication adherence and adverse outcomes in patients with type 2 diabetes mellitus: a prospective, randomized study. <i>Croatian Medical Journal</i> , 2018, 59, 290-297.	0.7	10
1170	Fresh Bitter Melon Fruit (<i>Momordica charantia</i>) Attenuated Oxidative Stress, Fibrosis and Renal Injury in Carbon Tetrachloride Treated Rats. <i>Dhaka University Journal of Pharmaceutical Sciences</i> , 2018, 16, 205-214.	0.2	2
1171	Prevençió en diabetes mellitus y riesgo cardiovascular: enfoque m´dico y nutricional. <i>Revista Facultad De Medicina</i> , 2018, 66, 459-468.	0.2	7
1172	La bith´rapie antidiab´tique orale en pratique m´dicale courante en Afrique subsaharienne : résultats déune ´tude observationnelle multicentrique sur six mois. <i>Medecine Des Maladies Metaboliques</i> , 2018, 12, 306-312.	0.1	2
1173	A systematic review comparing the evidence for kidney function outcomes between oral antidiabetic drugs for type 2 diabetes. <i>Wellcome Open Research</i> , 2018, 3, 74.	1.8	6
1174	Monotherapy in Type 2 Diabetes Mellitus Patients 2017: A Position Statement of the Korean Diabetes Association. <i>Journal of Korean Diabetes</i> , 2018, 19, 15.	0.3	1

#	ARTICLE	IF	CITATIONS
1175	Goal Attainment Rate for Parameters of Metabolic Adjustment in Elderly Patients with Type 2 Diabetes Taking a Hypoglycemic Agent. Journal of Korean Diabetes, 2018, 19, 58.	0.3	1
1176	Canagliflozin in the Diabetic-Obese and Poorly Controlled. Epidemiology (Sunnyvale, Calif), 2018, 08, .	0.3	0
1180	Î±-AMYLASE INHIBITION AND ELECTROCHEMICAL BEHAVIOR OF SOME OXOVANADIUM (IV) COMPLEXES OF L-AMINO ACIDS. Asian Journal of Pharmaceutical and Clinical Research, 2018, 11, 218.	0.3	6
1181	Diabetes and cognitive decline: Extra care required. Practice Nursing, 2018, 29, 76-82.	0.1	0
1183	A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes. Journal of Diabetes Research, 2018, 2018, 1-9.	2.3	2
1184	Management of bone and metabolic effects of androgen deprivation therapy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 704-712.	1.6	10
1185	Safety and efficacy of Momordica charantia Linnaeus in pre-diabetes and type 2 diabetes mellitus patients: a systematic review and meta-analysis protocol. Systematic Reviews, 2018, 7, 192.	5.3	6
1186	Calorie Restriction Mimetics: Upstream-Type Compounds for Modulating Glucose Metabolism. Nutrients, 2018, 10, 1821.	4.1	50
1187	Type-2 diabetes mellitus and cardiovascular disease. Future Cardiology, 2018, 14, 491-509.	1.2	197
1188	Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes: a systematic review and network meta-analysis study protocol. BMJ Open, 2018, 8, e023206.	1.9	4
1189	Expert Opinion: Patient Selection for Premixed Insulin Formulations in Diabetes Care. Diabetes Therapy, 2018, 9, 2185-2199.	2.5	19
1190	Glucose Intolerance in Myotonic Dystrophy. , 2018, , 149-159.		0
1192	The Efficacy and Safety of Co-Administration of Sitagliptin With Metformin in Patients With Type 2 Diabetes at Hospital Discharge. Endocrine Practice, 2018, 24, 556-564.	2.1	14
1193	Comparison Of Hba1C Goals Proposed By An Algorithm To Those Set By Different Members Of Healthcare Teams Within The Dartmouth Hitchcock Health System. Endocrine Practice, 2018, 24, 705-709.	2.1	2
1194	Choosing the Best Oral Diabetic Agents in T2 Diabetes Mellitus-Physicians Challenge. Journal of Diabetes & Metabolism, 2018, 09, .	0.2	1
1195	Informed shared decision-making programme for patients with type 2 diabetes in primary care: cluster randomised controlled trial. BMJ Open, 2018, 8, e024004.	1.9	15
1196	A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2018, 146, 240-250.	2.8	17
1198	Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ: British Medical Journal, 2018, 363, k4880.	2.3	33

#	ARTICLE	IF	CITATIONS
1199	Factors associated with choice of intensification treatment for type 2 diabetes after metformin monotherapy: a cohort study in UK primary care. <i>Clinical Epidemiology</i> , 2018, Volume 10, 1639-1648.	3.0	11
1200	Glucagon-Like Peptide 1 Receptor Agonists For Type 2 Diabetes: A Comprehensive Review of How to Weigh The Options, Select the Right Patients, and Maximize Benefits. <i>Endocrine Practice</i> , 2018, 24, 8-19.	2.1	1
1201	Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). <i>Cardiovascular Diabetology</i> , 2018, 17, 150.	6.8	149
1202	Treatment choice, medication adherence and glycemic efficacy in people with type 2 diabetes: a UK clinical practice database study. <i>BMJ Open Diabetes Research and Care</i> , 2018, 6, e000512.	2.8	37
1203	Health Literacy and Adults With Low Basic Skills. <i>Adult Education Quarterly</i> , 2018, 68, 297-315.	1.5	9
1204	Clinical inertia in basal insulin-treated patients with type 2 diabetes – Results from a retrospective database study in Japan (JDDM 43). <i>PLoS ONE</i> , 2018, 13, e0198160.	2.5	15
1205	Development of an HPLC-MS/MS method to determine janagliflozin in human plasma and urine: application in clinical study. <i>Bioanalysis</i> , 2018, 10, 1439-1454.	1.5	6
1206	Cardiovascular Outcomes Trials Update: Insights from the DEVOTE Trial. <i>Current Diabetes Reports</i> , 2018, 18, 102.	4.2	6
1207	SGLT-2 Inhibitors and DPP-4 Inhibitors as Second-Line Drugs in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Clinical Trials. <i>Hormone and Metabolic Research</i> , 2018, 50, 768-777.	1.5	9
1209	Association of metformin administration with gut microbiome dysbiosis in healthy volunteers. <i>PLoS ONE</i> , 2018, 13, e0204317.	2.5	96
1210	The Trend of High-Dose Insulin Usage Among Patients with Diabetes in the UK: A Retrospective Study. <i>Diabetes Therapy</i> , 2018, 9, 2245-2257.	2.5	12
1211	Effect of high-flow high-volume-intermittent hemodiafiltration on metformin-associated lactic acidosis with circulatory failure: a case report. <i>Journal of Medical Case Reports</i> , 2018, 12, 280.	0.8	9
1212	Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2018, 61, 2461-2498.	6.3	1,002
1213	Risk of Serious Trauma with Glucose-Lowering Drugs in Older Persons: A Nested Case-Control Study. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 2086-2091.	2.6	2
1214	mHealth for diabetes self-management in the Kingdom of Saudi Arabia: barriers and solutions. <i>Journal of Multidisciplinary Healthcare</i> , 2018, Volume 11, 535-546.	2.7	18
1215	Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study. <i>Endocrinology, Diabetes and Metabolism</i> , 2018, 1, e00036.	2.4	24
1216	Enquête sur la prise en charge des patients diabétiques de type 2 par les médecins généralistes en Bourgogne. Implications pour l'enseignement post-universitaire. <i>Medicine Des Maladies Metaboliques</i> , 2018, 12, 520-526.	0.1	0
1217	Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease – Implications for Clinical Practice. <i>European Endocrinology</i> , 2018, 14, 40.	1.5	13

#	ARTICLE	IF	CITATIONS
1218	Le traitement du diabète de type 2 en France est dynamique plutôt qu'inerte : analyse des prescriptions de 847 122 patients. <i>Medecine Des Maladies Metaboliques</i> , 2018, 12, 346-352.	0.1	4
1219	Automatic processing of Electronic Medical Records using Deep Learning. , 2018, , .		3
1220	Mechanisms of Drug-Induced Cardiovascular Toxicity: Cardiotoxicity Associated With Diabetes Medications. , 2018, , 419-431.		0
1222	Diabetes and Atherosclerosis: Old Players in a New Field, Osteoporosis. <i>Current Vascular Pharmacology</i> , 2018, 16, 524-527.	1.7	11
1223	Effects of exenatide versus insulin glargine on body composition in overweight and obese T2DM patients: a randomized controlled trial. <i>Nutrition and Metabolism</i> , 2018, 15, 67.	3.0	19
1224	Treatment with Oral Drugs. <i>Endocrinology</i> , 2018, , 527-569.	0.1	0
1225	Stacked classifiers for individualized prediction of glycemic control following initiation of metformin therapy in type 2 diabetes. <i>Computers in Biology and Medicine</i> , 2018, 103, 109-115.	7.0	22
1226	The effects of 12-month administration of tofogliflozin on electrolytes and dehydration in mainly elderly Japanese patients with type 2 diabetes mellitus. <i>Journal of International Medical Research</i> , 2018, 46, 5117-5126.	1.0	4
1227	Modern Sulfonylureas Strike Back – Exploring the Freedom of Flexibility. <i>European Endocrinology</i> , 2018, 14, 20.	1.5	1
1228	Preclinical discovery and development of colesevelam for the treatment of type 2 diabetes. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 1161-1167.	5.0	9
1229	Metformin use is associated with a low risk of tuberculosis among newly diagnosed diabetes mellitus patients with normal renal function: A nationwide cohort study with validated diagnostic criteria. <i>PLoS ONE</i> , 2018, 13, e0205807.	2.5	30
1230	Effect of different methods for estimating persistence and adherence to new glucose-lowering drugs: results of an observational, inception cohort study in Portugal. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 1471-1482.	1.8	4
1232	Risk of hypoglycaemia in people aged ≥65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus. <i>International Journal of Clinical Practice</i> , 2018, 72, e13240.	1.7	5
1233	Improved Treatment Engagement Among Patients with Diabetes Treated with Insulin Glargine 300 U/mL Who Participated in the COACH Support Program. <i>Diabetes Therapy</i> , 2018, 9, 2143-2153.	2.5	6
1234	Second-generation Insulin Analogues – a Review of Recent Real-world Data and Forthcoming Head-to-head Comparisons. <i>European Endocrinology</i> , 2018, 14, 2.	1.5	20
1235	The –A to Z– of Managing Type 2 Diabetes in Culturally Diverse Populations. <i>Frontiers in Endocrinology</i> , 2018, 9, 479.	3.5	29
1236	Predictive factors of efficacy of combination therapy with basal insulin and liraglutide in type 2 diabetes when switched from longstanding basal-bolus insulin: Association between the responses of β - and α -cells to GLP-1 stimulation and the glycaemic control at 6 months after switching therapy. <i>Diabetes Research and Clinical Practice</i> , 2018, 144, 161-170.	2.8	5
1237	Twice-daily insulin degludec/insulin aspart effectively improved morning and evening glucose levels and quality of life in patients previously treated with premixed insulin: an observational study. <i>Diabetology and Metabolic Syndrome</i> , 2018, 10, 64.	2.7	15

#	ARTICLE	IF	CITATIONS
1238	Characterization of changes in HbA1c in patients with and without secondary failure after metformin treatments by a population pharmacodynamic analysis using mixture models. Drug Metabolism and Pharmacokinetics, 2018, 33, 264-269.	2.2	1
1239	Sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes in North India: A 12-month prospective study in real-world setting. International Journal of Clinical Practice, 2018, 72, e13237.	1.7	7
1240	Predictors of glycemic control in type-2 diabetes mellitus: Evidence from a multicenter study in Ghana. Translational Metabolic Syndrome Research, 2018, 1, 1-8.	0.8	20
1241	2018 Standards of Care Update: Pharmacologic Approaches to Glycemic Management in People With Type 2 Diabetes. Diabetes Spectrum, 2018, 31, 254-260.	1.0	7
1242	Periodontal complications of hyperglycemia/diabetes mellitus: Epidemiologic complexity and clinical challenge. Periodontology 2000, 2018, 78, 59-97.	13.4	150
1243	iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes. Diabetes Spectrum, 2018, 31, 145-154.	1.0	22
1244	Gastric Emptying and the Personalized Management of Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3503-3506.	3.6	5
1245	Association of Patient Profile with Glycemic Control and Hypoglycemia with Insulin Glargine 300 U/mL in Type 2 Diabetes: A Post Hoc Patient-Level Meta-Analysis. Diabetes Therapy, 2018, 9, 2043-2053.	2.5	6
1246	Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis. PLoS ONE, 2018, 13, e0202563.	2.5	12
1247	Neuroprotective exendin-4 enhances hypothermia therapy in a model of hypoxic-ischaemic encephalopathy. Brain, 2018, 141, 2925-2942.	7.6	35
1248	Metformin in cancer. Diabetes Research and Clinical Practice, 2018, 143, 409-419.	2.8	200
1249	European Medicines Agency: Approval of new glucose-lowering medicines for type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 2057-2058.	4.4	0
1250	Initial combination therapy with vildagliptin plus metformin in drug-naïve patients with T2DM: a 24-week real-life study from Asia. Current Medical Research and Opinion, 2018, 34, 1605-1611.	1.9	9
1251	Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial. Diabetes, Obesity and Metabolism, 2018, 20, 2200-2209.	4.4	33
1252	Effect of short-term treatment with sitagliptin or glibenclamide on daily glucose fluctuation in drug-naïve Japanese patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2018, 20, 2274-2281.	4.4	10
1253	Diabetes del paciente anciano. EMC - Tratado De Medicina, 2018, 22, 1-8.	0.0	1
1254	Discovery of potent α -glucosidase inhibitor flavonols: Insights into mechanism of action through inhibition kinetics and docking simulations. Bioorganic Chemistry, 2018, 79, 257-264.	4.1	72
1255	Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?. Expert Opinion on Pharmacotherapy, 2018, 19, 773-777.	1.8	5

#	ARTICLE	IF	CITATIONS
1256	The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2371-2378.	4.4	14
1257	Effectiveness of a computerised system of patient education in clinical practice: a longitudinal nested cohort study. <i>BMJ Open</i> , 2018, 8, e020621.	1.9	5
1258	Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations. <i>Advances in Therapy</i> , 2018, 35, 939-965.	2.9	14
1259	Fatal Case of Metformin-Associated Lactic Acidosis Associated With Temporary Ileostomy. <i>Journal of Wound, Ostomy and Continence Nursing</i> , 2018, 45, 364-365.	1.0	2
1260	Metformin use in the first year after kidney transplant, correlates, and associated outcomes in diabetic transplant recipients: A retrospective analysis of integrated registry and pharmacy claims data. <i>Clinical Transplantation</i> , 2018, 32, e13302.	1.6	23
1261	Diabetes and Hyperglycemia in Lower-Extremity Total Joint Arthroplasty. <i>JBJS Reviews</i> , 2018, 6, e10-e10.	2.0	17
1262	Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study. <i>Diabetes Therapy</i> , 2018, 9, 1477-1490.	2.5	12
1264	Persistence et durabilité de l'efficacité du liraglutide : au-delà des études randomisées. <i>Medicine Des Maladies Metaboliques</i> , 2018, 12, 279-283.	0.1	0
1265	Systematic review and meta-analysis of the effect of SGLT-2 inhibitors on microvascular outcomes in patients with type 2 diabetes: a review protocol. <i>BMJ Open</i> , 2018, 8, e020692.	1.9	4
1266	Women with Type 1 Diabetes Mellitus: Effect of Disease and Psychosocial-Related Correlates on Health-Related Quality of Life. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-10.	2.3	8
1267	2020 vision – An overview of prospects for diabetes management and prevention in the next decade. <i>Diabetes Research and Clinical Practice</i> , 2018, 143, 101-112.	2.8	33
1268	Calendar time as an instrumental variable in assessing the risk of heart failure with antihyperglycemic drugs. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 857-866.	1.9	8
1269	Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons. <i>Diabetes Therapy</i> , 2018, 9, 1491-1500.	2.5	11
1270	Empagliflozin: A Review in Type 2 Diabetes. <i>Drugs</i> , 2018, 78, 1037-1048.	10.9	94
1271	HbA1c presents low sensitivity as a post-pregnancy screening test for both diabetes and prediabetes in Greek women with history of gestational diabetes mellitus. <i>Hormones</i> , 2018, 17, 255-259.	1.9	10
1272	Discovery of a potent glucokinase activator with a favorable liver and pancreas distribution pattern for the treatment of type 2 diabetes mellitus. <i>European Journal of Medicinal Chemistry</i> , 2018, 156, 269-294.	5.5	25
1273	A path model linking health literacy, medication self-efficacy, medication adherence, and glycemic control. <i>Patient Education and Counseling</i> , 2018, 101, 1906-1913.	2.2	47
1274	Efficacy and Renal Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Also Receiving Metformin: A Real-Life Experience. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-5.	2.3	3

#	ARTICLE	IF	CITATIONS
1275	Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulin-naïve individuals with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2894-2898.	4.4	3
1276	Evolution of Glucose-Lowering Drugs for Type 2 Diabetes. , 2018, , 431-454.		2
1277	The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents. <i>Diabetes Research and Clinical Practice</i> , 2018, 143, 1-14.	2.8	43
1278	Efficacy of iGlarLixi, a fixed-ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2680-2684.	4.4	4
1279	Diabetic Foot. <i>Endocrinology</i> , 2018, , 1-22.	0.1	0
1280	Management Strategies for Posttransplant Diabetes Mellitus after Heart Transplantation: A Review. <i>Journal of Transplantation</i> , 2018, 2018, 1-14.	0.5	19
1281	Agonism of receptors in the gut-pancreas axis in type 2 diabetes: are two better than one?. <i>Lancet, The</i> , 2018, 391, 2577-2578.	13.7	6
1282	Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes. <i>Annals of Pharmacotherapy</i> , 2018, 52, 1224-1232.	1.9	10
1283	Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2018, 168, 170.	3.9	28
1284	Diagnosis and management of bone fragility in diabetes: an emerging challenge. <i>Osteoporosis International</i> , 2018, 29, 2585-2596.	3.1	237
1285	Association of metformin use with vitamin B12 deficiency in the institutionalized elderly. <i>Archives of Gerontology and Geriatrics</i> , 2018, 79, 57-62.	3.0	25
1286	Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial. <i>Diabetes Care</i> , 2018, 41, 2136-2146.	8.6	73
1287	Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Pharmacology</i> , 2018, 9, 576.	3.5	31
1288	Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea. <i>Korean Circulation Journal</i> , 2018, 48, 395.	1.9	11
1289	Insulin Monotherapy Versus Insulin Combined with Other Glucose-Lowering Agents in Type 2 Diabetes: A Narrative Review. <i>International Journal of Endocrinology and Metabolism</i> , 2018, 16, e65600.	1.0	19
1290	In type 2 diabetes, weekly semaglutide reduced HbA _{1c} and increased weight loss more than weekly exenatide ER. <i>Annals of Internal Medicine</i> , 2018, 168, JC46.	3.9	1
1291	Valsartan prevents glycerol-induced acute kidney injury in male albino rats by downregulating TLR4 and NF- κ B expression. <i>International Journal of Biological Macromolecules</i> , 2018, 119, 565-571.	7.5	20
1292	Lack of coordination between partners: investigation of Physician-Preferred and Patient-Preferred (4P) basal insulin titration algorithms in the real world. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 1253-1259.	1.8	4

#	ARTICLE	IF	CITATIONS
1293	GOAL study: clinical and non-clinical predictive factors for achieving glycemic control in people with type 2 diabetes in real clinical practice. <i>BMJ Open Diabetes Research and Care</i> , 2018, 6, e000519.	2.8	29
1294	Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series. <i>Reviews on Recent Clinical Trials</i> , 2018, 13, 156-160.	0.8	15
1295	Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2018, 169, 165.	3.9	38
1296	Association of health literacy and medication self-efficacy with medication adherence and diabetes control. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 793-802.	1.8	56
1297	A Population-Based Study of the Bidirectional Association Between Obstructive Sleep Apnea and Type 2 Diabetes in Three Prospective U.S. Cohorts. <i>Diabetes Care</i> , 2018, 41, 2111-2119.	8.6	88
1298	Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. <i>Diabetes Care</i> , 2018, 41, 1844-1853.	8.6	91
1299	Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients. <i>Frontiers in Immunology</i> , 2018, 9, 1030.	4.8	36
1300	Should Metformin Remain First-Line Medical Therapy for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease? An Alternative Approach. <i>Current Diabetes Reports</i> , 2018, 18, 64.	4.2	27
1301	Predictors and Clinical Outcomes of Treatment Intensification in Patients with Type 2 Diabetes Uncontrolled on Basal Insulin in a Real-World Setting. <i>Endocrine Practice</i> , 2018, 24, 805-814.	2.1	6
1302	HbA1c method performance: The great success story of global standardization. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2018, 55, 408-419.	6.1	32
1303	Decreasing incidence of pharmacologically and non-pharmacologically treated type 2 diabetes in Norway: a nationwide study. <i>Diabetologia</i> , 2018, 61, 2310-2318.	6.3	43
1304	Real-world clinical experience of Xultophy in the management of patients with type 2 diabetes in a secondary care clinic. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2018, 12, 1079-1082.	3.6	4
1305	Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. <i>BMC Medicine</i> , 2018, 16, 116.	5.5	36
1306	Metformin use during pregnancy: Is it really safe?. <i>Journal of Diabetes</i> , 2018, 10, 984-985.	1.8	4
1307	Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild-to-moderate renal impairment. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2860-2868.	4.4	20
1308	Mechanisms of beneficial effects of metformin on fatty acid-treated human islets. <i>Journal of Molecular Endocrinology</i> , 2018, 61, 91-99.	2.5	22
1309	Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2018, 21, 222-235.	2.1	28
1310	A genetic perspective of Metformin induced Vitamin B12 deficiency in Type 2 Diabetes mellitus patients. <i>Asian Journal of Medical Sciences</i> , 2018, 9, 11-14.	0.1	2

#	ARTICLE	IF	CITATIONS
1311	Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes. BMC Health Services Research, 2018, 18, 78.	2.2	21
1312	A utility valuation study assessing the impact of postprandial glucose control on quality of life of individuals with type 1 or type 2 diabetes. Journal of Patient-Reported Outcomes, 2018, 2, 20.	1.9	2
1313	Regression modeling strategy for prediction of AUC of evogliptin, a novel dipeptidyl peptidase IV inhibitor in humans, using single dose PK data. International Journal of Pharmacokinetics, 2018, 3, 23-38.	0.5	0
1314	Japanese Clinical Practice Guideline for Diabetes 2016. Diabetology International, 2018, 9, 1-45.	1.4	215
1315	Why, when and how to use insulin in type 2 diabetes mellitus. Independent Nurse, 2018, 2018, 23-26.	0.1	1
1316	Does hypoglycaemia affect the improvement in QoL after the transition to insulin in people with type 2 diabetes?. Journal of Endocrinological Investigation, 2018, 41, 249-258.	3.3	10
1317	Individualised treatment targets in patients with type-2 diabetes and hypertension. Cardiovascular Diabetology, 2018, 17, 18.	6.8	19
1318	Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study. Cardiovascular Diabetology, 2018, 17, 20.	6.8	37
1319	DMTO: a realistic ontology for standard diabetes mellitus treatment. Journal of Biomedical Semantics, 2018, 9, 8.	1.6	60
1320	Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006â€“2014. PharmacoEconomics - Open, 2018, 2, 393-402.	1.8	14
1321	Efficacy and safety of sodium-glucose cotransporter 2 inhibitors as add-on to metformin and sulfonylurea treatment for the management of type 2 diabetes: a meta-analysis. Endocrine Journal, 2018, 65, 335-344.	1.6	17
1322	Study Protocol for the Initial Choice of DPP-4 Inhibitor in Japanese Patients with Type 2 diabetes Mellitus: Effect of Linagliptin on QOL (INTEL-QOL) Trial. Diabetes Therapy, 2018, 9, 1403-1412.	2.5	3
1323	Effects of linagliptin versus voglibose on treatment-related quality of life in patients with type 2 diabetes: sub-analysis of the L-STEP study. Endocrine Journal, 2018, 65, 657-668.	1.6	2
1324	Characteristics of insulin-NaÃ“ve people with type 2 diabetes who successfully respond to insulin glargine U100 after 24Ã“weeks of treatment: a meta-analysis of individual participant data from 3 randomized clinical trials. Clinical Diabetes and Endocrinology, 2018, 4, 10.	2.7	5
1325	Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017. Diabetes, Obesity and Metabolism, 2018, 20, 2159-2168.	4.4	63
1326	Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-Analysis. Diabetes Therapy, 2018, 9, 1945-1958.	2.5	20
1327	Current Level of Glycemic Control and Clinical Inertia in Subjects Using Insulin for the Treatment of Type 1 and Type 2 Diabetes in the Czech Republic and the Slovak Republic: Results of a Multinational, Multicenter, Observational Survey (DIAINFORM). Diabetes Therapy, 2018, 9, 1897-1906.	2.5	28
1329	Male Patients with Longstanding Type 2 Diabetes Have a Higher Incidence of Hypoglycemia Compared with Female Patients. Diabetes Therapy, 2018, 9, 1969-1977.	2.5	8

#	ARTICLE	IF	CITATIONS
1330	Cardiac Autonomic Neuropathy in Diabetes: A Predictor of Cardiometabolic Events. <i>Frontiers in Neuroscience</i> , 2018, 12, 591.	2.8	92
1331	Development of a model to predict 5-year risk of severe hypoglycemia in patients with type 2 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2018, 6, e000527.	2.8	22
1332	A Comparison of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline and the 2017 American Diabetes Association Diabetes and Hypertension Position Statement for U.S. Adults With Diabetes. <i>Diabetes Care</i> , 2018, 41, 2322-2329.	8.6	40
1333	The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis. <i>Endocrine</i> , 2018, 62, 535-545.	2.3	15
1334	Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2018, 379, 633-644.	27.0	888
1335	Approaches to rapid acting insulin intensification in patients with type 2 diabetes mellitus not achieving glycemic targets. <i>Annals of Medicine</i> , 2018, 50, 453-460.	3.8	3
1336	Anti-inflammatory Action of Metformin with Respect to CX3CL1/CX3CR1 Signaling in Human Placental Circulation in Normal-Glucose Versus High-Glucose Environments. <i>Inflammation</i> , 2018, 41, 2246-2264.	3.8	5
1337	Adjuvant Pharmacotherapies to Insulin for the Treatment of Type 1 Diabetes. <i>Current Diabetes Reports</i> , 2018, 18, 79.	4.2	8
1338	Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 707-719.	1.8	52
1339	Could vagus nerve stimulation have a role in the treatment of diabetes?. <i>Bioelectronics in Medicine</i> , 2018, 1, 13-15.	2.0	6
1340	GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES: A COMPREHENSIVE REVIEW OF HOW TO WEIGH THE OPTIONS, SELECT THE RIGHT PATIENTS, AND MAXIMIZE BENEFITS. <i>Endocrine Practice</i> , 2018, , .	2.1	1
1341	Diabetes Management and Healthcare Resource Use When Intensifying from Basal Insulin to Basal-Bolus: A Survey of Type 2 Diabetes Patients. <i>Diabetes Therapy</i> , 2018, 9, 1931-1944.	2.5	12
1342	Effects of Insulin Treatment with Glargine or Premixed Insulin Lispro Programs in Type 2 Diabetes Mellitus Patients: A Meta-analysis of Randomized Clinical Trials. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 622-627.	4.4	9
1343	Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function. <i>JAMA Internal Medicine</i> , 2018, 178, 903.	5.1	126
1344	Diabetes and the Cardiovascular System. <i>Endocrinology</i> , 2018, , 1-29.	0.1	0
1345	Contribution of basal and postprandial hyperglycaemia in type 2 diabetes patients treated by an intensified insulin regimen: Impact of pump therapy in the OPT2mise trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2435-2441.	4.4	4
1346	The value of fast-acting insulin aspart compared with insulin aspart for patients with diabetes mellitus treated with bolus insulin from a UK health care system perspective. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2018, 9, 187-197.	3.2	6
1347	Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies. <i>Diabetes and Metabolism</i> , 2018, 44, 386-392.	2.9	25

#	ARTICLE	IF	CITATIONS
1348	Reduced Glucose Variability With Glucose-Dependent Versus Glucose-Independent Therapies Despite Similar Glucose Control and Hypoglycemia Rates in a Randomized, Controlled Study of Older Patients With Type 2 Diabetes Mellitus. <i>Journal of Diabetes Science and Technology</i> , 2018, 12, 1184-1191.	2.2	8
1349	Type 1 diabetes. <i>Lancet, The</i> , 2018, 391, 2449-2462.	13.7	888
1350	Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes. <i>PLoS ONE</i> , 2018, 13, e0191953.	2.5	12
1351	Des normes et des cibles chez les patients diabétiques. <i>Medecine Des Maladies Metaboliques</i> , 2018, 12, 260-267.	0.1	0
1352	The relationship between intensification of blood glucose-lowering therapies, health status and quality of life in type 2 diabetes: The Fremantle Diabetes Study Phase II. <i>Diabetes Research and Clinical Practice</i> , 2018, 142, 294-302.	2.8	7
1354	Glycaemic impact of treatment intensification in patients with type 2 diabetes uncontrolled with oral antidiabetes drugs or basal insulin. <i>Endocrinology, Diabetes and Metabolism</i> , 2018, 1, e00019.	2.4	5
1355	Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes. <i>Canadian Journal of Diabetes</i> , 2019, 43, 136-145.	0.8	50
1356	Effectiveness and safety of empagliflozin-based quadruple therapy compared with insulin glargine-based therapy in patients with inadequately controlled type 2 diabetes: An observational study in clinical practice. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 173-177.	4.4	18
1357	Effects of Metformin on Cellular Proliferation and Steroid Hormone Receptors in Patient-Derived, Low-Grade Endometrial Cancer Cell Lines. <i>Reproductive Sciences</i> , 2019, 26, 609-618.	2.5	10
1358	Combination urate-lowering therapy in the treatment of gout: What is the evidence?. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 658-668.	3.4	21
1359	Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial. <i>Journal of Diabetes Investigation</i> , 2019, 10, 399-407.	2.4	77
1360	Oral Pharmacotherapy as Alternative Treatment for Type 2 Diabetes Mellitus in a 61 Year Old Ethnic Filipino Man with Insulin Allergies. <i>Laboratory Medicine</i> , 2019, 50, 93-95.	1.2	1
1361	Development of a self-efficacy questionnaire, the Insulin Therapy Self-efficacy Scale (ITSS)™, for insulin users in Japanese: The Self-efficacy-Q study. <i>Journal of Diabetes Investigation</i> , 2019, 10, 358-366.	2.4	3
1362	Efficacy and safety of MYL501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 129-135.	4.4	20
1363	Cause-specific risk of major adverse cardiovascular outcomes and hypoglycemic in patients with type 2 diabetes: a multicenter prospective cohort study. <i>Endocrine</i> , 2019, 63, 44-51.	2.3	8
1364	Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 3-14.	4.4	39
1365	The Role of Occupational Therapy in Secondary Prevention of Diabetes. <i>International Journal of Endocrinology</i> , 2019, 2019, 1-7.	1.5	2
1366	Metformin as Anti-Aging Therapy: Is It for Everyone?. <i>Trends in Endocrinology and Metabolism</i> , 2019, 30, 745-755.	7.1	154

#	ARTICLE	IF	CITATIONS
1367	Associations of obesity with antidiabetic medication use after living kidney donation: An analysis of linked national registry and pharmacy fill records. <i>Clinical Transplantation</i> , 2019, 33, e13696.	1.6	13
1368	Relevant patient characteristics for estimating healthcare needs according to healthcare providers and people with type 2 diabetes: a Delphi survey. <i>BMC Health Services Research</i> , 2019, 19, 575.	2.2	2
1369	Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). <i>Diabetes Care</i> , 2019, 42, 2098-2107.	8.6	37
1370	Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects. <i>Journal of Diabetes</i> , 2019, 11, 938-948.	1.8	30
1371	Diabetes and the Cardiovascular System. <i>Endocrinology</i> , 2019, , 1-29.	0.1	0
1372	The future of new drugs for diabetes management. <i>Diabetes Research and Clinical Practice</i> , 2019, 155, 107785.	2.8	28
1373	Relationship between diet/exercise and pharmacotherapy to enhance the GLP-1 levels in type 2 diabetes. <i>Endocrinology, Diabetes and Metabolism</i> , 2019, 2, e00068.	2.4	14
1374	The "Old" Oral Antidiabetics. , 2019, , 501-513.		0
1375	Foot self-care in diabetes mellitus: Evaluation of patient awareness. <i>Primary Care Diabetes</i> , 2019, 13, 515-520.	1.8	16
1376	The statins effects on HbA1c control among diabetic patients: An umbrella review of systematic reviews and meta-analyses of observational studies and clinical trials. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 2557-2564.	3.6	7
1377	Initial Therapeutic Choices for Type 2 Diabetes in the Portuguese Sentinel Practice Network. <i>Acta Medica Portuguesa</i> , 2019, 32, 375.	0.4	0
1378	Effectiveness and Safety of Physician-Led Versus Patient-Led Titration of Insulin Glargine in Indian Patients with Type 2 Diabetes Mellitus: A Subanalysis of the Asian Treat to Target Lantus Study (ATLAS). <i>Diabetes Technology and Therapeutics</i> , 2019, 21, 656-664.	4.4	7
1379	Simplifying Complex Insulin Regimens While Preserving Good Glycemic Control in Type 2 Diabetes. <i>Diabetes Therapy</i> , 2019, 10, 1869-1878.	2.5	28
1380	Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force. <i>Diabetes Therapy</i> , 2019, 10, 1645-1717.	2.5	32
1381	Quality of life and metabolic control in type 2 diabetes mellitus diagnosed individuals. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 2827-2832.	3.6	3
1382	Improving empowerment, motivation, and medical adherence in patients with poorly controlled type 2 diabetes: A randomized controlled trial of a patient-centered intervention. <i>Patient Education and Counseling</i> , 2019, 102, 2238-2245.	2.2	14
1383	Effect of Rice Processing towards Lower Rapidly Available Glucose (RAG) Favors Idli, a South Indian Fermented Food Suitable for Diabetic Patients. <i>Nutrients</i> , 2019, 11, 1497.	4.1	4
1384	Reduction in HbA1c using professional flash glucose monitoring in insulin-treated type 2 diabetes patients managed in primary and secondary care settings: A pilot, multicentre, randomised controlled trial. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 385-395.	2.0	47

#	ARTICLE	IF	CITATIONS
1385	Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on metformin: a meta-analysis. Archives of Endocrinology and Metabolism, 2019, 63, 478-486.	0.6	13
1386	Frailty in the older person: Implications for pharmacists. American Journal of Health-System Pharmacy, 2019, 76, 1980-1987.	1.0	2
1387	Rosiglitazone metformin adduct inhibits hepatocellular carcinoma proliferation via activation of AMPK/p21 pathway. Cancer Cell International, 2019, 19, 13.	4.1	15
1388	Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus. Drug Safety, 2019, 42, 1311-1327.	3.2	16
1389	Influence of gallic and tannic acid on therapeutic properties of acarbose in vitro and in vivo in Drosophila melanogaster. Biomedical Journal, 2019, 42, 317-327.	3.1	24
1390	Prevalence of Hypoglycemia Among Patients With Type 2 Diabetes Mellitus in a Rural Health Center in South India. Journal of Primary Care and Community Health, 2019, 10, 215013271988063.	2.1	14
1391	High-Intensity Interval Training Versus Moderate-Intensity Continuous Training in Middle-Aged and Older Patients with Type 2 Diabetes: A Randomized Controlled Crossover Trial of the Acute Effects of Treadmill Walking on Glycemic Control. International Journal of Environmental Research and Public Health, 2019, 16, 4163.	2.6	37
1392	Patient-centred care in type 2 diabetes mellitus – Key aspects of PDM-ProValue are reflected in the 2018 ADA/EASD consensus report. Diabetes Research and Clinical Practice, 2019, 158, 107897.	2.8	7
1393	Patient and physician preferences for type 2 diabetes medications: a systematic review. Journal of Diabetes and Metabolic Disorders, 2019, 18, 643-656.	1.9	22
1394	Treatment patterns of drug-naïve patients with type 2 diabetes mellitus: a retrospective cohort study using a Japanese hospital database. Diabetology and Metabolic Syndrome, 2019, 11, 90.	2.7	20
1395	A Glimepiride-Metformin Multidrug Crystal: Synthesis, Crystal Structure Analysis, and Physicochemical Properties. Molecules, 2019, 24, 3786.	3.8	17
1396	Études cardiovasculaires chez le patient diabétique de type 2 à risque : conclusions et impact des essais publiés en 2017-2018. Médecine Des Maladies Métaboliques, 2019, 13, S10-S24.	0.1	6
1397	Safe Multi-quadcopter System Continuum Deformation Over Moving Frames. IEEE Transactions on Control of Network Systems, 2019, 6, 737-749.	3.7	8
1398	The Role of Vildagliptin in Treating Hypertension Through Modulating Serum VEGF in Diabetic Hypertensive Patients. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24, 254-261.	2.0	4
1399	Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes. Diabetes Therapy, 2019, 10, 1733-1752.	2.5	47
1400	Effect of Empagliflozin on Free Fatty Acids and Ketone Bodies in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial. Advances in Therapy, 2019, 36, 2769-2782.	2.9	21
1402	An up-to-date evaluation of alogliptin benzoate for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy, 2019, 20, 1679-1687.	1.8	0
1403	A retrospective cross-sectional study of type 2 diabetes overtreatment in patients admitted to the geriatric ward. BMC Geriatrics, 2019, 19, 242.	2.7	11

#	ARTICLE	IF	CITATIONS
1404	Reduction of Severe Hypoglycaemia in People with Type 2 Diabetes after a Structured Inpatient Intervention. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2021, 129, 587-592.	1.2	7
1405	Stakeholder perceptions on patient-centered care at primary health care level in rural eastern Uganda: A qualitative inquiry. <i>PLoS ONE</i> , 2019, 14, e0221649.	2.5	18
1406	Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: Prescription According to Reimbursement Constraints and Guideline Recommendations in Catalonia. <i>Journal of Clinical Medicine</i> , 2019, 8, 1389.	2.4	7
1407	Insulin glargine/lixisenatide in type 2 diabetes: a profile of its use. <i>Drugs and Therapy Perspectives</i> , 2019, 35, 470-480.	0.6	4
1408	Disturbances in Insulinâ€“Glucose Metabolism in Patients With Advanced Renal Disease With and Without Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4949-4966.	3.6	27
1409	Feasibility Studies on Nafion Membrane Actuated Micropump Integrated With Hollow Microneedles for Insulin Delivery Device. <i>Journal of Microelectromechanical Systems</i> , 2019, 28, 987-996.	2.5	17
1411	Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings. <i>Diabetes and Metabolism</i> , 2019, 45, 528-535.	2.9	25
1412	A systematic review exploring characteristics of lifestyle modification interventions in newly diagnosed type 2 diabetes for delivery in community pharmacyâ€“. <i>International Journal of Pharmacy Practice</i> , 2019, 27, 3-16.	0.6	2
1413	Glucocentric risk factors for macrovascular complications in diabetes: Glucose â€“legacyâ€™ and â€“variabilityâ€™-what we see, know and try to comprehend. <i>Diabetes and Metabolism</i> , 2019, 45, 401-408.	2.9	26
1414	The challenge of managing Type 1 diabetes in frail older people. <i>Diabetic Medicine</i> , 2019, 36, 453-456.	2.3	0
1415	Albuminuria Regression and All-Cause Mortality among Insulin-Treated Patients with Type 2 Diabetes: Analysis of a Large UK Primary Care Cohort. <i>American Journal of Nephrology</i> , 2019, 49, 146-155.	3.1	16
1416	Does Adjuvant Treatment with Chinese Herbal Medicine to Antidiabetic Agents Have Additional Benefits in Patients with Type 2 Diabetes? A System Review and Meta-Analysis of Randomized Controlled Trials. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019, 2019, 1-14.	1.2	8
1417	Trends in global prescribing of antidiabetic medicines in primary care: A systematic review of literature between 2000â€“2018. <i>Primary Care Diabetes</i> , 2019, 13, 409-421.	1.8	13
1418	Improved treatment satisfaction in patients with type 2 diabetes treated with onceâ€“weekly semaglutide in the SUSTAIN trials. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2315-2326.	4.4	13
1419	Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. <i>Diabetes and Metabolism Journal</i> , 2019, 43, 287.	4.7	17
1420	Effects of vitamin D supplementation on depressive symptoms in type 2 diabetes mellitus patients: Randomized placebo-controlled double-blind clinical trial. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 2375-2380.	3.6	30
1421	Controversies for Glucose Control Targets in Type 2 Diabetes: Exposing the Common Ground. <i>Diabetes Care</i> , 2019, 42, 1615-1623.	8.6	8
1422	Cardiorespiratory Fitness and Health Care Costs in Diabetes: The Veterans Exercise Testing Study. <i>American Journal of Medicine</i> , 2019, 132, 1084-1090.	1.5	17

#	ARTICLE	IF	CITATIONS
1423	Post-Basal Insulin Intensification and Healthcare Resource Use in Type 2 Diabetes: A Web-Based Physician Survey in the United States and United Kingdom. <i>Diabetes Therapy</i> , 2019, 10, 1323-1336.	2.5	3
1424	Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease. <i>Endocrinology, Diabetes and Metabolism</i> , 2019, 2, e00072.	2.4	1
1425	Biodistribution of [¹¹ C]-Metformin and mRNA Expression of Placentae Metformin Transporters in the Pregnant Chinchilla. <i>Contrast Media and Molecular Imaging</i> , 2019, 2019, 1-6.	0.8	3
1426	Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial. <i>Diabetes Care</i> , 2019, 42, 1464-1472.	8.6	5
1427	Guidelines for Medical Nutrition Therapy in Gestational Diabetes Mellitus: Systematic Review and Critical Appraisal. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2019, 119, 1320-1339.	0.8	36
1428	Racial differences in performance of HbA _{1c} for the classification of diabetes and prediabetes among US adults of non-Hispanic black and white race. <i>Diabetic Medicine</i> , 2019, 36, 1234-1242.	2.3	10
1429	Mean centering-triple divisor and ratio derivative-zero crossing for simultaneous determination of some diabetes drugs in their quaternary mixture with severely overlapping spectra. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2019, 222, 117261.	3.9	14
1430	Individual and Combined Relationship between Reduced eGFR and/or Increased Urinary Albumin Excretion Rate with Mortality Risk among Insulin-Treated Patients with Type 2 Diabetes in Routine Practice. <i>Kidney Diseases (Basel, Switzerland)</i> , 2019, 5, 91-99.	2.5	5
1431	Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDI-liraglutide study 5). <i>Obesity Science and Practice</i> , 2019, 5, 130-140.	1.9	8
1432	Association between Metformin Use and Coronary Artery Calcification in Type 2 Diabetic Patients. <i>Journal of Diabetes Research</i> , 2019, 2019, 1-8.	2.3	11
1433	Intensification to injectable therapy in type 2 diabetes: mixed methods study (protocol). <i>BMC Health Services Research</i> , 2019, 19, 284.	2.2	5
1434	Modulation of Diabetes by Natural Products and Medicinal Plants via Incretins. <i>Planta Medica</i> , 2019, 85, 825-839.	1.3	11
1435	Initiation and Titration of Basal Insulin in Primary Care: Barriers and Practical Solutions. <i>Journal of the American Board of Family Medicine</i> , 2019, 32, 431-447.	1.5	29
1436	Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: real-world evidence from a Mediterranean area. <i>Current Medical Research and Opinion</i> , 2019, 35, 1735-1744.	1.9	10
1437	High level of clinical inertia in insulin initiation in type 2 diabetes across Central and South-Eastern Europe: insights from SITIP study. <i>Acta Diabetologica</i> , 2019, 56, 1045-1049.	2.5	15
1438	Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report. <i>Diabetes Care</i> , 2019, 42, 731-754.	8.6	734
1439	Proximal HbA _{1c} Level and First Hypoglycemia Hospitalization in Adults With Incident Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1989-1998.	3.6	2
1440	Clinical Management of Intermittent Fasting in Patients with Diabetes Mellitus. <i>Nutrients</i> , 2019, 11, 873.	4.1	83

#	ARTICLE	IF	CITATIONS
1441	<p>>Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials</p><p>>. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 447-455.	2.4	13
1442	Effect of a single dose of insulin glargine/lixisenatide fixed ratio combination (iGlarLixi) on postprandial glucodynamic response in Japanese patients with type 2 diabetes mellitus: A phase I randomized trial. Diabetes, Obesity and Metabolism, 2019, 21, 2001-2005.	4.4	8
1443	Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin. Diabetes, Obesity and Metabolism, 2019, 21, 2048-2057.	4.4	26
1444	A Greek registry of current type 2 diabetes management, aiming to determine core clinical approaches, patterns and strategies. BMC Endocrine Disorders, 2019, 19, 39.	2.2	8
1445	A View Beyond HbA1c: Role of Continuous Glucose Monitoring. Diabetes Therapy, 2019, 10, 853-863.	2.5	116
1446	Impact of ischaemic heart disease severity and age on risk of cardiovascular outcome in diabetes patients in Sweden: a nationwide observational study. BMJ Open, 2019, 9, e027199.	1.9	5
1447	Use of Insulin Glargine 100ÂU/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review. Diabetes Therapy, 2019, 10, 805-833.	2.5	4
1448	<p>Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA</p>. ClinicoEconomics and Outcomes Research, 2019, Volume 11, 271-282.	1.9	3
1449	GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data. Diabetes Therapy, 2019, 10, 1067-1088.	2.5	33
1450	Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. Diabetes Technology and Therapeutics, 2019, 21, 273-285.	4.4	26
1451	Physical activity and risk of diabetic retinopathy: a systematic review and meta-analysis. Acta Diabetologica, 2019, 56, 823-837.	2.5	35
1452	Insulin Initiation and Titration in Patients With Type 2 Diabetes. Diabetes Spectrum, 2019, 32, 104-111.	1.0	33
1453	Metformin and Breast Cancer: Molecular Targets. Journal of Mammary Gland Biology and Neoplasia, 2019, 24, 111-123.	2.7	57
1454	An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes. Expert Opinion on Pharmacotherapy, 2019, 20, 781-790.	1.8	4
1455	Accuracy of a composite event definition for hypoglycemia. Pharmacoepidemiology and Drug Safety, 2019, 28, 625-631.	1.9	3
1456	Drug treatment of type 2 diabetes: Its cost is significantly associated with HbA1c levels. International Journal of Clinical Practice, 2019, 73, e13336.	1.7	5
1457	Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study. BMJ Open, 2019, 9, e025806.	1.9	67
1458	Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1520-1574.	3.6	305

#	ARTICLE	IF	CITATIONS
1459	Real-World Effectiveness and Safety of Lixisenatide as Add-On to Oral Antidiabetic Drugs as Part of Routine Clinical Practice in Bulgaria: LIXODAR Study. <i>Diabetes Therapy</i> , 2019, 10, 981-993.	2.5	2
1460	Greater Combined Reductions in HbA1C \approx 1.0% and Weight \approx 5.0% with Semaglutide Versus Comparators in type 2 Diabetes. <i>Endocrine Practice</i> , 2019, 25, 589-597.	2.1	10
1462	Implications of Removing Rosiglitazone's Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 72-79.	0.9	9
1463	Pancreatic Safety in Studies of The Glucagon-Like Peptide-1 Receptor Agonist Albiglutide. <i>Endocrine Practice</i> , 2019, 25, 698-716.	2.1	0
1464	Prognostic impact of visit-to-visit glycemic variability on the risks of major adverse cardiovascular outcomes and hypoglycemia in patients with different glycemic control and type 2 diabetes. <i>Endocrine</i> , 2019, 64, 536-543.	2.3	19
1465	Updates on Managing Type 2 Diabetes Mellitus with Natural Products: Towards Antidiabetic Drug Development. <i>Current Medicinal Chemistry</i> , 2019, 25, 5395-5431.	2.4	60
1466	Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care. <i>Circulation</i> , 2019, 139, 2822-2830.	1.6	167
1467	Diabetes management and treatment approaches outside of North America and West Europe in 2006 and 2015. <i>Acta Diabetologica</i> , 2019, 56, 889-897.	2.5	4
1469	Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. <i>Scientific Reports</i> , 2019, 9, 5389.	3.3	64
1470	Consensus pour la prise en charge de l'hyperglycémie dans le diabète de type 2 en Afrique subsaharienne. Rédigé par un groupe d'experts africains du diabète. <i>Medecine Des Maladies Metaboliques</i> , 2019, 13, 210-216.	0.1	4
1471	The Self-Management Assessment Scale: Development and psychometric testing of a screening instrument for person-centred guidance and self-management support. <i>Nursing Open</i> , 2019, 6, 504-513.	2.4	9
1473	Deintensification in older patients with type 2 diabetes: A systematic review of approaches, rates and outcomes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1668-1679.	4.4	56
1474	Efficacy and Safety of Basal Analog Regimens in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Diabetes Therapy</i> , 2019, 10, 1051-1066.	2.5	7
1475	Factors influencing safe glucose-lowering in older adults with type 2 diabetes: A Person-centred Approach To Individualised (PROACTIVE) Glycemic Goals for older people. <i>Primary Care Diabetes</i> , 2019, 13, 330-352.	1.8	28
1476	Decision aids for people with Type 2 diabetes mellitus: an effectiveness rapid review and meta-analysis. <i>Diabetic Medicine</i> , 2019, 36, 557-568.	2.3	9
1477	Association of smoking and cardiometabolic parameters with albuminuria in people with type 2 diabetes mellitus: a systematic review and meta-analysis. <i>Acta Diabetologica</i> , 2019, 56, 839-850.	2.5	28
1478	Metformin and tenovin synergistically induces apoptosis through LKB1-independent SIRT1 down-regulation in non-small cell lung cancer cells. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 2872-2889.	3.6	27
1479	The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world setting. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1429-1436.	4.4	28

#	ARTICLE	IF	CITATIONS
1480	Weight loss in patients with type 2 diabetes receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A <i>post-hoc</i> analysis of the AWARD-4 study across baseline body mass index subgroups. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1340-1348.	4.4	6
1481	Effect of Weight Change on Economic Outcomes Among Persons with Type 2 Diabetes Mellitus in the United States: Beyond Glycemic Control. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 658-668.	0.9	6
1482	Metformin triggers the intrinsic apoptotic response in human AGS gastric adenocarcinoma cells by activating AMPK and suppressing mTOR/AKT signaling. <i>International Journal of Oncology</i> , 2019, 54, 1271-1281.	3.3	39
1483	Sodium-glucose cotransporter 2 inhibitor plus pioglitazone vs pioglitazone alone in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. <i>Endocrinology, Diabetes and Metabolism</i> , 2019, 2, e00050.	2.4	10
1484	Relative contribution of basal and postprandial hyperglycaemia stratified by HbA1c categories before and after treatment intensification with dulaglutide. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1365-1372.	4.4	5
1485	Hypertriglyceridemia and Its Association with HbA1c Test: A Prospective <i>In Vivo</i> Controlled Study. <i>International Journal of Endocrinology</i> , 2019, 2019, 1-6.	1.5	3
1486	Managing care for people with diabetes undergoing dialysis. <i>Journal of Renal Care</i> , 2019, 45, 59-67.	1.2	5
1487	Importance of Postprandial Glucose in Relation to A1C and Cardiovascular Disease. <i>Clinical Diabetes</i> , 2019, 37, 250-259.	2.2	16
1488	Influence of Sodium Glucose Cotransporter 2 Inhibition on Physiological Adaptation to Endurance Exercise Training. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1953-1966.	3.6	26
1489	A Pilot Study to Assess Clinical Utility and User Experience of Professional Continuous Glucose Monitoring Among People With Type 2 Diabetes. <i>Clinical Diabetes</i> , 2019, 37, 57-64.	2.2	3
1490	ANTIDIABETIC MEDICINAL PLANTS: A REVIEW. <i>International Research Journal of Pharmacy</i> , 2019, 10, 31-37.	0.2	3
1491	Mortality and potential years of life lost attributable to non-optimal glycaemic control in men and women with diabetes in the United Arab Emirates: a population-based retrospective cohort study. <i>BMJ Open</i> , 2019, 9, e032654.	1.9	0
1492	6. Glycemic Targets: <i>Standards of Medical Care in Diabetes</i> 2019. <i>Diabetes Care</i> , 2019, 42, S61-S70.	8.6	583
1493	ApoB/ApoA1 ratio and non-HDL-cholesterol/HDL-cholesterol ratio are associated to metabolic syndrome in patients with type 2 diabetes mellitus subjects and to ischemic cardiomyopathy in diabetic women. <i>Endocrinologia, Diabetes Y Nutrición</i> , 2019, 66, 502-511.	0.3	7
1495	Glucose Control In Diabetic Patients Considering Daily Real Life Factors. , 2019, , .		5
1496	Factors affecting follow-up non-attendance in patients with Type 2 diabetes mellitus and hypertension: a systematic review. <i>Singapore Medical Journal</i> , 2019, 60, 216-223.	0.6	41
1497	Why are there Variations in the Responses of Glucagon-like Peptide-1 Agonists among the Type 2 Diabetic Patients?. <i>Current Clinical Pharmacology</i> , 2019, 14, 247-248.	0.6	0
1498	Insulin Glargine U100 Utilization in Patients with Type 2 Diabetes in an Italian Real-World Setting: A Retrospective Study. <i>Journal of Diabetes Research</i> , 2019, 2019, 1-10.	2.3	1

#	ARTICLE	IF	CITATIONS
1499	<p><p>Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus</p></p>. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 2725-2733.	2.4	3
1500	Experimental Evaluation of Continuum Deformation with a Five Quadrotor Team. , 2019, , .		8
1501	Benefits and harms of intensive glycemic control in patients with type 2 diabetes. BMJ: British Medical Journal, 2019, 367, l5887.	2.3	84
1502	Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks. BMJ Open Diabetes Research and Care, 2019, 7, e000728.	2.8	10
1503	Association between clinical outcomes and metformin use in adults with sickle cell disease and diabetes mellitus. Blood Advances, 2019, 3, 3297-3306.	5.2	9
1504	Recognising the importance of self-management for people with diabetes. British Journal of Health Care Management, 2019, 25, 224-229.	0.2	1
1505	Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus. BMJ Open, 2019, 9, e024954.	1.9	100
1506	Management of patients with type 2 diabetes in cardiovascular rehabilitation. European Journal of Preventive Cardiology, 2019, 26, 133-144.	1.8	11
1507	ApoB/ApoA1 ratio and non-HDL-cholesterol/HDL-cholesterol ratio are associated to metabolic syndrome in patients with type 2 diabetes mellitus subjects and to ischemic cardiomyopathy in diabetic women. Endocrinolog&Aa Diabetes Y Nutrici&A3n (English Ed), 2019, 66, 502-511.	0.2	2
1508	Practical Guidance on Effective Basal Insulin Titration for Primary Care Providers. Clinical Diabetes, 2019, 37, 368-376.	2.2	16
1509	Eurotium Cristatum Fermented Okara as a Potential Food Ingredient to Combat Diabetes. Scientific Reports, 2019, 9, 17536.	3.3	26
1510	Decreases in Circulating Concentrations of Long-Chain Acylcarnitines and Free Fatty Acids During the Glucose Tolerance Test Represent Tissue-Specific Insulin Sensitivity. Frontiers in Endocrinology, 2019, 10, 870.	3.5	23
1511	Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study. PLoS Medicine, 2019, 16, e1002999.	8.4	9
1512	Expression of the Biologically Active Insulin Analog SCI-57 in Nicotiana Benthamiana. Frontiers in Pharmacology, 2019, 10, 1335.	3.5	7
1513	Impacts of nurse-led clinic and nurse-led prescription on hemoglobin A1c control in type 2 diabetes. Medicine (United States), 2019, 98, e15971.	1.0	14
1514	Glucagon&Alike peptide&A1 receptor agonists in type 2 diabetes treatment: are they all the same?. Diabetes/Metabolism Research and Reviews, 2019, 35, e3070.	4.0	161
1515	Effects of metformin and alogliptin on body composition in people with type 2 diabetes. Journal of Diabetes Investigation, 2019, 10, 723-730.	2.4	11
1516	Towards a better understanding of postprandial hyperglycemic episodes in people with diabetes: impact on daily functioning. Current Medical Research and Opinion, 2019, 35, 525-533.	1.9	4

#	ARTICLE	IF	CITATIONS
1517	Titration and optimization trial for the initiation of insulin glargine 100 U/mL in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 439-443.	4.4	9
1518	Evolution of type 2 diabetes mellitus treatment approaches. <i>Journal of Diabetes</i> , 2019, 11, 4-6.	1.8	2
1519	Pharmacists' role in glycemic management in the inpatient setting: An opinion of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2019, 2, 167-176.	1.0	3
1520	Efficacy and safety of sitagliptin added to treatment of patients with type 2 diabetes inadequately controlled with premixed insulin. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 408-411.	4.4	2
1521	A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide. <i>Diabetes Therapy</i> , 2019, 10, 21-33.	2.5	10
1522	Sustained low-efficiency dialysis for metformin-associated lactic acidosis in patients with acute kidney injury. <i>Journal of Nephrology</i> , 2019, 32, 297-306.	2.0	15
1523	Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. <i>Acta Diabetologica</i> , 2019, 56, 605-617.	2.5	50
1524	Health-related quality of life in adults with type 2 diabetes mellitus starting with new glucose lowering drugs: An inception cohort study. <i>Primary Care Diabetes</i> , 2019, 13, 221-232.	1.8	5
1525	Heart Failure in Type 2 Diabetes Mellitus. <i>Circulation Research</i> , 2019, 124, 121-141.	4.5	411
1526	New pharmacological strategies for protecting kidney function in type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 397-412.	11.4	64
1527	Efficacy and Safety of IDegAsp Versus BAsp 30, Both Twice Daily, in Elderly Patients with Type 2 Diabetes: Post Hoc Analysis of Two Phase 3 Randomized Controlled BOOST Trials. <i>Diabetes Therapy</i> , 2019, 10, 107-118.	2.5	9
1528	Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT Study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 781-790.	4.4	19
1529	Metabolomics Based on MS in Mice with Diet-Induced Obesity and Type 2 Diabetes Mellitus: the Effect of Vildagliptin, Metformin, and Their Combination. <i>Applied Biochemistry and Biotechnology</i> , 2019, 188, 165-184.	2.9	11
1530	Efficacy of DPP-4 inhibitors, GLP-1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: a model-based meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 393-402.	2.4	19
1531	Diabetes: the place of new therapies. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881880759.	3.2	10
1532	Temporal trends in optimal diabetic care and complications of elderly type 2 diabetes patients in Thailand: A nationwide study. <i>Journal of Evidence-Based Medicine</i> , 2019, 12, 22-28.	2.4	7
1533	Pharmacoeconomic evaluation of sodium-glucose transporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 151-161.	1.8	19
1534	Chronic kidney disease among US adults with type 2 diabetes and cardiovascular diseases: A national estimate of prevalence by KDIGO 2012 classification. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 612-615.	3.6	20

#	ARTICLE	IF	CITATIONS
1535	Type 2 diabetes treatment and progression of chronic kidney disease in Italian family practice. Journal of Endocrinological Investigation, 2019, 42, 787-796.	3.3	2
1536	Conceptualizing multiple drug use in patients with comorbidity and multimorbidity: proposal for standard definitions beyond the term polypharmacy. Journal of Clinical Epidemiology, 2019, 106, 98-107.	5.0	12
1537	Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSITE-M study. Diabetes, Obesity and Metabolism, 2019, 21, 1128-1135.	4.4	7
1538	Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multicentre, randomized, controlled trial. Diabetes, Obesity and Metabolism, 2019, 21, 939-948.	4.4	3
1539	Cardiovascular efficacy and safety of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis. Diabetic Medicine, 2019, 36, 444-452.	2.3	30
1540	Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes. Drugs, 2019, 79, 173-186.	10.9	13
1541	Comparative Effectiveness of Metformin Dosage Uptitration Versus Adding Another Antihyperglycemic Medication on Glycemic Control in Type 2 Diabetes Patients Failing Initial Metformin Monotherapy: A Retrospective Cohort Study. Population Health Management, 2019, 22, 457-463.	1.7	3
1542	Patterns and trends in insulin initiation and intensification among patients with Type 2 diabetes mellitus in the Middle East and North Africa region. Diabetes Research and Clinical Practice, 2019, 149, 18-26.	2.8	16
1543	Exercise training for patients with type 2 diabetes and cardiovascular disease: What to pursue and how to do it. A Position Paper of the European Association of Preventive Cardiology (EAPC). European Journal of Preventive Cardiology, 2019, 26, 709-727.	1.8	68
1544	Changing the Concept of Type 2 Diabetes: Beta Cell Workload Hypothesis Revisited. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2019, 19, 121-127.	1.2	13
1545	Toward Better Understanding of Insulin Therapy by Translation of a PK-PD Model to Visualize Insulin and Glucose Action Profiles. Journal of Clinical Pharmacology, 2019, 59, 258-270.	2.0	2
1546	Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial. Diabetes, Obesity and Metabolism, 2019, 21, 631-639.	4.4	10
1547	Nutrition and Disease: Type 2 Diabetes Mellitus. , 2019, , 43-48.		1
1548	Kidney Transplant Management. , 2019, , .		1
1549	Pharmacokinetics of a Lobeglitazone/Metformin Fixed-Dose Combination Tablet (CKD-395 0.5/1000mg) Versus Concomitant Administration of Single Agents and the Effect of Food on the Metabolism of CKD-395 in Healthy Male Subjects. Clinical Pharmacology in Drug Development, 2019, 8, 576-584.	1.6	3
1550	Basal insulin therapy: Unmet medical needs in Asia and the new insulin glargine in diabetes treatment. Journal of Diabetes Investigation, 2019, 10, 560-570.	2.4	11
1551	Predictive factors associated with three years of response to HbA1c goals with exenatide QW or insulin glargine: <i>Post-hoc</i> analysis of the DURATION-3 study. Diabetes, Obesity and Metabolism, 2019, 21, 1049-1053.	4.4	1
1552	Medications for the Treatment of Type II Diabetes. , 2019, , 101-106.		0

#	ARTICLE	IF	CITATIONS
1553	Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. <i>Annals of Internal Medicine</i> , 2019, 170, 423.	3.9	34
1554	Long-Term Clinical Benefits of Canagliflozin 100 mg Versus Sulfonylurea in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin in India. <i>Value in Health Regional Issues</i> , 2019, 18, 65-73.	1.2	3
1555	The Effect of Linagliptin versus Metformin Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2019, 10, 119-134.	2.5	4
1556	Oral semaglutide for the treatment of type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 133-141.	1.8	33
1557	A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes. <i>Diabetes Therapy</i> , 2019, 10, 5-19.	2.5	54
1558	Type 1 and 2 diabetes mellitus: A review on current treatment approach and gene therapy as potential intervention. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 364-372.	3.6	236
1559	Artificial Pancreas Systems for People With Type 2 Diabetes: Conception and Design of the European CLOSE Project. <i>Journal of Diabetes Science and Technology</i> , 2019, 13, 261-267.	2.2	13
1560	Metformin for lung cancer prevention and improved survival: a novel approach. <i>European Journal of Cancer Prevention</i> , 2019, 28, 311-315.	1.3	7
1561	Impact of sex and glucose-lowering treatments on hypoglycaemic symptoms in people with type 2 diabetes and chronic kidney disease. The French Chronic Kidney Disease "Renal Epidemiology and Information Network (CKD-REIN) Study. <i>Diabetes and Metabolism</i> , 2019, 45, 175-183.	2.9	9
1562	Heart Failure With Preserved Ejection Fraction: Prevention and Management. <i>American Journal of Lifestyle Medicine</i> , 2019, 13, 182-189.	1.9	16
1563	Quality of Life, Glycemic Control, Safety and Tolerability Associated with Liraglutide or Insulin Initiation in Patients with Type 2 Diabetes in Germany: Results from the Prospective, Non-interventional LIBERTY Study. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2020, 128, 170-181.	1.2	6
1564	Impact of Timing Between Insulin Administration and Meal Consumption on Glycemic Fluctuation and Outcomes in Hospitalized Patients With Type 2 Diabetes. <i>Journal of Pharmacy Practice</i> , 2020, 33, 449-456.	1.0	2
1565	Real-World Adequacy of Glycaemic Control in Treatment-Naïve Greek Patients with Type 2 Diabetes Mellitus Initiating Treatment with Metformin Monotherapy at the Maximum Tolerated Dose: The Reload Study. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2020, 128, 224-230.	1.2	1
1566	Liraglutide vs. lixisenatide in obese type 2 diabetes mellitus patients: What effect should we expect in routine clinical practice?. <i>Primary Care Diabetes</i> , 2020, 14, 68-74.	1.8	4
1567	The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 152-162.	3.6	17
1568	Pharmacological treatment initiation for type 2 diabetes in Australia: are the guidelines being followed?. <i>Diabetic Medicine</i> , 2020, 37, 1367-1373.	2.3	4
1569	Mexican population sub-analysis of the lixilan clinical program with the fixed ratio combination of insulin glargine and lixisenatide (iGlarLixi). <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107389.	2.3	2
1570	Incretins in obesity and diabetes. <i>Annals of the New York Academy of Sciences</i> , 2020, 1461, 104-126.	3.8	57

#	ARTICLE	IF	CITATIONS
1571	The association between diabetes medication and weight change in a non-surgical weight management intervention: an intervention cohort study. <i>Diabetic Medicine</i> , 2020, 37, 248-255.	2.3	3
1572	In Silico Examination of Initiation of Long-Acting Insulin Analogs Toujeo Compared to Lantus Under 3 Dosing Titration Rules in Virtual Type 2 Diabetes Subjects. <i>Journal of Diabetes Science and Technology</i> , 2020, 14, 898-907.	2.2	3
1573	Diabetes, dysglycemia, and vascular surgery. <i>Journal of Vascular Surgery</i> , 2020, 71, 701-711.	1.1	10
1574	Titration of insulin glargine 100ÂU/mL when added to oral antidiabetic drugs in patients with type 2 diabetes: results of the TOP-1 real-world study. <i>Acta Diabetologica</i> , 2020, 57, 89-99.	2.5	7
1575	The relationship between urinary albumin excretion, cardiovascular outcomes and total mortality among a large cohort of insulin-treated patients with type 2 diabetes in routine primary care practices. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 471-477.	0.7	2
1576	Glycaemic control among patients with type 2 diabetes followed in a rural African primary care setting – A reality check in the Democratic Republic of Congo. <i>Primary Care Diabetes</i> , 2020, 14, 139-146.	1.8	9
1577	Efficacy of Intermittently Scanned Continuous Glucose Monitoring in the Prevention of Recurrent Severe Hypoglycemia. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 367-373.	4.4	19
1578	A population-based analysis of antidiabetic medications in four Canadian provinces: Secular trends and prescribing patterns. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 86-92.	1.9	10
1579	Adult attachment insecurity and associations with diabetes distress, daily stressful events and self-management in type 1 diabetes. <i>Journal of Behavioral Medicine</i> , 2020, 43, 695-706.	2.1	2
1580	Combination of Oligofructose and Metformin Alters the Gut Microbiota and Improves Metabolic Profiles, Contributing to the Potentiated Therapeutic Effects on Diet-Induced Obese Animals. <i>Frontiers in Endocrinology</i> , 2019, 10, 939.	3.5	15
1581	Insulin Glargine 300ÂU/mL and Insulin Glulisine Treatment in Patients with Type 2 Diabetes: A Non-Interventional Study of Effectiveness in Routine Clinical Practice. <i>Diabetes Therapy</i> , 2020, 11, 467-478.	2.5	2
1582	Adaptive Treatment Strategies With Survival Outcomes: An Application to the Treatment of Type 2 Diabetes Using a Large Observational Database. <i>American Journal of Epidemiology</i> , 2020, 189, 461-469.	3.4	7
1583	The EMPagliflozin comparative effectiveness and Safety (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00103.	2.4	18
1584	New Antidiabetic Targets of α -Glucosidase Inhibitory Peptides, SVPA, SEPA, STYV and STY: Inhibitory Effects on Dipeptidyl Peptidase-IV and Lipid Accumulation in 3T3-L1 Differentiated Adipocytes with Scavenging Activities Against Methylglyoxal and Reactive Oxygen Species. <i>International Journal of Peptide Research and Therapeutics</i> , 2020, 26, 1949-1963.	1.9	4
1585	Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes. <i>Diabetes Therapy</i> , 2020, 11, 573-584.	2.5	25
1586	Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. <i>Diabetes Care</i> , 2020, 43, 643-652.	8.6	38
1587	Male and female sexual dysfunction in diabetic subjects: Focus on new antihyperglycemic drugs. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 57-65.	5.7	24
1588	User Centered Design to Improve Information Exchange in Diabetes Care Through eHealth. <i>Journal of Medical Systems</i> , 2020, 44, 2.	3.6	18

#	ARTICLE	IF	CITATIONS
1589	Cardiovascular risk following metformin treatment in patients with type 2 diabetes mellitus: Results from meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2020, 160, 108001.	2.8	53
1590	Analysis of urinary metabolic alteration in type 2 diabetic rats treated with metformin using the metabolomics of quantitative spectral deconvolution ¹ H NMR spectroscopy. <i>Microchemical Journal</i> , 2020, 153, 104513.	4.5	10
1591	Gardenia fructus antidepressant formula for depression in diabetes patients: A systematic review and meta-analysis. <i>Complementary Therapies in Medicine</i> , 2020, 48, 102248.	2.7	4
1592	The right place for metformin today. <i>Diabetes Research and Clinical Practice</i> , 2020, 159, 107946.	2.8	29
1593	Biosynthetic Human Insulin and Insulin Analogs. <i>American Journal of Therapeutics</i> , 2020, 27, e42-e51.	0.9	23
1594	Chronic Kidney Disease as Risk Factor for Enlarged Perivascular Spaces in Patients With Stroke and Relation to Racial Group. <i>Stroke</i> , 2020, 51, 3348-3351.	2.0	9
1595	Development and Validation of a Hypoglycemia Risk Model for Intensive Insulin Therapy in Patients with Type 2 Diabetes. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-7.	2.3	4
1596	Postprandial Glucose Spikes, an Important Contributor to Cardiovascular Disease in Diabetes?. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 570553.	2.4	29
1597	Validity of the Good Practice Guidelines: The example of type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2020, 169, 108459.	2.8	2
1598	Quality-of-Life Comparison of Dapagliflozin Versus Dipeptidyl Peptidase-4 Inhibitors in Patients with Type-2 Diabetes Mellitus: A Randomized Controlled Trial (J-BOND Study). <i>Diabetes Therapy</i> , 2020, 11, 2959-2977.	2.5	7
1599	Clinical inertia in type 2 diabetes management in a middle-income country: A retrospective cohort study. <i>PLoS ONE</i> , 2020, 15, e0240531.	2.5	11
1600	Total Synthesis of Semaglutide Based on a Soluble Hydrophobic-Support-Assisted Liquid-Phase Synthetic Method. <i>ACS Combinatorial Science</i> , 2020, 22, 821-825.	3.8	7
1601	Adherence to the National Guidelines for Follow-Up Protocol in Subjects with Type 2 Diabetes Mellitus in Greece: The GLANCE Study. <i>Diabetes Therapy</i> , 2020, 11, 2887-2908.	2.5	3
1602	Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Societ� Italiana Farmacologia (SIF) multidisciplinary consensus position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 154, 103066.	4.4	7
1603	Patient decisional needs when considering treatment intensification for type 2 diabetes: A qualitative study in China. <i>Diabetes Research and Clinical Practice</i> , 2020, 170, 108471.	2.8	2
1604	Titrateable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2020, 170, 108478.	2.8	14
1605	Level of glycemic control and its associated factors among type II diabetic patients in debre tabor general hospital, northwest Ethiopia. <i>Metabolism Open</i> , 2020, 8, 100056.	2.9	19
1606	DIA-DB: A Database and Web Server for the Prediction of Diabetes Drugs. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 4124-4130.	5.4	12

#	ARTICLE	IF	CITATIONS
1607	Effect of clinical inertia and trial participation in younger and older adults with diabetes having comorbidities and progressive complications. <i>Diabetes Research and Clinical Practice</i> , 2020, 166, 108310.	2.8	1
1608	Does Renal Function or Heart Failure Diagnosis Affect Primary Care Prescribing for Sodium-Glucose Co-Transporter Δ 2 Inhibitors in Type Δ 2 Diabetes?. <i>Diabetes Therapy</i> , 2020, 11, 2169-2175.	2.5	1
1609	The effectiveness of insulin glargine 300 U/mL among type 2 diabetes patients: Analysis of a real-world data in Israel. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00124.	2.4	0
1610	Versatile Nutraceutical Potentials of Watermelon—A Modest Fruit Loaded with Pharmaceutically Valuable Phytochemicals. <i>Molecules</i> , 2020, 25, 5258.	3.8	34
1611	Trends in national pharmaceutical expenditure on diabetes in Ireland 2011–2015: a repeated cross-sectional study. <i>BMJ Open</i> , 2020, 10, e037382.	1.9	3
1612	RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020. <i>International Journal of Diabetes in Developing Countries</i> , 2020, 40, 1-122.	0.8	16
1613	Suboptimal glycemic control among subjects with diabetes mellitus in India: a subset analysis of cross-sectional wave-7 (2016) data from the International Diabetes Management Practices Study (IDMPS). <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2020, 11, 204201882093721.	3.2	9
1614	Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. <i>Diabetes Care</i> , 2020, 43, 2509-2518.	8.6	33
1615	The Boomers Come of Age. <i>Physician Assistant Clinics</i> , 2020, 5, 247-258.	0.1	0
1616	Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, metformin, and thiazolidinediones. <i>International Review of Neurobiology</i> , 2020, 155, 37-64.	2.0	24
1618	6. Glycemic Targets: <i>Standards of Medical Care in Diabetes—2020</i>. <i>Diabetes Care</i> , 2020, 43, S66-S76.	8.6	614
1619	Evaluation of the Antidiabetic and Insulin Releasing Effects of <i>A. squamosa</i> , Including Isolation and Characterization of Active Phytochemicals. <i>Plants</i> , 2020, 9, 1348.	3.5	17
1620	Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012–2018. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001279.	2.8	41
1621	Time course and dose effect of metformin on weight in patients with different disease states. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1169-1177.	3.1	5
1622	Social support, strain, and glycemic control: A path analysis. <i>Personal Relationships</i> , 2020, 27, 592-612.	1.5	9
1623	Efficacy and safety of insulin glargine 300 U/mL (Gla-300) during hospitalization and therapy intensification at discharge in patients with insufficiently controlled type 2 diabetes: results of the phase IV COBALTA trial. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001518.	2.8	10
1624	Formation of β TC3 and MIN6 Pseudoislets Changes the Expression Pattern of Gpr40, Gpr55, and Gpr119 Receptors and Improves Lysophosphatidylcholines-Potentiated Glucose-Stimulated Insulin Secretion. <i>Cells</i> , 2020, 9, 2062.	4.1	8
1625	An online mobile/desktop application for supporting sustainable chronic disease self-management and lifestyle change. <i>Health Informatics Journal</i> , 2020, 26, 2860-2876.	2.1	4

#	ARTICLE	IF	CITATIONS
1626	Decreased Antihyperglycemic Drug Use Driven by High Out-of-Pocket Costs Despite Medicare Coverage Gap Closure. <i>Diabetes Care</i> , 2020, 43, 2121-2127.	8.6	7
1627	Type of diabetes mellitus and health-related quality of life in Nigeria: Ethnic and sex differences. <i>Journal of Psychology in Africa</i> , 2020, 30, 529-534.	0.6	0
1628	<p>Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds</p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 10215-10240.	6.7	44
1629	Real World Use of Antidiabetic Drugs in the Years 2011â€“2017: A Population-Based Study from Southern Italy. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 9514.	2.6	5
1630	MicroRNAs (âˆ“146a, âˆ“21 and âˆ“34a) are diagnostic and prognostic biomarkers for diabetic retinopathy. <i>Biomedical Journal</i> , 2021, 44, S242-S251.	3.1	9
1631	Health behaviour change considerations for weight loss and type 2 diabetes: nutrition, physical activity and sedentary behaviour. <i>Practical Diabetes</i> , 2020, 37, 228.	0.3	4
1632	<p>Antimicrobial Susceptibility Testing and Phenotypic Detection of MRSA Isolated from Diabetic Foot Infection</p>. <i>International Journal of General Medicine</i> , 2020, Volume 13, 1349-1357.	1.8	14
1633	The overtreatment of type 2 diabetes in frail older people. <i>Journal of Prescribing Practice</i> , 2020, 2, 496-502.	0.1	0
1634	Sulfonylureas use and fractures risk in elderly patients with type 2 diabetes mellitus: a meta-analysis study. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 2133-2139.	2.9	12
1635	Overview of Therapeutic Inertia in Diabetes: Prevalence, Causes, and Consequences. <i>Diabetes Spectrum</i> , 2020, 33, 8-15.	1.0	25
1636	Variations in the Delivery of Primary Diabetes Care in Malaysia: Lessons to Be Learnt and Potential for Improvement. <i>Health Services Research and Managerial Epidemiology</i> , 2020, 7, 233339282091874.	0.9	2
1637	Descending Expression of miR320 in Insulin-Resistant Adipocytes Treated with Ascending Concentrations of Metformin. <i>Biochemical Genetics</i> , 2020, 58, 661-676.	1.7	6
1638	Pathophysiology and Management of Type 2 Diabetes Mellitus Bone Fragility. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-18.	2.3	55
1639	Finding the clinical utility of 1,5-anhydroglucitol among primary care practitioners. <i>Journal of Clinical and Translational Endocrinology</i> , 2020, 20, 100224.	1.4	1
1640	Initial Therapy, Regimen Change, and Persistence in a Spanish Cohort of Newly Treated Type 2 Diabetes Patients: A Retrospective, Observational Study Using Real-World Data. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 3742.	2.6	7
1641	Evaluation of the safety of sodiumâ€“glucose coâ€“transporterâ€“2 inhibitors for treating patients with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1767-1776.	4.4	6
1642	The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2020, 109, 154295.	3.4	18
1643	The overtreatment of type 2 diabetes in frail older people. <i>Practice Nursing</i> , 2020, 31, 240-244.	0.1	0

#	ARTICLE	IF	CITATIONS
1644	Hemoglobin structure at higher levels of hemoglobin A1C in type 2 diabetes and associated complications. Chinese Medical Journal, 2020, 133, 1138-1143.	2.3	5
1645	Cancer Biology and Prevention in Diabetes. Cells, 2020, 9, 1380.	4.1	39
1646	<p>Metformin Promotes Beclin1-Dependent Autophagy to Inhibit the Progression of Gastric Cancer</p>. OncoTargets and Therapy, 2020, Volume 13, 4445-4455.	2.0	17
1647	Baseline Characteristics of Patients with Type 2 Diabetes Initiating Second-Line Treatment in Japan: Findings from the J-DISCOVER Study. Diabetes Therapy, 2020, 11, 1563-1578.	2.5	8
1648	Scientific independence and objectivity: many questions linger about treatment of type 2 diabetes, such as scientific study design, optimal glucose control and the safety of injecting exogenous insulin. Postgraduate Medicine, 2020, 132, 667-675.	2.0	0
1649	Centella asiatica: its potential for the treatment of diabetes. , 2020, , 213-222.		1
1650	The impact of online self-management interventions on midlife adults with type 2 diabetes: a systematic review. British Journal of Nursing, 2020, 29, 266-272.	0.7	10
1651	Physicians' choices in the first- and second-line management of type 2 diabetes in the Kingdom of Saudi Arabia. Saudi Pharmaceutical Journal, 2020, 28, 329-337.	2.7	10
1652	Improving Dissolution and Cytotoxicity by Forming Multidrug Crystals. Molecules, 2020, 25, 1343.	3.8	6
1653	Correlates of Blood Pressure and Cholesterol Level Testing Among a Socially-Disadvantaged Population in Poland. International Journal of Environmental Research and Public Health, 2020, 17, 2123.	2.6	3
1654	Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial. Acta Diabetologica, 2020, 57, 991-1000.	2.5	3
1656	A Cohort Study of Exposure to Antihyperglycemic Therapy and Survival in Patients with Lung Cancer. International Journal of Environmental Research and Public Health, 2020, 17, 1747.	2.6	1
1657	How Significant Is Severe Hypoglycemia in Older Adults With Diabetes?. Diabetes Care, 2020, 43, 512-514.	8.6	13
1658	The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease. Diabetes Care, 2020, 43, 948-955.	8.6	76
1659	Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain. BMJ Open Diabetes Research and Care, 2020, 8, e001052.	2.8	56
1660	Approximate Bayesian Bootstrap procedures to estimate multilevel treatment effects in observational studies with application to type 2 diabetes treatment regimens. Statistical Methods in Medical Research, 2020, 29, 3362-3380.	1.5	2
1661	Functional loss of pancreatic islets in type 2 diabetes: How can we halt it?. Metabolism: Clinical and Experimental, 2020, 110, 154304.	3.4	25
1662	Advanced Nanoscale Build-Up Sensors for Daily Life Monitoring of Diabetics. Advanced Materials Interfaces, 2020, 7, 2000153.	3.7	23

#	ARTICLE	IF	CITATIONS
1663	Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4725.	4.1	66
1664	Metformin Alleviates Left Ventricular Diastolic Dysfunction in a Rat Myocardial Ischemia Reperfusion Injury Model. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1489.	4.1	9
1665	Effect of a mindfulness programme for long-term care residents with type 2 diabetes: A cluster randomised controlled trial measuring outcomes of glycaemic control, relocation stress and depression. <i>International Journal of Older People Nursing</i> , 2020, 15, e12312.	1.3	16
1666	Nanoscale dynamic chemical, biological sensor material designs for control monitoring and early detection of advanced diseases. <i>Materials Today Bio</i> , 2020, 5, 100044.	5.5	18
1667	Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 147, 105281.	4.0	9
1668	The Growing Epidemic of Diabetes Mellitus. <i>Current Vascular Pharmacology</i> , 2020, 18, 104-109.	1.7	188
1669	The Invested in Diabetes Study Protocol: a cluster randomized pragmatic trial comparing standardized and patient-driven diabetes shared medical appointments. <i>Trials</i> , 2020, 21, 65.	1.6	11
1670	The impact of pharmacist care on diabetes outcomes in primary care settings: An umbrella review of published systematic reviews. <i>Primary Care Diabetes</i> , 2020, 14, 393-400.	1.8	24
1671	Metformin upregulates mitophagy in patients with T2DM: A randomized placebo-controlled study. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 2832-2846.	3.6	48
1672	Utility of Precision Medicine in the Management of Diabetes: Expert Opinion from an International Panel. <i>Diabetes Therapy</i> , 2020, 11, 411-422.	2.5	6
1673	A Practitioner's Toolkit for Insulin Motivation in Adults with Type 1 and Type 2 Diabetes Mellitus: Evidence-Based Recommendations from an International Expert Panel. <i>Diabetes Therapy</i> , 2020, 11, 585-606.	2.5	11
1674	Current molecular aspects in the development and treatment of diabetes. <i>Journal of Physiology and Biochemistry</i> , 2020, 76, 13-35.	3.0	20
1675	A sustained zero-order release carrier for long-acting, peakless basal insulin therapy. <i>Journal of Materials Chemistry B</i> , 2020, 8, 1952-1959.	5.8	15
1676	Living with diabetes: literature review and secondary analysis of qualitative data. <i>Diabetic Medicine</i> , 2020, 37, 493-503.	2.3	18
1677	Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study. <i>BMJ, The</i> , 2020, 369, m1186.	6.0	63
1678	Metformin Treatment Is Associated with a Decreased Risk of Nonproliferative Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-12.	2.3	17
1679	Glucose Lowering Treatment Modalities of Type 2 Diabetes Mellitus. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1307, 7-27.	1.6	11
1680	Prevalence and correlation of glycemic control achievement in patients with type 2 diabetes in Iraq: A retrospective analysis of a tertiary care database over a 9-year period. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 265-272.	3.6	18

#	ARTICLE	IF	CITATIONS
1681	The effect of L-carnitine supplementation on blood pressure in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. <i>Obesity Medicine</i> , 2020, 18, 100230.	0.9	1
1682	Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study. <i>Diabetes Care</i> , 2020, 43, 1326-1335.	8.6	41
1683	Lifestyle advice, processes of care and glycaemic control amongst patients with type 2 diabetes in a South African primary care facility. <i>African Journal of Primary Health Care and Family Medicine</i> , 2020, 12, e1-e6.	0.8	7
1684	Lysophosphatidylcholine Containing Anisic Acid Is Able to Stimulate Insulin Secretion Targeting G Protein Coupled Receptors. <i>Nutrients</i> , 2020, 12, 1173.	4.1	17
1685	Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?. <i>Metabolism: Clinical and Experimental</i> , 2020, 107, 154242.	3.4	17
1686	Successful Treatment with Bedtime Basal Insulin Added to Metformin without Weight Gain or Hypoglycaemia over Three Years. <i>Journal of Clinical Medicine</i> , 2020, 9, 1153.	2.4	1
1687	An evaluation of empagliflozin and its applicability to hypertension as a therapeutic option. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1157-1166.	1.8	4
1688	Metabolic endoscopy by duodenal mucosal resurfacing: expert review with critical appraisal of the current technique and results. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 375-381.	3.0	3
1689	Efficacy and safety of metformin and sitagliptin-based dual and triple therapy in elderly Chinese patients with type 2 diabetes: Subgroup analysis of STRATEGY study. <i>Journal of Diabetes Investigation</i> , 2020, 11, 1532-1541.	2.4	3
1690	Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 1023-1033.	2.4	4
1691	Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2192-e2206.	3.6	23
1692	Evidence gap on antihyperglycemic pharmacotherapy in frail older adults. <i>Zeitschrift Fur Gerontologie Und Geriatrie</i> , 2021, 54, 278-284.	1.8	11
1693	Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis. <i>Acta Diabetologica</i> , 2021, 58, 5-18.	2.5	15
1694	Effect of the FreeStyle Libre, a flash glucose monitoring system on glycemic control in individuals with type 2 diabetes treated with basal-bolus insulin therapy: An open label, prospective, multicenter trial in Japan. <i>Journal of Diabetes Investigation</i> , 2021, 12, 82-90.	2.4	11
1695	Current comments on contrast media administration in patients with renal insufficiency. <i>Clinical Imaging</i> , 2021, 69, 37-44.	1.5	4
1696	Mobile Diabetes Telemedicine Clinics for Aboriginal First Nation People With Reported Diabetes in British Columbia. <i>Canadian Journal of Diabetes</i> , 2021, 45, 89-95.	0.8	8
1697	Close relationships and diabetes management across the lifespan: The good, the bad, and autonomy. <i>Journal of Health Psychology</i> , 2021, 26, 226-237.	2.3	6
1698	Self-Compassion, Metabolic Control and Health Status in Individuals with Type 2 Diabetes: A UK Observational Study. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2021, 129, 413-419.	1.2	13

#	ARTICLE	IF	CITATIONS
1699	Vascular risk factor control and adherence to secondary preventive medication after ischaemic stroke. <i>Journal of Internal Medicine</i> , 2021, 289, 355-368.	6.0	11
1700	Metformin Prescription Associated with Reduced Abdominal Aortic Aneurysm Growth Rate and Reduced Chemokine Expression in a Swedish Cohort. <i>Annals of Vascular Surgery</i> , 2021, 70, 425-433.	0.9	27
1701	The perspectives of physicians regarding antidiabetic therapy deintensification and factors affecting their treatment choicesâ€”A crossâ€”sectional study. <i>International Journal of Clinical Practice</i> , 2021, 75, e13662.	1.7	1
1702	Acute effects of delayed-release hydrolyzed pine nut oil on glucose tolerance, incretins, ghrelin and appetite in healthy humans. <i>Clinical Nutrition</i> , 2021, 40, 2169-2179.	5.0	5
1703	Metformin dosage patterns in type 2 diabetes patients in a real-world setting in the United States. <i>Diabetes Research and Clinical Practice</i> , 2021, 172, 108531.	2.8	3
1704	The Novel Phosphate and Bile Acid Sequestrant Polymer SAR442357 Delays Disease Progression in a Rat Model of Diabetic Nephropathy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 376, 190-203.	2.5	8
1705	6. Glycemic Targets: <i>Standards of Medical Care in Diabetesâ€”2021</i>. <i>Diabetes Care</i> , 2021, 44, S73-S84.	8.6	591
1706	Safety and efficacy of empagliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post hoc analysis of data from the SACRA study. <i>Journal of Clinical Hypertension</i> , 2021, 23, 860-869.	2.0	10
1707	A study to assess the unmet medical needs associated with the use of basal insulin in patients with type 2 diabetes. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00164.	2.4	1
1708	Psychometric Analysis Regarding the Barriers to Providing Effective Insulin Treatment in Type 2 Diabetic Patients. <i>Diabetes Therapy</i> , 2021, 12, 159-170.	2.5	6
1709	Risk factors for diabetic foot complications in type 2 diabetesâ€”A systematic review. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00175.	2.4	32
1710	Phase III, randomized, doubleâ€”blind, placeboâ€”controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. <i>Journal of Diabetes Investigation</i> , 2021, 12, 537-545.	2.4	8
1711	Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition. <i>Drug Delivery and Translational Research</i> , 2021, 11, 1166-1185.	5.8	41
1712	Liraglutide and Dulaglutide Have Comparable HbA1c Reduction in Emirati Patients with T2DM. <i>Open Journal of Endocrine and Metabolic Diseases</i> , 2021, 11, 103-117.	0.2	0
1713	Acute coronary syndrome in diabetes mellitus: features of pathogenesis, course and therapy. <i>Profilakticheskaya Meditsina</i> , 2021, 24, 89.	0.6	2
1714	Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2021, 20, 30.	6.8	27
1715	Inspiratory Muscle Training on Glucose Control in Diabetes: A Randomized Clinical Trial. <i>International Journal of Sport Nutrition and Exercise Metabolism</i> , 2021, 31, 21-31.	2.1	3
1716	Hospitalization for hypoglycaemia in people with diabetes in Denmark, 1997â€”2017: Time trends in incidence and HbA_{1c} and glucoseâ€”lowering drug use before and after hypoglycaemia. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00227.	2.4	1

#	ARTICLE	IF	CITATIONS
1717	Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis. Journal of Lipid and Atherosclerosis, 2021, 10, 210.	3.5	3
1718	Diabetes in Cancer Patients: Risks, Goals and Management. Frontiers of Hormone Research, 2021, 54, 1-12.	1.0	5
1719	Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882110421.	3.2	12
1720	The ICF Classification System to Assess Risk Factors for CVD in Secondary Prevention after Ischemic Stroke and Intracerebral Hemorrhage. Medicina (Lithuania), 2021, 57, 190.	2.0	4
1721	Drug-Drug Interactions at Organic Cation Transporter 1. Frontiers in Pharmacology, 2021, 12, 628705.	3.5	14
1722	Design, Synthesis, and In Silico Multitarget Pharmacological Simulations of Acid Bioisosteres with a Validated In Vivo Antihyperglycemic Effect. Molecules, 2021, 26, 799.	3.8	8
1723	Engineering of smart nanoconstructs for delivery of glucagon-like peptide-1 analogs. International Journal of Pharmaceutics, 2021, 597, 120317.	5.2	7
1724	Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns. Frontiers in Endocrinology, 2021, 12, 616514.	3.5	10
1725	Therapeutic inertia in patients with type 2 diabetes treated with non-insulin agents. Journal of Diabetes and Its Complications, 2021, 35, 107828.	2.3	9
1726	Report from the CVOT Summit 2020: new cardiovascular and renal outcomes. Cardiovascular Diabetology, 2021, 20, 75.	6.8	9
1727	Krebs cycle: activators, inhibitors and their roles in the modulation of carcinogenesis. Archives of Toxicology, 2021, 95, 1161-1178.	4.2	35
1728	Diabetes duration and glycaemic control as predictors of cardiovascular disease and mortality. Diabetes, Obesity and Metabolism, 2021, 23, 1361-1370.	4.4	33
1729	Metformin improves survival in patients with concurrent diabetes and small cell lung cancer: a meta-analysis. Minerva Endocrinology, 2021, , .	1.1	1
1730	Association Between Preadmission Metformin Use and Outcomes in Intensive Care Unit Patients With Sepsis and Type 2 Diabetes: A Cohort Study. Frontiers in Medicine, 2021, 8, 640785.	2.6	63
1731	Using Natural Language Processing to Measure and Improve Quality of Diabetes Care: A Systematic Review. Journal of Diabetes Science and Technology, 2021, 15, 553-560.	2.2	15
1732	Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis. Diabetologia, 2021, 64, 1563-1571.	6.3	24
1733	Effect of Metformin on Cardiovascular Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Frontiers in Endocrinology, 2021, 12, 616514.	3.5	10
1734	Patient Work and Treatment Burden in Type 2 Diabetes: A Mixed-Methods Study. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 359-367.	2.4	11

#	ARTICLE	IF	CITATIONS
1735	Natural Antidiabetic Agents: Molecular Docking Study using the Extra Precision Method. Letters in Drug Design and Discovery, 2021, 18, 143-171.	0.7	0
1736	One Hundred Years of Insulin: Value Beyond Price in Type 2 Diabetes Mellitus. Diabetes Therapy, 2021, 12, 1593-1604.	2.5	3
1737	Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits. Journal of Pharmaceutical Policy and Practice, 2021, 14, 35.	2.4	1
1738	The influence of living conditions and individual behaviors on the oral-systemic disease connection: a cross-sectional analysis. Journal of Public Health Dentistry, 2021, , .	1.2	1
1740	Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes mellitus?. Turkish Journal of Medical Sciences, 2021, 51, 735-742.	0.9	7
1741	Hardware-in-the-loop control of glucose in diabetic patients based on nonlinear time-varying blood glucose model. Biomedical Signal Processing and Control, 2021, 66, 102467.	5.7	8
1742	Noninvasive blood glucose monitor via multi-sensor fusion and its clinical evaluation. Sensors and Actuators B: Chemical, 2021, 332, 129445.	7.8	12
1743	Association between control of diabetes mellitus and polypharmacy at the Brazilian Longitudinal Study of Adult Health (ELISA-Brazil). Pharmacoeconomics and Drug Safety, 2021, 30, 749-757.	1.9	3
1744	Association between metformin use on admission and outcomes in intensive care unit patients with acute kidney injury and type 2 diabetes: A retrospective cohort study. Journal of Critical Care, 2021, 62, 206-211.	2.2	13
1745	Is there a role for glucagon-like peptide-1 receptor agonists in the treatment of male infertility?. Andrology, 2021, 9, 1499-1503.	3.5	15
1746	Experience of emergency department patients after a visit for hyperglycaemia: implications for communication and factors affecting adherence postdischarge. Emergency Medicine Journal, 2021, , emermed-2020-210677.	1.0	1
1747	“When nothing happens, nobody is afraid!”beliefs and perceptions around self-care and health-seeking behaviours: Voices of patients living with diabetic lower extremity amputation in primary care. International Wound Journal, 2021, 18, 850-861.	2.9	11
1748	Ethnopharmacological perspectives of glucokinase activators in the treatment of diabetes mellitus. Natural Product Research, 2022, 36, 2962-2976.	1.8	8
1750	Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus: DosInGlar Study. Advances in Therapy, 2021, 38, 3857-3871.	2.9	3
1751	Effect of Lifestyle Modification on Glycemic Control of Type 2 Diabetic Patients at Suez Canal University Hospitals. , 0, , .		0
1752	Saffron improves life and sleep quality, glycaemic status, lipid profile and liver function in diabetic patients: A double-blind, placebo-controlled, randomised clinical trial. International Journal of Clinical Practice, 2021, 75, e14334.	1.7	26
1753	Treatment Patterns, Effectiveness, and Satisfaction Among Patients with Type 2 Diabetes Treated with Insulin in Saudi Arabia: Results of the RIMODIS Study. Diabetes Therapy, 2021, 12, 1965-1978.	2.5	4
1754	Feline comorbidities: Pathophysiology and management of the obese diabetic cat. Journal of Feline Medicine and Surgery, 2021, 23, 639-648.	1.6	8

#	ARTICLE	IF	CITATIONS
1755	The Genetics of Adverse Drug Outcomes in Type 2 Diabetes: A Systematic Review. <i>Frontiers in Genetics</i> , 2021, 12, 675053.	2.3	6
1756	Safety and Efficacy of SGLT2 Inhibitors: A Multiple-Treatment Meta-Analysis of Clinical Decision Indicators. <i>Journal of Clinical Medicine</i> , 2021, 10, 2713.	2.4	5
1757	The effect of apple cider vinegar on lipid profiles and glycemic parameters: a systematic review and meta-analysis of randomized clinical trials. <i>BMC Complementary Medicine and Therapies</i> , 2021, 21, 179.	2.7	14
1758	Risk Factors for the Recurrence of CVD Incidents in Post-Stroke Patients over a 5-Year Follow-Up Period Based on the ICF Classification. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 6021.	2.6	1
1759	Special Considerations in the Management and Education of Older Persons With Diabetes. <i>ADCES in Practice</i> , 2021, 9, 30-42.	0.2	0
1760	Evidence-based use of newer agents in type 2 diabetes. <i>Journal of Prescribing Practice</i> , 2021, 3, 224-234.	0.1	1
1761	Acute metformin administration increases mean power and the early Power phase during a Wingate test in healthy male subjects. <i>European Journal of Sport Science</i> , 2022, 22, 1065-1072.	2.7	1
1762	Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus without established cardiovascular disease: Do they have a role in primary prevention?. <i>Metabolism Open</i> , 2021, 10, 100082.	2.9	1
1763	Mortality rates and cardiovascular disease burden in type 2 diabetes by occupation, results from all Swedish employees in 2002â€“2015. <i>Cardiovascular Diabetology</i> , 2021, 20, 129.	6.8	4
1764	Trends in HbA1c and Body Mass Index Among Individuals with Type 2 Diabetes: Evidence from a US Database 2012â€“2019. <i>Diabetes Therapy</i> , 2021, 12, 2077-2087.	2.5	19
1765	Use Of The GLYCEMIZERÂ® Tool By General Practitioners To Meet Individual Glycated Hemoglobin Goals In Patients With Type 2 Diabetes Mellitus. <i>Russian Open Medical Journal</i> , 2021, 10, .	0.3	0
1766	Effects of Incretin-Related Diabetes Drugs on Bone Formation and Bone Resorption. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6578.	4.1	13
1767	Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin. <i>BMC Pharmacology & Toxicology</i> , 2021, 22, 34.	2.4	2
1768	Chemical Group Profiling, In Vitro and In Silico Evaluation of <i>Aristolochia ringens</i> on $\hat{\pm}$ -Amylase and $\hat{\pm}$ -Glucosidase Activity. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-12.	1.2	7
1769	Knowledge, Attitude, and Practice of Metformin Extended-Release Tablets Among Clinicians in China: A Cross-Sectional Survey. <i>Frontiers in Pharmacology</i> , 2021, 12, 634561.	3.5	2
1770	Impact of non-antibiotic drugs on the human intestinal microbiome. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 911-924.	3.1	13
1771	Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study. <i>Diabetologia</i> , 2021, 64, 2204-2214.	6.3	9
1772	Fasting Glucose of 6.1â€‰mmol/L as a Possible Optimal Target for Type 2 Diabetic Patients with Insulin Glargine: A Randomized Clinical Trial. <i>Journal of Diabetes Research</i> , 2021, 2021, 1-9.	2.3	4

#	ARTICLE	IF	CITATIONS
1773	Influence of Diabetes Duration and Glycemic Control on Dementia: A Cohort Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 2062-2070.	3.6	20
1774	Improving outcomes for older people with diabetes. Practice Nursing, 2021, 32, 270-276.	0.1	0
1775	Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care. Drugs, 2021, 81, 1373-1379.	10.9	13
1776	Management of bone fragility in type 2 diabetes: Perspective from an interdisciplinary expert panel. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2210-2233.	2.6	7
1777	Ameliorative effect of Annona reticulata L. leaf extract on antihyperglycemic activity and its hepato-renal protective potential in streptozotocin induced diabetic rats. Journal of Ayurveda and Integrative Medicine, 2021, 12, 415-426.	1.7	5
1778	Effect of different HbA1c levels on the gut microbiota in patients with type 2 diabetes mellitus. World Academy of Sciences Journal, 2021, 3, .	0.6	0
1779	Assessment of Patient Satisfaction with On-Site Point-of-Care Hemoglobin A1c Testing: An Observational Study. Diabetes Therapy, 2021, 12, 2531-2544.	2.5	6
1780	Efficacy and safety of 28-day treatment with oral insulin (ORMD-0801) in patients with type 2 diabetes: A randomized, placebo-controlled trial. Diabetes, Obesity and Metabolism, 2021, 23, 2529-2538.	4.4	21
1781	Effects of a Lifestyle Intervention on Bone Turnover in Persons with Type 2 Diabetes: A Post Hoc Analysis of the U-TURN Trial. Medicine and Science in Sports and Exercise, 2022, 54, 38-46.	0.4	4
1782	The effect of metformin on mortality and severity in COVID-19 patients with diabetes mellitus. Diabetes Research and Clinical Practice, 2021, 178, 108977.	2.8	29
1783	Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet, The, 2021, 398, 583-598.	13.7	274
1784	Novel approaches to pharmacological management of type 2 diabetes in Japan. Expert Opinion on Pharmacotherapy, 2021, 22, 2235-2249.	1.8	2
1785	Oral Semaglutide in the Management of Type 2 DM: Clinical Status and Comparative Analysis. Current Drug Targets, 2022, 23, 311-327.	2.1	1
1786	Metabolic Switch and Cytotoxic Effect of Metformin on Burkitt Lymphoma. Frontiers in Oncology, 2021, 11, 661102.	2.8	3
1787	An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy, 2022, 23, 29-42.	1.8	4
1788	Role of Gliclazide in safely navigating type 2 diabetes mellitus patients towards euglycemia: Expert opinion from India. Endocrine and Metabolic Science, 2021, 4, 100102.	1.6	0
1789	Erectile dysfunction and diabetes: A melting pot of circumstances and treatments. Diabetes/Metabolism Research and Reviews, 2022, 38, e3494.	4.0	74
1790	Syringaldehyde promoting intestinal motility with suppressing α -amylase hinders starch digestion in diabetic mice. Biomedicine and Pharmacotherapy, 2021, 141, 111865.	5.6	12

#	ARTICLE	IF	CITATIONS
1791	Diabetes Self-Management Among Healthcare Providers in King Abdulaziz Medical City, Riyadh: A Cross-Sectional Pilot Study. <i>Cureus</i> , 2021, 13, e18155.	0.5	0
1792	Associations of time-varying obesity and metabolic syndrome with risk of incident heart failure and its subtypes: Findings from the Multi-Ethnic Study of Atherosclerosis. <i>International Journal of Cardiology</i> , 2021, 338, 127-135.	1.7	4
1793	Discovery, synthesis and in combo studies of Schiffâ€™s bases as promising dipeptidyl peptidase-IV inhibitors. <i>Molecular Diversity</i> , 2022, 26, 1213-1225.	3.9	4
1794	Cardiologist's approach to the diabetic patient: No further delay for a paradigm shift. <i>International Journal of Cardiology</i> , 2021, 338, 248-257.	1.7	1
1795	Heterogeneity of Treatment Effects Among Patients With Type 2 Diabetes and Elevated Body Mass Index in a Study Comparing Group Medical Visits Focused on Weight Management and Medication Intensification. <i>Medical Care</i> , 2021, Publish Ahead of Print, 1031-1038.	2.4	0
1796	Thirty days of combined consumption of a high-fat diet and fructose-rich beverages promotes insulin resistance and modulates inflammatory response and histomorphometry parameters of liver, pancreas, and adipose tissue in Wistar rats. <i>Nutrition</i> , 2021, 91-92, 111403.	2.4	1
1797	Egyptian consensus on treat-to-target approach for osteoporosis: a clinical practice guideline from the Egyptian Academy of bone health and metabolic bone diseases. <i>Egyptian Rheumatology and Rehabilitation</i> , 2021, 48, .	0.6	15
1798	Diabetic Foot. <i>Endocrinology</i> , 2020, , 355-376.	0.1	1
1801	Diabetic Foot. <i>Endocrinology</i> , 2018, , 355-376.	0.1	2
1803	Les complications du diabÃ©te de type 2 exigent une prÃ©vention multifactorielle qui passe obligatoirement par un contrÃ¢le optimisÃ© de lâ€™Ã©quilibre glycÃ©mique. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2015, 199, 1211-1213.	0.0	2
1804	Impact of hypoglycemic events and HbA1c level on sulfonylurea discontinuation and down-titration. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 213-220.	1.4	2
1805	Systematic review: human gut dysbiosis induced by nonâ€™antibiotic prescription medications. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 332-345.	3.7	172
1806	Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1793-1797.	4.4	7
1807	Early combination versus initial metformin monotherapy in the management of newly diagnosed type 2 diabetes: Anâ€™East Asianâ€™perspective. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 3-17.	4.4	16
1808	Required reading to remain relevant. <i>International Journal of Clinical Practice</i> , 2017, 71, e12965.	1.7	1
1809	Redesigning ambulatory care management for uncontrolled type 2 diabetes: a prospective cohort study of the impact of a Boot Camp model on outcomes. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000731.	2.8	9
1810	Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis. <i>BMJ Open</i> , 2017, 7, e017260.	1.9	17
1811	Short-term outcomes of patients with Type 2 diabetes mellitus treated with canagliflozin compared with sitagliptin in a real-world setting. <i>Singapore Medical Journal</i> , 2018, 59, 251-256.	0.6	4

#	ARTICLE	IF	CITATIONS
1812	Clinical use of sodium-glucose co-transporter-2 inhibitors in Chinese patients with type 2 diabetes mellitus. Singapore Medical Journal, 2019, 60, 309-313.	0.6	2
1813	In vitro antidiabetic potentials, antioxidant activities and phytochemical profile of african black pepper (Piper guineense). Clinical Phytoscience, 2020, 6, .	1.6	9
1814	Genomic Characterization of Metformin Hepatic Response. PLoS Genetics, 2016, 12, e1006449.	3.5	41
1815	Monoconjugation of Human Amylin with Methylpolyethyleneglycol. PLoS ONE, 2015, 10, e0138803.	2.5	21
1816	Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth. PLoS ONE, 2015, 10, e0139709.	2.5	28
1817	Weight and Glucose Reduction Observed with a Combination of Nutritional Agents in Rodent Models Does Not Translate to Humans in a Randomized Clinical Trial with Healthy Volunteers and Subjects with Type 2 Diabetes. PLoS ONE, 2016, 11, e0153151.	2.5	8
1818	Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. PLoS ONE, 2016, 11, e0154206.	2.5	22
1819	Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial. PLoS ONE, 2016, 11, e0163350.	2.5	30
1820	Metformin Ameliorates Dysfunctional Traits of Glibenclamide- and Glucose-Induced Insulin Secretion by Suppression of Imposed Overactivity of the Islet Nitric Oxide Synthase-NO System. PLoS ONE, 2016, 11, e0165668.	2.5	14
1821	Simultaneous Quantification of Antidiabetic Agents in Human Plasma by a UPLC-MS/MS Method. PLoS ONE, 2016, 11, e0167107.	2.5	14
1822	TMG-123, a novel glucokinase activator, exerts durable effects on hyperglycemia without increasing triglyceride in diabetic animal models. PLoS ONE, 2017, 12, e0172252.	2.5	21
1823	Relation between cost of drug treatment and body mass index in people with type 2 diabetes in Latin America. PLoS ONE, 2017, 12, e0189755.	2.5	3
1824	The effect of concomitant DPP4i use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3. PLoS ONE, 2018, 13, e0190579.	2.5	2
1825	Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition. Diabetes Mellitus, 2019, 22, 1-121.	1.9	20
1826	Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies. Diabetes Mellitus, 2017, 20, 220-230.	1.9	43
1827	Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AY. 8th edition. Diabetes Mellitus, 2017, 20, 1-121.	1.9	142
1828	Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition. Diabetes Mellitus, 2019, 22, 1-121.	1.9	195
1829	Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V. (7th edition). Diabetes Mellitus, 2015, 18, 1-112.	1.9	15

#	ARTICLE	IF	CITATIONS
1830	Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study. <i>Journal of Clinical Medicine Research</i> , 2017, 9, 793-801.	1.2	2
1831	Differing Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Ipragliflozin on the Decrease of Fat Mass vs. Lean Mass in Patients With or Without Metformin Therapy. <i>Journal of Clinical Medicine Research</i> , 2019, 11, 297-300.	1.2	8
1832	New Therapeutic Strategies for Type 2 Diabetes ^{<sup>CME</sup>} . <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 14, 281.	1.0	8
1833	The Emerging Role of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes. Focus on Dapagliflozin. <i>Romanian Journal of Diabetes Nutrition and Metabolic Diseases</i> , 2016, 23, 113-120.	0.3	1
1834	Glycaemic control, glucose variability and the Triangle of Diabetes Care. <i>British Journal of Diabetes</i> , 0, 16, 3.	0.2	11
1835	Possible risk factors for the development of sodium-glucose co-transporter 2 inhibitor- associated diabetic ketoacidosis in type 2 diabetes. <i>British Journal of Diabetes</i> , 2016, 16, 78.	0.2	6
1836	Glucagon like peptide-1 receptor agonist (GLP-1RA) therapy in management of type 2 diabetes: choosing the right agent for individualised care. <i>British Journal of Diabetes</i> , 2016, 16, 128.	0.2	5
1837	Ambulatory glucose profile (AGP): utility in UK clinical practice. <i>British Journal of Diabetes</i> , 2017, 17, 26.	0.2	14
1838	Management of hyperglycaemia in type 2 diabetes: the 2018 consensus report by ADA/EASD Insights from one of the authors. <i>British Journal of Diabetes</i> , 2018, 18, 137-140.	0.2	6
1839	The new NICE guidelines for type 2 diabetes “a critical analysis. <i>British Journal of Diabetes and Vascular Disease</i> , 2015, 15, 3.	0.6	12
1840	Clinical inertia in the management of type 2 diabetes mellitus: a focused literature review. <i>British Journal of Diabetes and Vascular Disease</i> , 2015, 15, 65.	0.6	48
1841	SGLT2 inhibition and ketoacidosis “should we be concerned?”. <i>British Journal of Diabetes and Vascular Disease</i> , 2015, 15, 155.	0.6	10
1842	Recurrent lactic acidosis and hypoglycemia with inadvertent metformin use: a case of look-alike pills. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2017, 2017, .	0.5	4
1843	Quality of Life of Insulin-Dependent People with Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Drugs after the Addition of Insulin Glargine, in Every Day Clinical Practice in Greece. <i>Journal of Diabetes, Metabolic Disorders & Control</i> , 2015, 2, .	0.1	1
1844	Effect of Zinc Oxide and Titanium Dioxide Nanoparticles on Supported Lipid Bilayers. <i>Journal of Nanomedicine Research</i> , 2015, 2, .	1.8	1
1845	The Multicenter, Open-Label, Observational LEAD-Ph Study: Real-World Safety and Effectiveness of Liraglutide in Filipino Participants with Type 2 Diabetes. <i>Journal of the ASEAN Federation of Endocrine Societies</i> , 2018, 33, 114-123.	0.2	2
1846	Development of a Patient Decision Aid on the Choice of Diabetes Medication for Filipino Patients with Type 2 Diabetes Mellitus. <i>Journal of the ASEAN Federation of Endocrine Societies</i> , 2019, 34, 44-55.	0.2	4
1847	Potential drug interactions in drug therapy prescribed for older adults at hospital discharge: cross-sectional study. <i>Sao Paulo Medical Journal</i> , 2019, 137, 369-378.	0.9	9

#	ARTICLE	IF	CITATIONS
1848	The OPT2MISE Study – A Review of the Major Findings and Clinical Implications. <i>European Endocrinology</i> , 2015, 11, 70.	1.5	4
1849	Basal Insulin Inadequacy versus Failure – Using Appropriate Terminology. <i>European Endocrinology</i> , 2015, 11, 79.	1.5	3
1850	Individualizing treatment targets for elderly patients with type 2 diabetes: factors influencing clinical decision making in the 24-week, randomized INTERVAL study. <i>Aging</i> , 2017, 9, 769-777.	3.1	18
1851	A 7.0–7.7% value for glycated haemoglobin is better than a <7% value as an appropriate target for patient-centered drug treatment of type 2 diabetes mellitus. <i>Annals of Translational Medicine</i> , 2019, 7, S122-S122.	1.7	3
1852	Protective Effects of Pomegranate in Endothelial Dysfunction. <i>Current Pharmaceutical Design</i> , 2020, 26, 3684-3699.	1.9	8
1853	A Review on Molecular Mechanism of Flavonoids as Antidiabetic Agents. <i>Mini-Reviews in Medicinal Chemistry</i> , 2019, 19, 762-786.	2.4	16
1854	Comparative Study of Different Derivative Spectrophotometric Techniques for the Analysis and Separation of Metformin, Empagliflozin, and Glimepiride. <i>Current Pharmaceutical Analysis</i> , 2020, 16, 916-934.	0.6	2
1855	The Prevalence and Correlates of Pre-Diabetes and Diabetes Mellitus Among Public Category Workers in Akure, Nigeria. <i>Open Public Health Journal</i> , 2017, 10, 167-176.	0.4	5
1856	Toward a Digital Platform for the Self-Management of Noncommunicable Disease: Systematic Review of Platform-Like Interventions. <i>Journal of Medical Internet Research</i> , 2020, 22, e16774.	4.3	34
1857	Perceptions of Persons With Type 2 Diabetes Treated in Swedish Primary Health Care: Qualitative Study on Using eHealth Services for Self-Management Support. <i>JMIR Diabetes</i> , 2018, 3, e7.	1.9	31
1858	Overcoming Clinical Inertia: A Randomized Clinical Trial of a Telehealth Remote Monitoring Intervention Using Paired Glucose Testing in Adults With Type 2 Diabetes. <i>Journal of Medical Internet Research</i> , 2015, 17, e178.	4.3	91
1860	Metformin Inhibits Migration and Invasion of Cholangiocarcinoma Cells. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 473-477.	1.2	18
1861	Therapeutic Inertia: Still a Long Way to Go That Cannot Be Postponed. <i>Diabetes Spectrum</i> , 2020, 33, 50-57.	1.0	9
1862	Management of diabetes mellitus in chronic kidney disease. <i>Minerva Endocrinologica</i> , 2019, 44, 273-287.	1.8	23
1863	Unexpected bleeding after Exenatide treatment: a causative relationship or a coincidence?. <i>Endocrine Regulations</i> , 2018, 52, 159-162.	1.3	2
1864	Biomarkers in Obesity. <i>Romanian Journal of Laboratory Medicine</i> , 2018, 26, 353-358.	0.2	5
1865	Novel Considerations about Diabetes Management Strategies in Chinese Immigrants in America: Possible Corollaries of the Use of Traditional Chinese Medicines. <i>Innovations in Pharmacy</i> , 2017, 8, .	0.6	4
1866	Modern approaches to management of cardiovascular risk factors at patients with diabetes mellitus type 2. <i>Terapevticheskii Arkhiv</i> , 2018, 90, 113-117.	0.8	1

#	ARTICLE	IF	CITATIONS
1867	Time in Range: Ein neuer Parameter â€“ komplement�r zum HbA 1c. , O, , .		5
1868	Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT. Health Technology Assessment, 2018, 22, 1-64.	2.8	28
1869	Good Long-Term Glycemic Compensation Is Associated With Better Trabecular Bone Score in Postmenopausal Women With Type 2 Diabetes. Physiological Research, 2019, 68, S149-S156.	0.9	14
1870	Current status of managing diabetes mellitus in Korea. Korean Journal of Internal Medicine, 2016, 31, 845-850.	1.7	35
1871	Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association. Korean Journal of Internal Medicine, 2017, 32, 947-958.	1.7	12
1872	Monotherapy in patients with type 2 diabetes mellitus. Korean Journal of Internal Medicine, 2017, 32, 959-966.	1.7	5
1873	Pratique de lâ€™auto-surveillance glyc�mique en France�: donn�es d�une enqu�te nationale. Sante Publique, 2017, Vol. 29, 229-240.	0.1	5
1874	Immunohistochemical Expression of Insulin and Glucagon, Superoxide Dismutase and Catalase Activity in Pancreas in Hyperglycaemia Condition. Asian Journal of Biochemistry, 2016, 11, 177-185.	0.5	5
1875	The role of hemoglobin A1c in the assessment of diabetes and cardiovascular risk. Cleveland Clinic Journal of Medicine, 2016, 83, S4-S10.	1.3	13
1876	Optimizing diabetes treatment in the presence of obesity. Cleveland Clinic Journal of Medicine, 2017, 84, S22-S29.	1.3	12
1877	Medical Treatment of Diabetes Mellitus. Cleveland Clinic Journal of Medicine, 2017, 84, S57-S61.	1.3	4
1878	Diabetes medications and cardiovascular outcome trials: Lessons learned. Cleveland Clinic Journal of Medicine, 2017, 84, 759-767.	1.3	13
1879	Preventing cardiovascular disease in older adults: One size does not fit all. Cleveland Clinic Journal of Medicine, 2018, 85, 55-64.	1.3	16
1880	Type 2 diabetes: Evolving concepts and treatment. Cleveland Clinic Journal of Medicine, 2019, 86, 494-504.	1.3	5
1881	Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance. Translational Lung Cancer Research, 2015, 4, 576-83.	2.8	26
1882	Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea. Diabetes and Metabolism Journal, 2019, 43, 432.	4.7	2
1883	Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial. Diabetes and Metabolism Journal, 2020, 44, 532.	4.7	6
1884	The association between gallstone disease and plaque in the abdominopelvic arteries. Journal of Research in Medical Sciences, 2017, 22, 11.	0.9	6

#	ARTICLE	IF	CITATIONS
1885	Strengthening diabetes management at primary health level. Indian Journal of Endocrinology and Metabolism, 2015, 19, 443.	0.4	4
1886	Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement. Indian Journal of Endocrinology and Metabolism, 2015, 19, 577.	0.4	77
1887	Short-term outcomes of type 2 diabetes mellitus patients treated with canagliflozin in real-world setting. Indian Journal of Endocrinology and Metabolism, 2016, 20, 137.	0.4	4
1888	Flexibility in insulin prescription. Indian Journal of Endocrinology and Metabolism, 2016, 20, 408.	0.4	10
1889	Liraglutide effect and action in diabetes-In (LEAD-In): A prospective observational study assessing safety and effectiveness of liraglutide in patients with type 2 diabetes mellitus treated under routine clinical practice conditions in India. Indian Journal of Endocrinology and Metabolism, 2016, 20, 838.	0.4	6
1890	Continuation of metformin till night before surgery and lactate levels in patients undergoing coronary artery bypass graft surgery. Indian Journal of Endocrinology and Metabolism, 2019, 23, 416.	0.4	6
1891	Sodium-glucose cotransporter-2 inhibitors in combination with other glucose-lowering agents for the treatment of type 2 diabetes mellitus. Indian Journal of Endocrinology and Metabolism, 2018, 22, 827.	0.4	17
1892	RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. Indian Journal of Endocrinology and Metabolism, 2020, 24, 1.	0.4	85
1893	Pentads and hexads in diabetes care: Numbers as targets; Numbers as tools. Indian Journal of Endocrinology and Metabolism, 2017, 21, 794.	0.4	6
1894	Consensus statement on dose modifications of antidiabetic agents in patients with hepatic impairment. Indian Journal of Endocrinology and Metabolism, 2017, 21, 341.	0.4	48
1895	Management of glycemia in acute febrile illness. Indian Journal of Endocrinology and Metabolism, 2017, 21, 460.	0.4	2
1896	A review of pharmacist-led interventions on diabetes outcomes: An observational analysis to explore diabetes care opportunities for pharmacists. Journal of Pharmacy and Bioallied Sciences, 2019, 11, 299.	0.6	19
1897	Managing diabetes patients in India: Is the future more bitter or less sweet?. Perspectives in Clinical Research, 2018, 9, 1.	1.0	4
1898	Simple Insulin Dose Adjustment Using 3-3-1 Algorithm in Japanese Patients with Type 2 Diabetes: Start Kanazawa Study (Self-Titration Aggressive Algorithm with Glargine Trial). Journal of Diabetes Mellitus, 2016, 06, 197-203.	0.3	1
1899	The Role of Inhaled Insulin in the Management of Type 2 Diabetes. Pharmacology & Pharmacy, 2016, 07, 162-169.	0.7	1
1900	Update on biomarkers of glycemic control. World Journal of Diabetes, 2019, 10, 1-15.	3.5	53
1901	Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonists role in treatment; from the past to future. World Journal of Diabetes, 2019, 10, 446-453.	3.5	17
1902	Chronic kidney disease in type 2 diabetic patients followed-up by primary care physicians in Switzerland: prevalence and prescription of antidiabetic drugs. Swiss Medical Weekly, 2016, 146, w14282.	1.6	8

#	ARTICLE	IF	CITATIONS
1903	Cell-based Screening For Identification Of The Novel Vanadium Complexes With Multidirectional Activity Relative To The Cells And The Mechanisms Associated With Metabolic Disorders. Science Technology and Innovation, 2019, 4, 47-54.	0.0	3
1904	Efficacy and safety of sitagliptin added to metformin and insulin compared with voglibose in patients with newly diagnosed type 2 diabetes. Clinics, 2019, 74, e736.	1.5	6
1905	Pharmacological Management of Obesity in Patients with Type 2 Diabetes: An Update. The Korean Journal of Obesity, 2016, 25, 121-128.	0.2	2
1906	Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin. Drugs in Context, 2015, 4, 1-7.	2.2	6
1907	Noninvasive Blood Glucose Concentration Measurement Based on Conservation of Energy Metabolism and Machine Learning. Sensors, 2021, 21, 6989.	3.8	3
1908	ARISEâ€”a prospective, non-interventional, single-arm study assessing clinical parameters associated with the use of insulin degludec/insulin aspart in patients with type 2 diabetes in real-world settings: rationale and design. Endocrine, 2021, 74, 530-537.	2.3	4
1909	Prevention of Hyperglycemia. , 0, , .		0
1910	Surprising Results of the EMPA-REG OUTCOME Study have brought a New Insight into Use of Sodium-Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes. Tropical Medicine & Surgery, 2015, 03, .	0.1	1
1912	Magnesium Rich Extract of Cashew Tree (Anacardium Occidentale) Nut and its Principal Compound, Anacardic Acid, Stimulate Glucose Uptake in C2C12 Muscle Cells. International Journal of Complementary & Alternative Medicine, 2015, 1, .	0.1	1
1913	Influence of Fixed Combination of Metformin SR and Glimepiride on Carbohydrate, Lipid Metabolism and Arterial Wall Stiffness in Patients with Diabetes Mellitus Type 2. MÃ¼narodnij EndokrinologÃ¼nij Å½urnal, 2016, .	0.4	0
1914	Combined Therapy with Antihyperglycemic Oral Agents (Metformin, Sulfonylureas) and Insulin in the Management of Type 2 Diabetic Patients (Pathogenic Substantiation and Clinical Utility). MÃ¼narodnij EndokrinologÃ¼nij Å½urnal, 2016, .	0.4	0
1915	Possible benefits of early combination therapy of type 2 diabetes. Problemy Endokrinologii, 2015, 61, 56-59.	0.8	1
1916	Effects of Low-Dose Pioglitazone on Serum Levels of Adiponectin, Dehydroepiandrosterone, Amyloid Beta Peptide, and Lipid Profile in Elderly Japanese People with Type 2 Diabetes. Advances in Endocrinology, 2015, 2015, 1-6.	0.1	1
1917	Amaryl® SR: a New Release Form, New Possibilities for The Patients. MÃ¼narodnij EndokrinologÃ¼nij Å½urnal, 2016, .	0.4	0
1918	Insulin Toujeo® â€” a Novel Basal Long-Acting Insulin Formulation. Part 1. Pharmacokinetic and Pharmacodynamic Aspects. MÃ¼narodnij EndokrinologÃ¼nij Å½urnal, 2016, .	0.4	0
1919	Solid Dose Form of Metformin with Ethyl Eicosapentaenoic Acid Does Not Improve Metformin Plasma Availability. Pharmacology & Pharmacy, 2016, 07, 29-35.	0.7	0
1920	ArtÃ©riopathie oblitÃ©rante des membres infÃ©rieurs : principes de prise en charge mÃ©dicale. , 2016, , 259-261.		0
1921	The Role of Incretins in Insulin Secretion. , 2016, , 1-13.		0

#	ARTICLE	IF	CITATIONS
1922	Stroke of Diabetic Subject: Experience of The Neurology Service of Cocody Teaching Hospital at Abidjan (Ivory Coast). Journal of Neurological Disorders, 2016, 04, .	0.1	1
1923	Retrospective Observational Dose-Titration Study of Subjects with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on 15 mg of Pioglitazone. Journal of Korean Diabetes, 2016, 17, 51.	0.3	0
1925	Choice of the Add-on Therapy to Metformin in Type 2 Diabetes Patients in Clinical Practice. Initial Results from a Non-Interventional Multicenter Study in Romania (REALITY). Acta Endocrinologica, 2016, 12, 455-460.	0.3	1
1926	Treating Type 2 Diabetes Mellitus. , 2016, , 1-24.		0
1927	Cardiovascular Outcomes with Empagliflozin â€“ News for Type 2 Diabetes Therapy. European Endocrinology, 2016, 12, 31.	1.5	0
1928	Phenotypic and genetic characteristics of patients with type 2 diabetes with different responses to metformin therapy in Novosibirsk region. Diabetes Mellitus, 2016, 19, 125-131.	1.9	1
1929	Guidelines and recommendations for use. , 2016, , 61-75.		0
1930	12.ÂDiabetes. , 2016, , .		0
1931	Sodium Glucose Cotransporter-2 Inhibitors in Clinical Practice: Impact beyond Glycemic Control. Hypertension Journal, 2016, 2, 74-79.	0.1	2
1933	Efficacy and safety of Dapagliflozin vs. Canagliflozin in addition to metformin for treatment of type 2 diabetes, a randomized, double-blind, non-inferiority clinical trial. , 2016, 2, .		0
1934	The features of sulfonylureaâ€™s usÐµ in the general practice: a systematic review of glimepiride researches. LÃ¼ki UkraÃ¼ni, 2016, .	0.1	0
1936	CONTEMPORARY PREVENTION AREAS OF DIABETES AND ITS COMPLICATIONS: THE ROLE OF THE FAMILY PHYSICIAN. Problemi Endokrinnoi Patologii, 2016, 57, 60-68.	0.2	0
1937	Treatment of type 2 diabetes: the stability of the effectiveness of hypoglycemic medications. Obesity and Metabolism, 2016, 13, 32-36.	1.2	0
1938	Guidelines for the Treatment of Type 2 Diabetes Mellitus. , 2017, , 37-50.		1
1939	Diabetes Integrated Care: Are We There Yet?. , 2017, , 233-248.		0
1940	Diabetes-Old Therapies Revisited. Endocrinology&Metabolism International Journal, 2016, 3, .	0.1	0
1941	LIRA 365 Plus-A Real World Experience of 19 Months Use of Liraglutide in the Obese Indian Type 2 Diabetic Subjects. Advances in Obesity Weight Management & Control, 2016, 5, .	0.2	0
1942	In Tune with the World Trends: Clinical Aspects of Liraglutide Use in Combination with Insulin in Patients with Diabetes Mellitus (Literature Review and Clinical Observations). MÃ¼Ã¼narodnij EndokrinologÃ¼Ã¼nij Ã¼½urnal, 2016, .	0.4	1

#	ARTICLE	IF	CITATIONS
1943	Choice of insulin in type 2 diabetes: A Southeast Asian perspective. Indian Journal of Endocrinology and Metabolism, 2017, 21, 478.	0.4	3
1944	Dose modification of antidiabetic agents in patients with type 2 diabetes mellitus and heart failure. Indian Journal of Endocrinology and Metabolism, 2017, 21, 618.	0.4	2
1945	Effect of Initiation of Basal Insulin Glargine on Glycemic Control in Patients with Diabetes: Real Life Experience from Hong Kong. Journal of Diabetes Mellitus, 2017, 07, 108-120.	0.3	1
1946	Knowledge, Attitudes and Practices Survey in Management of Type 2 Diabetes by General Practitioners in Dakar. Journal of Diabetes Mellitus, 2017, 07, 294-301.	0.3	0
1947	Treating Type 2 Diabetes Mellitus. , 2017, , 905-927.		0
1948	The Role of Incretins in Insulin Secretion. , 2017, , 57-69.		0
1949	Gesamtliteraturverzeichnis. , 2017, , 1-153.		0
1950	Newer Long-Acting Basal Insulin Preparations. Endocrine Practice, 2017, 23, 13-17.	2.1	0
1951	Concentrated Rapid-Acting Insulin Preparations. Endocrine Practice, 2017, 23, 18-23.	2.1	0
1952	National Clinical Guidelines. , 2017, , .		2
1953	Treating Type 2 Diabetes Mellitus. , 2017, , 1-24.		0
1954	Management of Diabetes in Elderly. International Journal of Medicine and Surgery, 2017, 4, 26-33.	0.0	0
1955	Long-acting insulins in the treatment of type 2 diabetes and their position in the current treatment algorithm. Vnitřní Lekarství, 2017, 63, 87-92.	0.2	0
1956	Comments on current guidelines of type 2 diabetes mellitus treatment. Vnitřní Lekarství, 2017, 63, 211-217.	0.2	1
1957	Evaluación de la prescripción de glibenclamida en diabéticos tipo 2. Revista De La Universidad Industrial De Santander Salud, 2017, 49, 9-15.	0.2	1
1958	Managing vascular risk factors among obese quitters with diabetes: how intensive lifestyle intervention and novel pharmacotherapy can work in concert?. British Journal of Diabetes, 2017, 17, 19.	0.2	0
1959	Journal of ISSN: 2374-6947 JDMDC Diabetes, Metabolic Disorders & Control Review Article Volume 4 Issue 2 - 2017 Pharmacoeconomic Meta-Analysis of Oral Dual Therapy Options in Overweight Patients with Uncontrolled Diabetes. Journal of Diabetes, Metabolic Disorders & Control, 2017, 4, .	0.1	0
1960	Diabetology: a field of new possibilities. Interni Medicina Pro Praxi, 2017, 19, 54-56.	0.0	0

#	ARTICLE	IF	CITATIONS
1961	Advantages of the combined therapy with metformin and glimepiride in patients with type 2 diabetes mellitus. MÃ¼narodnij EndokrinologÃ¼nij Å½urnal, 2017, 13, 118-122.	0.4	1
1962	Sarcopenia in type 2 diabetes mellitus (review and own observations). MÃ¼narodnij EndokrinologÃ¼nij Å½urnal, 2017, 13, 186-194.	0.4	0
1963	Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance. Diabetes Mellitus, 2017, 20, 142-150.	1.9	0
1964	LEPTIN RESISTANCE AND TYPE 2 DIABETES. International Journal of Medicine and Medical Research, 2017, , .	0.2	0
1965	Efficiency Evaluation of the Combination Therapy for Comorbid Arterial Hypertension with Diabetes Mellitus 2 Type Depending on the Genetic Polymorphism of the Angiotensin-Converting Enzyme. UkraÃ¼nskij Å½urnal Medicini BÃ¼ologÃ¼ Ta Sportu, 2017, 2, 36-42.	0.2	0
1966	Metformina en enfermedad renal diabÃ©tica: estado actual. Revista Colombiana De NefrologÃ­a, 2017, 4, 188.	0.1	1
1967	Glycemic control for prevention vascular complication in diabetic patient. Universa Medicina, 2017, 36, 77-79.	0.2	0
1968	Diabetic retinopathy and sex hormone-binding globulin: hypothesis or the real relationship?. Clinical Endocrinology and Endocrine Surgery, 2017, .	0.1	0
1969	Diabetes mellitus and cognitive disorders from the diabetologist's perspective. Vnitri Lekarstvi, 2017, 63, 717-720.	0.2	2
1970	Treatment strategy of type 2 diabetes used in Czech Republic after metformin therapy failure. Vnitri Lekarstvi, 2017, 63, 647-657.	0.2	0
1971	Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes. Diabetes Mellitus, 2017, 20, 286-298.	1.9	4
1973	Effects of Resistance and Aerobic Exercise Training or Education Associated with a Dietetic Program on Visfatin Concentrations and Body Composition in Overweight and Obese Women. Asian Journal of Sports Medicine, 2017, In Press, .	0.3	2
1974	Chapter 17: Diabetes Mellitus. , 2017, , .		0
1975	Influence of the factors of the progression of diabetic retinopathy on the concentration of blood fibrinogen at type 2 diabetes as the component of metabolic syndrome. Clinical Endocrinology and Endocrine Surgery, 2017, .	0.1	0
1976	Second line therapy in type 2 diabetes: legacy effect activation. Diabetes Mellitus, 2017, 20, 356-362.	1.9	1
1977	Long-term effects of sitagliptin in patients with type 2 diabetes mellitus and hypertension: results from the PROLOGUE study. Oncotarget, 2017, 8, 111979-111997.	1.8	2
1978	Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors and Incidence of Adverse Events in Patients with Type 2 Diabetes. Korean Journal of Clinical Pharmacy, 2017, 27, 214-220.	0.3	0
1979	PROSPECTS OF NEPHROPROTECTION AGAINST TYPE 2 DIABETES USING THE DPP-4 INHIBITOR VILDAGLIPTIN. Meditsinskiy Sovet, 2017, , 8-16.	0.5	2

#	ARTICLE	IF	CITATIONS
1980	Beginning With Very Low Dose (0.2mg) Liraglutide in Indian Type 2 Diabetic Patients Appears Better Tolerated: Experience from Real Life Practice. Journal of Diabetes, Metabolic Disorders & Control, 2017, 4, .	0.1	1
1981	Pharmacotherapy of Diabetic Macular Edema and Retinopathy. , 2018, , 35-50.		0
1982	Insulin Treatment. Endocrinology, 2018, , 617-640.	0.1	1
1983	New Research Progress of the Effect of Metformin on Plasma Vitamin B12 and Homocysteine. Advances in Clinical Medicine, 2018, 08, 480-485.	0.0	0
1984	Diabetes and the Cardiovascular System. Endocrinology, 2018, , 131-159.	0.1	0
1985	Comparison of Therapeutic Effects of Linagliptin and Metformin in Patients with Type 2 Diabetes: A systematic Review and Meta-Analysis. Journal of Ardabil University of Medical Sciences, 2018, 18, 21-33.	0.2	1
1986	A consensual therapeutic recommendation for type 2 diabetes mellitus by the Slovak Diabetes Society (2018). Vnitřní Lekarství, 2018, 64, 405-426.	0.2	0
1987	Effectiveness and safety of lixisenatide for treatment of diabetes in the real world: data from the Monitoring Registry in a Real-Life Cohort in the Czech and Slovak Republic. Vnitřní Lekarství, 2018, 64, 357-366.	0.2	1
1988	Modern type 2 diabetes treatment - practical implications. Medicína Pro Praxi, 2018, 15, 71-75.	0.0	0
1989	Le contrôle glycémique réduit-il les complications cardiovasculaires du diabète de type 2?. Bulletin De L'Académie Nationale De Médecine, 2018, 202, 897-908.	0.0	0
1990	Lifestyle modification and dietary nutrition in patients with arterial hypertension and diabetes mellitus: recommendations of European consensus and the facts of life (literature review). МАНРодний Ендокринологічний Журнал, 2018, 14, 182-193.	0.4	0
1991	Diagnostics of impaired carbon metabolism in patients with ischemic heart disease.. Medicni Perspektivi, 2018, 23, 46-52.	0.4	2
1995	Risk of Type 2 Diabetes Among the Pakistani Population: Results of a Cross-sectional Survey. Cureus, 2018, 10, e3144.	0.5	3
1996	The Insulin Regimen That Works. Journal of Doctoral Nursing Practice, 2018, 11, 165-168.	0.1	0
1997	Diabetes in Kidney Transplant Recipients. , 2019, , 113-131.		1
1998	Diabetes mellitus in complex older patients. Vnitřní Lekarství, 2018, 64, 1005-1008.	0.2	0
1999	Features of Antioxidant Defense Depending on the Thyroid Gland Functional State in Different Age Patients with Comorbid Pathology. Український Журнал Медичної Біології та Sportu, 2018, 3, 129-134.	0.2	0
2000	Influence of hypothyroidism on the level of 8-hydroxy-2'-deoxyguanosine as a biomarker of oxidative damage in comorbid conditions. Ukrainian Therapeutical Journal, 2018, .	0.0	0

#	ARTICLE	IF	CITATIONS
2001	The Influence of Combined Therapy on Lipid, Glucose Profile in Patients with Diabetes Mellitus Type II. Family Medicine, 2018, .	0.1	0
2003	Management of cardiovascular risk at patients with a diabetes mellitus type 2.. Klinicheskaia Meditsina, 2018, 96, 696-701.	0.1	2
2004	Glycemic sensors in treatment of diabetes. PraktickĀĀkĀrenstvĀ; 2018, 14, e10-e17.	0.1	2
2005	PROGNOSTIC ROLE AND FEATURES OF INFLUENCE OF ARTERIAL HYPERTENSION, METABOLIC AND ENDOCRINE DISBALANCE ON AGING RATE IN PATIENTS OF DIFFERENT AGE GROUPS WITH COMORBID PATHOLOGY. Bulletin of Problems Biology and Medicine, 2019, 2, 139.	0.1	0
2006	Diabetic Foot. Endocrinology, 2019, , 1-22.	0.1	0
2007	Fiches cliniques. , 2019, , 541-557.		0
2008	DĀsordres glycĀmiques. , 2019, , 53-90.		0
2010	Diabetes Management in theĀUnited States. , 2019, , 255-271.		1
2011	DIABETES MELLITUS: THE MODERN STATE OF THE ISSUE (PART 2). Avicenna Bulletin, 2019, 21, 661-674.	0.3	0
2012	Mesures hygiĀno-diĀtĀtiques et Ātats diabĀtiques. , 2019, , 113-140.		0
2013	ThĀrapeutique des dĀsordres glycĀmiques. , 2019, , 141-252.		0
2014	EFFECT OF LEVOTHYROXINE ON THE STATE OF OXIDANT-ANTIOXIDANT BALANCE IN PATIENTS WITH COMBINED COURSE OF HYPERTENSION, TYPE 2 DIABETES AND SUBCLINICAL HYPOTHYROIDISM. Bulletin of Problems Biology and Medicine, 2019, 4, 126.	0.1	0
2015	Reliable choice in therapy of type 2 diabetes mellitus: focus on alogliptin. Meditsinskiy Sovet, 2019, , 138-145.	0.5	1
2016	The effect of low and high dose empagliflozin on HbA1c and lipid profile in Type 2 Diabetes mellitus: A real world data. Āstanbul Kuzey Klinikleri, 2019, 7, 167-173.	0.3	6
2017	Diabetes and the Cardiovascular System. Endocrinology, 2019, , 1-29.	0.1	0
2018	The Influence of Combined Therapy on Lipid, Glucose Profile in Patients with Diabetes Mellitus Type 2. Family Medicine, 2019, .	0.1	0
2019	How well we treat with insulin in the Czech Republic and in the Slovak Republic A summary of results and comments on the original Czech-Slovak DIAINFORM study. Vnitřni Lekarstvi, 2019, 65, 279-283.	0.2	2
2020	Management of diabetic patients with lower extremity peripheral arterial disease. Vnitřni Lekarstvi, 2019, 65, 326-334.	0.2	0

#	ARTICLE	IF	CITATIONS
2021	Metformin poisoning treated with high dose insulin dextrose therapy: a case series. Acta Medica Lituanica, 2019, 26, 72-78.	0.3	1
2022	Effectiveness and Safety of Hydroxychloroquine compared to Teneligliptin in uncontrolled T2DM patients as add-on therapy. Journal of the ASEAN Federation of Endocrine Societies, 2019, 34, 87-91.	0.2	4
2023	Effect of Lawsonia inermis Linn. Extracts on Blood Glucose Level in Normal and Streptozotocin-Induced Diabetic Rats. Pakistan Journal of Nutrition, 2019, 18, 671-676.	0.2	1
2024	The Impact of Structured Diabetes Education on Glycemic Control in Patients with Type 2 Diabetes at Initiation of Basal Insulin – The Basal-EDUC-RO Study: A Randomized Prospective Study. Romanian Journal of Diabetes Nutrition and Metabolic Diseases, 2019, 26, 185-198.	0.3	2
2025	Vitamin B12 deficiency in the elderly and the possibility of influencing the nature of drug treatment type 2 diabetes. Family Medicine, 2019, .	0.1	0
2026	Insulin-associated Weight Gain in Type 2 Diabetes and Its Relation with Caloric Intake. Cureus, 2019, 11, e5275.	0.5	0
2027	Metformin-associated Lactic Acidosis Successfully Treated with Continuous Renal Replacement Therapy. Cureus, 2019, 11, e5330.	0.5	3
2028	The effect of combined therapy with statins and levothyroxine on the lipid profile dynamics in patients with a comorbid course of arterial hypertension, type 2 diabetes mellitus and subclinical hypothyroidism. Clinical Pharmacy, 2019, 23, 57-63.	0.2	0
2029	Gender features of lipid metabolism disorders in elderly patients with subclinical hypothyroidism on the background of comorbid pathology. Bukovinian Medical Herald, 2019, 23, 72-78.	0.1	0
2030	Early combination therapy for type 2 diabetes. Time for new decisions. Meditsinskiy Sovet, 2019, , 115-121.	0.5	0
2032	Basal insulin persistence in Brazilian participants with T2DM. Revista Da Associação Médica Brasileira, 2019, 65, 1254-1264.	0.7	1
2033	Clinical potential of treatment with semaglutide in type 2 diabetes patients. Drugs in Context, 2019, 8, 1-11.	2.2	4
2034	Diabetes as a Systemic Factor for Peri-implantitis. , 2020, , 59-67.		0
2035	Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients. Drug Metabolism and Personalized Therapy, 2021, .	0.6	2
2036	Characteristics of the type 2 diabetic patients with hypoglycemia in a tertiary referral hospital. Mădărarodnii Endokrinologij Jurnal, 2021, 17, 472-476.	0.4	0
2037	The Effect of Levothyroxine on the State of Endothelial Dysfunction in Patients with a Combined Course of Arterial Hypertension, Type 2 Diabetes Mellitus and Subclinical Hypothyroidism. Ukraïnskij Jurnal Medicini Biologičesko Ta Sportu, 2020, 5, 161-166.	0.2	0
2038	Glycemic Control and Future Perspectives for Treatment. , 2021, , 73-86.		0
2039	Diabetes as an Indication for Bariatric Surgery. Difficult Decisions in Surgery: an Evidence-based Approach, 2021, , 25-38.	0.0	1

#	ARTICLE	IF	CITATIONS
2041	Is the Ketogenic Diet an Effective and Safe Approach to Type 2 Diabetes Management and Weight Loss?. US Endocrinology, 2020, 16, 15.	0.3	1
2042	Diabetes and the Cardiovascular System. Endocrinology, 2020, , 131-159.	0.1	0
2044	Short-term renal and metabolic effects of low dose vildagliptin treatment added-on insulin therapy in non-proteinuric patients with type 2 diabetes: open-label randomized prospective study. Archives of Endocrinology and Metabolism, 2020, 64, 418-426.	0.6	1
2045	Level of Glycemic Control and Its Associated Factors among Type II Diabetic Patients in Debre Tabor General Hospital, Northwest Ethiopia. Journal of Diabetes and Endocrinology Research, 0, , .	0.0	0
2046	Graventric approach to Type 2 Diabetes therapy. The success prediction. A proof-of-concept. Pharmacy Formulas, 2020, 2, 48-60.	0.2	0
2047	Insulin pump therapy and continuous glucose monitoring in adults with type 2 diabetes: where are we now?. Exploration of Medicine, 2020, 1, 314-330.	1.5	2
2048	Kontrol altÄ±nda olmayan tip 2 diyabetes mellitus hastalarÄ±nda insÄ¼lin tedavisinden eksenatid bazlıÄ± tedaviye geÄ±Ä±n etkinliÄ±. Cukurova Medical Journal, 2020, 45, 820-826.	0.2	0
2049	Guiding Glucose Management Discussions Among Adults With Type 2 Diabetes in General Practice: Development and Pretesting of a Clinical Decision Support Tool Prototype Embedded in an Electronic Medical Record. JMIR Formative Research, 2020, 4, e17785.	1.4	5
2050	Management of Diabetes Mellitus in Acute and Chronic Cardiorenal Syndromes. , 2021, , 295-313.		0
2051	Effects of an actual insulin injection demonstration on insulin acceptance among patients with T2DM: a pragmatic randomised controlled trial. Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne, 2020, 59, 151-158.	0.6	0
2052	Towards a genotype-based approach for a patient-centered pharmacologic therapy of type 2 diabetes. Annals of Translational Medicine, 2015, 3, S36.	1.7	2
2053	Serial Medication Nonadherence in Patients with Type 2 Diabetes. American Health and Drug Benefits, 2015, 8, S12-6.	0.5	0
2054	Mitigating the Burden of Type 2 Diabetes: Challenges and Opportunities. American Health and Drug Benefits, 2015, 8, S3-S11.	0.5	2
2055	Adherence to Insulin Pen Therapy Is Associated with Reduction in Healthcare Costs Among Patients with Type 2 Diabetes Mellitus. American Health and Drug Benefits, 2015, 8, 148-58.	0.5	16
2056	Glyxambi (Empagliflozin/Linagliptin): A Dual-Acting Oral Medication Approved for the Treatment of Patients with Type 2 Diabetes. American Health and Drug Benefits, 2015, 8, 171-5.	0.5	6
2057	TREATMENT OF TYPE 2 DIABETES WITH BIPHASIC INSULIN ANALOGUES. European Medical Journal Diabetes, 2016, 4, 74-83.	4.0	7
2058	Prevalence of poor glycemic and blood pressure control and pattern of drug use among primary health-care outpatients in Al Ahsa Saudi Arabia. International Journal of Health Sciences, 2017, 11, 38-44.	0.4	1
2059	Pharmacological Agents Utilized in Patients With Type-2 Diabetes: Beyond Lowering A1c. P and T, 2018, 43, 214-227.	0.9	3

#	ARTICLE	IF	CITATIONS
2060	Cardiovascular outcomes and safety with antidiabetic drugs. International Journal of Health Sciences, 2018, 12, 70-83.	0.4	5
2061	Effects of 25-hydroxyvitamin D on bone microstructure in T2MD rats. Journal of Musculoskeletal Neuronal Interactions, 2018, 18, 525-529.	0.1	0
2062	Bolus Insulin Prescribing Recommendations for Patients With Type 2 Diabetes Mellitus. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2017, 34, S26-S31.	0.6	1
2063	Some Facts on the Diabetes Surveillance in Rural Regions of Iran. Iranian Journal of Public Health, 2018, 47, 1967-1968.	0.5	0
2064	The Effect of Acupressure on Fasting Blood Glucose and Glycosylated Hemoglobin Levels in Diabetic Patients: A Randomized Controlled Trial. International Journal of Community Based Nursing and Midwifery, 2021, 9, 152-158.	0.2	0
2065	The perspectives of nurse practitioners and physicians on increasing the number of registered nurses in primary care. Nursing Economics, 2018, 36, 182-188.	0.3	1
2066	Dynamics of heart rate variability in patients with type 2 diabetes mellitus during spinal anesthesia using dexmedetomidine. American Journal of Translational Research (discontinued), 2021, 13, 5395-5403.	0.0	0
2067	Comparison of the Effect of Cardiac Rehabilitation on Functional Capacity of Diabetic and Nondiabetic Patients after CABG. International Journal of Preventive Medicine, 2021, 12, 30.	0.4	0
2068	Structure and properties of insulin. , 2022, , 29-70.		1
2069	Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians. Metabolites, 2021, 11, 794.	2.9	0
2070	Diabetes and Cancer: Risk, Challenges, Management and Outcomes. Cancers, 2021, 13, 5735.	3.7	40
2071	Low risk of hypoglycemia and high efficacy of gliclazide MB: results of recent studies. Diabetes Mellitus, 2021, 24, 350-356.	1.9	1
2072	Dendrocalamus latiflorus and its component rutin exhibit glucose-lowering activities by inhibiting hepatic glucose production via AKT activation. Acta Pharmaceutica Sinica B, 2022, 12, 2239-2251.	12.0	8
2073	Diabetes mellitus: Antidiabetika fÃ¼r Ã„ltere mit Bedacht wÃ¤hlen. , 0, , .		0
2074	Metformin Inhibits Advanced Glycation End Products-Induced Cell Apoptosis and Oxidative Stress of Human Skin Fibroblasts by Downregulating MicroRNA-126. , 2021, 83, .		0
2075	Comparative efficacy and safety of antihyperglycemic drug classes for patients with type 2 diabetes following failure with metformin monotherapy: A systematic review and network meta-analysis of randomized controlled trials. Diabetes/Metabolism Research and Reviews, 2022, 38, e3515.	4.0	5
2076	Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Reviews in Endocrine and Metabolic Disorders, 2022, 23, 521-539.	5.7	29
2077	Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar <scp>Insulinâ€™R</scp> with the <scp>US</scp>-licensed <scp>HumulinÂ® R</scp> formulation in healthy subjects: Results from the <scp>RHINE</scp>-1 (<scp>Recombinant Human INsulin Equivalenceâ€™1</scp>) study. Diabetes, Obesity and Metabolism, 2022, 24, 713-721.	4.4	7

#	ARTICLE	IF	CITATIONS
2078	Efficacy and Safety of Empagliflozin as Add-On Therapy in Patients of Type-2 Diabetes Mellitus. Journal of Gandhara Medical and Dental Science, 2022, 9, 24-27.	0.1	1
2079	Optimizing the treatment of newly diagnosed type 2 diabetes mellitus with combination of dipeptidyl peptidase-4 inhibitors and metformin: An expert opinion. Journal of Family Medicine and Primary Care, 2021, 10, 4398.	0.9	1
2081	Effectiveness and safety of basal insulin therapy in type 2 diabetes mellitus patients with or without metformin observed in a national cohort in China. BMC Endocrine Disorders, 2022, 22, 26.	2.2	2
2082	Regulation and role of amp-activated protein kinase at the cellular level and relevance to diabetes mellitus. , 2022, 1, 18.		0
2083	Combination of mulberry leaf active components possessed synergetic effect on SD rats with diabetic nephropathy by mediating metabolism, Wnt/ β -catenin and TGF- β 2/Smads signaling pathway. Journal of Ethnopharmacology, 2022, 292, 115026.	4.1	8
2084	Correction to: "Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: A Meta-Analysis" Journal of Lipid and Atherosclerosis, 2022, 11, 89.	3.5	2
2085	Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials. Pharmacological Research, 2022, 175, 106039.	7.1	26
2087	Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases. Drugs, 2022, 82, 311.	10.9	12
2088	Patient preferences for the treatment of type 2 diabetes in Australia: A discrete choice experiment. Journal of Diabetes and Metabolic Disorders, 0, , 1.	1.9	0
2090	HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial. Diabetes Care, 2022, , .	8.6	4
2091	Differential effects of treatment targets on risks of adverse outcomes according to diabetes duration, age and complications: Can these characteristics be used to individualize diabetes treatment? The Rio de Janeiro type 2 diabetes cohort. Journal of Diabetes and Its Complications, 2022, 36, 108124.	2.3	5
2092	Metformin alleviates ionizing radiation-induced senescence by restoring BARD1-mediated DNA repair in human aortic endothelial cells. Experimental Gerontology, 2022, 160, 111706.	2.8	12
2093	Long-term clinical and cost-effectiveness of collaborative care in people with uncontrolled type 2 diabetes mellitus and polypharmacy: A multicenter randomized controlled trial. Primary Care Diabetes, 2022, 16, 188-195.	1.8	4
2094	Increased Prevalence of Cardiovascular Risk Factors in Newly Diagnosed Type 2 Diabetes Patients " a Retrospective Study. Acta Endocrinologica, 2021, 17, 331-336.	0.3	0
2095	Uso inicial de insulina en pacientes hospitalizados con diabetes mellitus tipo 2. Revista Colombiana De Endocrinología, Diabetes & Metabolismo, 2021, 8, .	0.0	0
2097	Web-based intervention to reduce psychological barriers to insulin therapy among adults with non-insulin-treated type 2 diabetes: study protocol for a two-armed randomised controlled trial of "Is insulin right for me?"™. BMJ Open, 2022, 12, e051524.	1.9	3
2098	Inhibition Mechanism of Components Isolated from Morus alba Branches on Diabetes and Diabetic Complications via Experimental and Molecular Docking Analyses. Antioxidants, 2022, 11, 383.	5.1	9
2099	Therapeutic Potential of Silybum Marianum and Pergularia Tomentosa Extracts from Jordanian Origin in Diabetes Mellitus. Current Bioactive Compounds, 2022, 18, .	0.5	3

#	ARTICLE	IF	CITATIONS
2100	Results of a multidisciplinary strategy to improve the management of cardiovascular risk factors after liver transplantation. <i>Liver Transplantation</i> , 2022, 28, 1332-1344.	2.4	4
2101	New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation. <i>Frontiers of Medicine</i> , 2022, 16, 17-24.	3.4	2
2102	Metformin reverses tamoxifen resistance through the lncRNA GAS5-mediated mTOR pathway in breast cancer. <i>Annals of Translational Medicine</i> , 2022, 10, 366-366.	1.7	10
2103	Serum ErbB2 concentration positively correlated to the glycemic variations in newly diagnosed Type 2 diabetic patients. <i>Scientific Reports</i> , 2022, 12, 4940.	3.3	5
2104	Assessment of CVD Risk Factors in Secondary Prevention after Ischemic Stroke Using the ICF. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3368.	2.6	2
2105	Pioglitazone, Bladder Cancer, and the Presumption of Innocence. <i>Current Drug Safety</i> , 2022, 17, 294-318.	0.6	5
2106	Socioeconomic inequalities in glycaemic control in recently diagnosed adults with type 1 and type 2 diabetes. <i>Diabetic Medicine</i> , 2022, 39, e14833.	2.3	3
2107	Effect of liraglutide on markers of insulin production in persons with type 2 diabetes treated with multiple daily insulin injections. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108110.	2.3	1
2108	System usability, user satisfaction and long-term adherence to mobile hyperacuity home monitoring—prospective follow-up study. <i>Eye</i> , 2022, , .	2.1	0
2109	Effects of dapagliflozin in the progression of atherosclerosis in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, 41.	2.7	5
2110	Targeting Myotonic Dystrophy Type 1 with Metformin. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2901.	4.1	13
2111	Safety and Effectiveness of Insulin Glargine 300 U/mL in Participants with Type 2 Diabetes Who Fast During Ramadan in The Gulf Region: A Subgroup Analysis of the Real-World ORION Study. <i>Diabetes Therapy</i> , 2022, 13, 569-581.	2.5	3
2112	Evolving Type 2 diabetes management focuses on clinical outcomes. <i>Drugs and Therapy Perspectives</i> , 0, , 1.	0.6	0
2114	Safety and efficacy of once weekly dipeptidyl-peptidase-4 inhibitor trelagliptin in type-2 diabetes: A meta-analysis. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022, 16, 102469.	3.6	1
2115	<i>KCNQ1</i> variant rs163184 is a potential biomarker of glycemic response to exenatide. <i>Pharmacogenomics</i> , 2022, 23, 355-361.	1.3	4
2116	6. Glycemic Targets: <i>Standards of Medical Care in Diabetes—2022</i>. <i>Diabetes Care</i> , 2022, 45, S83-S96.	8.6	388
2117	In Vitro and In Vivo Antidiabetic Potential of Monoterpenoids: An Update. <i>Molecules</i> , 2022, 27, 182.	3.8	18
2118	deterioro cognitivo como una complicaci3n de la Diabetes Mellitus Tipo 2. <i>Nova</i> , 2021, 19, 25-41.	0.1	1

#	ARTICLE	IF	CITATIONS
2119	Adherence, control of cardiometabolic factors and therapeutic inertia in patients with type 2 diabetes in the primary care setting. <i>Endocrinology, Diabetes and Metabolism</i> , 2022, 5, e00320.	2.4	3
2120	Comprehensive Geriatric Assessment (CGA) in patients with DM. <i>Journal of Gerontology and Geriatrics</i> , 2021, 69, 258-261.	0.5	0
2121	Circulating Nucleic Acid-Based Biomarkers of Type 2 Diabetes. <i>International Journal of Molecular Sciences</i> , 2022, 23, 295.	4.1	8
2122	Comparative efficiency and safety of insulin degludec/aspart with insulin glargine in type 2 diabetes: a meta-analysis of randomized controlled trials. <i>Endocrine Journal</i> , 2022, , .	1.6	1
2123	Cardiovascular and renal outcomes of initial combination therapy with glucose-lowering agents versus a stepwise approach in newly diagnosed or treatment-naïve type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1469-1482.	4.4	0
2137	Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients. <i>Drug Metabolism and Drug Interactions</i> , 2020, 35, .	0.3	1
2141	Association between different diabetes medication classes and risk of <scp>Parkinson</scp>'s disease in people with diabetes. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 875-882.	1.9	8
2142	Association Between DPP-4 Inhibitors and Events of Colorectal and Liver Cancers in Patients With Diabetes Receiving Second-Line Agents: A Nested Case-Control Study. <i>Frontiers in Oncology</i> , 2022, 12, .	2.8	2
2143	Effects of diet and antihyperglycemic drugs on erectile dysfunction: A systematic review. <i>Andrology</i> , 2023, 11, 282-294.	3.5	14
2144	Perceptions of Type 2 Diabetes Patients for Starting Insulin: A Qualitative Content Analysis. <i>Turkish Journal of Diabetes and Obesity</i> , 2021, 5, 317-324.	0.3	0
2145	Diabetic vascular disease: Cellular and molecular approach. , 2017, 51, 18-28.		2
2146	Exploring the Pharmacological Potential of Metformin for Neurodegenerative Diseases. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 838173.	3.4	13
2148	Glycemic control in newly insulin-initiated patients with type 2 diabetes mellitus: A retrospective follow-up study at a university hospital in Ethiopia. <i>PLoS ONE</i> , 2022, 17, e0268639.	2.5	8
2149	Effects of continuous subcutaneous insulin infusion on the microstructures, mechanical properties and bone mineral compositions of lumbar spines in type 2 diabetic rats. <i>BMC Musculoskeletal Disorders</i> , 2022, 23, .	1.9	1
2150	Time to Treatment Intensification in Patients Receiving DPP4 Inhibitors Versus Sulfonylureas as the First Add-On to Metformin Monotherapy: A Retrospective Cohort Study. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	0
2151	Neuroimaging perspective in targeted treatment for type 2 diabetes melitus and sleep disorders. <i>Intelligent Medicine</i> , 2022, 2, 209-220.	3.1	4
2152	Comorbidities in Recent-Onset Adult Type 1 Diabetes: A Comparison of German Cohorts. <i>Frontiers in Endocrinology</i> , 2022, 13, .	3.5	1
2153	A Comparative Study of Natural Language Processing Algorithms Based on Cities Changing Diabetes Vulnerability Data. <i>Healthcare (Switzerland)</i> , 2022, 10, 1119.	2.0	0

#	ARTICLE	IF	CITATIONS
2154	Efficacy and Safety of Insulin Glargine 300ÂU/mL in People with TypeÂ2 Diabetes Uncontrolled on Basal Insulin: The 26-Week Interventional, Single-Arm ARTEMIS-DM Study. Diabetes Therapy, 0, , .	2.5	0
2155	The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis. Contemporary Clinical Trials Communications, 2022, 28, 100944.	1.1	12
2156	Chlorogenic acid improves anti-lipogenic activity of metformin by positive regulating of AMPK signaling in HepG2 cells. Cell Biochemistry and Biophysics, 2022, 80, 537-545.	1.8	4
2157	Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials. Pharmacological Reviews, 2022, 74, 506-551.	16.0	106
2158	Knowledge and practice of community pharmacists towards SGLT2 inhibitors. F1000Research, 0, 11, 659.	1.6	0
2159	Self-care management of bothersome symptoms as recommended by clinicians for patients with a chronic condition: A Delphi study. Heart and Lung: Journal of Acute and Critical Care, 2022, 56, 40-49.	1.6	2
2160	Twenty Years of Insulin Gla-100: A Systematic Evaluation of Its Efficacy and Safety in Type 2 Diabetes Mellitus. Diabetes Therapy, 2022, 13, 1409-1481.	2.5	2
2161	Real-world experience of angiotensin receptor neprilysin inhibitor on the glucose-lowering effect. Scientific Reports, 2022, 12, .	3.3	1
2162	Knowledge and practice of community pharmacists towards SGLT2 inhibitors. F1000Research, 0, 11, 659.	1.6	0
2163	Association of Serum Homocysteine with Controlled and Uncontrolled Type2 Diabetes Mellitus in Sulaimani City. Al Mustansiriyah Journal of Pharmaceutical Sciences, 2022, 22, 7-19.	0.6	0
2164	Medicinal Plants for the Treatment of Type 2 Diabetes. Advances in Medical Diagnosis, Treatment, and Care, 2022, , 163-177.	0.1	0
2166	Metformin Exhibits an Attractive Antineoplastic Effect on Human Endometrial Cancer by Regulating the Hippo Signaling Pathway. Journal of Oncology, 2022, 2022, 1-11.	1.3	1
2168	Insulin Secretory Actions of Ethanol Extract of Eucalyptus citriodora Leaf, including Plasma DPP-IV and GLP-1 Levels in High-Fat-Fed Rats, as Well as Characterization of Biologically Effective Phytoconstituents. Metabolites, 2022, 12, 757.	2.9	9
2169	Predictors of HbA1c reduction and hypoglycemia in type 2 diabetes mellitus individuals switching from premixed to basal insulin: an exploratory analysis of optimization study. Current Medical Research and Opinion, 0, , 1-8.	1.9	1
2170	The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome. Life, 2022, 12, 1222.	2.4	6
2171	Once-Weekly Semaglutide Use in Patients with Type 2 Diabetes: Results from the SURE Spain Multicentre, Prospective, Observational Study. Journal of Clinical Medicine, 2022, 11, 4938.	2.4	9
2172	CXCL13 and CXCR5 are upregulated in PCOS mice ovaries but downregulated following metformin administration. Molecular and Cellular Endocrinology, 2022, 556, 111730.	3.2	3
2173	Part Five: The Role of Deprescribing and Adjusting Glycemic Targets in Older People With Diabetes. , 2022, 37, 384-393.		0

#	ARTICLE	IF	CITATIONS
2174	The consumption of sea buckthorn (<i>Hippophae rhamnoides</i> L.) effectively alleviates type 2 diabetes symptoms in spontaneous diabetic rats. <i>Research in Veterinary Science</i> , 2022, 152, 261-269.	1.9	6
2175	Pharmacotherapy in Clinical Trials for Abdominal Aortic Aneurysms: A Systematic Review and Meta-Analysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962211204.	1.7	6
2176	Comparing time to intensification between insulin degludec/insulin aspart and insulin glargine: A single-center experience from India. <i>Journal of Diabetology</i> , 2022, 13, 171.	0.3	0
2177	Real-world observational study to capture demographic details of newly diagnosed type 2 diabetes mellitus. <i>International Journal of Research in Medical Sciences</i> , 2022, 10, 2251.	0.1	0
2178	The dual role of empagliflozin: Cardio renal protection in T2DM patients. <i>Annals of Medicine and Surgery</i> , 2022, 81, .	1.1	2
2179	Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database. <i>Clinical Drug Investigation</i> , 2022, 42, 965-975.	2.2	4
2180	A minireview of pharmacotherapy of type 2 diabetes “drugs and mechanisms. <i>Research, Society and Development</i> , 2022, 11, e474111234900.	0.1	0
2181	Hypoglycemic events and glycemic control effects between NPH and premixed insulin in patients with type 2 diabetes mellitus: A real-world experience at a comprehensive specialized hospital in Ethiopia. <i>PLoS ONE</i> , 2022, 17, e0275032.	2.5	1
2182	Insulinoterapia en pacientes con diabetes mellitus tipo 2. Una revisión narrativa. <i>Enfermería Universitaria</i> , 2022, 18, 368-381.	0.1	0
2183	Bioactive peptides in fermented foods and their application: a critical review. <i>Systems Microbiology and Biomanufacturing</i> , 2023, 3, 88-109.	2.9	8
2184	First-Line Therapy for Type 2 Diabetes With Sodium“Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. <i>Annals of Internal Medicine</i> , 2022, 175, 1392-1400.	3.9	32
2185	Prediction of janagliflozin pharmacokinetics in type 2 diabetes mellitus patients with liver cirrhosis or renal impairment using a physiologically based pharmacokinetic model. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 179, 106298.	4.0	4
2186	Enhance the flavonoids content and α -glucosidase inhibitor efficiency of mulberry leaves by fermented with <i>Ganoderma lucidum</i> . , 2021, 2, .		0
2187	A retrospective analysis of the incidence, outcome and factors associated with the occurrence of euglycemic ketoacidosis in diabetic patients on sodium glucose co-transporter “2 inhibitors undergoing cardiac surgery. <i>Annals of Cardiac Anaesthesia</i> , 2022, 25, 460.	0.6	1
2188	Methicillin-Resistant <i>Staphylococcus aureus</i> in Diabetic Foot Infections: Protein Profiling, Virulence Determinants, and Antimicrobial Resistance. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 10803.	2.5	6
2189	Pharmacologic Treatment of Type 2 Diabetes in the U.S., Sweden, and Israel. <i>Diabetes Care</i> , 2022, 45, 2926-2934.	8.6	6
2190	Automated Insulin Delivery Systems as a Treatment for Type 2 Diabetes Mellitus: A Review. <i>Endocrine Practice</i> , 2023, 29, 214-220.	2.1	6
2191	Red Blood Cell Lifespan < 74 Days Can Clinically Reduce Hb1Ac Levels in Type 2 Diabetes. <i>Journal of Personalized Medicine</i> , 2022, 12, 1738.	2.5	2

#	ARTICLE	IF	CITATIONS
2192	<i>Hibiscus sabdariffa</i> L. polyphenolic-rich extract promotes muscle glucose uptake and inhibits intestinal glucose absorption with concomitant amelioration of Fe ²⁺ -induced hepatic oxidative injury. <i>Journal of Food Biochemistry</i> , 2022, 46, .	2.9	3
2193	The impact of peer coach-led type 2 diabetes mellitus interventions on glycaemic control and self-management outcomes: A systematic review and meta-analysis. <i>Primary Care Diabetes</i> , 2022, 16, 719-735.	1.8	9
2194	Evaluation of the effectiveness of long-acting insulin analogs in patients with type 2 diabetes mellitus. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 0, , .	1.6	0
2195	Drug therapy and medication adherence in type 2 diabetes in a care facility: A cross sectional survey. <i>Exploratory Research in Clinical and Social Pharmacy</i> , 2022, , 100200.	1.0	0
2196	Determinants of response to the glucagon-like peptide-1 receptor agonists in a type 2 diabetes population in the real-world. <i>Primary Care Diabetes</i> , 2022, , .	1.8	0
2197	Glucose-responsive nanoparticles designed via a molecular-docking-driven method for insulin delivery. <i>Journal of Controlled Release</i> , 2022, 352, 527-539.	9.9	5
2198	Pharmacotherapy of type 2 diabetes: An update and future directions. <i>Metabolism: Clinical and Experimental</i> , 2022, 137, 155332.	3.4	35
2199	The Role of the Person Focused IARA Model in Reducing Anxiety and Improving Body Awareness and Illness Management in Diabetics with Acquired Lipodystrophy: A Mixed-Method Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 1865.	2.5	2
2201	Socio-demographic, behavioural and clinical factors influencing control of diabetes and hypertension in urban Mysore, South India: a mixed-method study conducted in 2018. <i>Archives of Public Health</i> , 2022, 80, .	2.4	5
2202	Mode of treatments and achievement of treatment targets among type 2 diabetes patients with different comorbidities â€” a register-based retrospective cohort study in Finland. , 2022, 23, .		1
2203	Empagliflozin activates JAK2/STAT3 signaling and protects cardiomyocytes from hypoxia/reoxygenation injury under high glucose conditions. <i>Journal of Thrombosis and Thrombolysis</i> , 2023, 55, 116-125.	2.1	4
2204	Insulin degludec/liraglutide versus its monotherapy on T2D patients: A lifetime cost-utility analysis in China. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	2
2205	Identifying Gaps in Real-World Management of Diabetes in Nigeria: A Subset Analysis of Cross-Sectional Wave-7 Data from the International Diabetes Management Practices Study. <i>Journal of Diabetes Mellitus</i> , 2022, 12, 284-301.	0.3	2
2206	Attenuation of hyperglycemia-associated dyslipidemic, oxidative, cognitive, and inflammatory crises via modulation of neuronal ChEs/NF- κ B/COX-2/NOx, and hepato-renal functional deficits by the <i>Tridax procumbens</i> extract. <i>Biomedicine and Pharmacotherapy</i> , 2023, 158, 114114.	5.6	2
2207	Prevalence of Rounded Shoulder in Computer Users. A cross-sectional survey. <i>Pak-Euro Journal of Medical and Life Sciences</i> , 2022, 5, 423-428.	0.1	0
2208	Assessment of Biotransformed Silica Nanoparticle on Blood Glucose Level in Human: An In Vitro Investigation. <i>Indian Journal of Clinical Biochemistry</i> , 2024, 39, 83-91.	1.9	1
2209	HOW did GLP-1RAs bring about a paradigm shift in the guidelines of managing T2DM: A path to gluco-cardio Centricity. <i>Indian Heart Journal</i> , 2022, , .	0.5	0
2210	6. Glycemic Targets: <i>Standards of Care in Diabetesâ€”2023</i>. <i>Diabetes Care</i> , 2023, 46, S97-S110.	8.6	205

#	ARTICLE	IF	CITATIONS
2211	Can probiotic, prebiotic, and synbiotic supplementation modulate the gut-liver axis in type 2 diabetes? A narrative and systematic review of clinical trials. <i>Frontiers in Nutrition</i> , 0, 9, .	3.7	2
2213	A qualitative study of blood glucose and side effect self-management among patients with type 2 diabetes undergoing chemotherapy for cancer. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2023, 10, 100172.	1.6	3
2214	Antidiabetic agents: Do they hit the right targets?. <i>Frigid Zone Medicine</i> , 2022, 2, 225-243.	0.3	0
2215	Influence of Metformin Dose and Treatment Adherence on Glycemic Control, Adiposity, and Cardiovascular Risk Markers in Iraqi Patients with T2DM. <i>Journal of the Faculty of Medicine, Baghdad</i> , 2023, 64, .	0.1	3
2216	Effects of liraglutide on weight control and blood pressure in type 2 diabetes mellitus Iraqi patients. <i>Journal of the Faculty of Medicine, Baghdad</i> , 2023, 64, 227-232.	0.1	1
2217	Use of Second-Generation Basal Insulin Gla-300 in Special Populations: A Narrative Mini-Review. <i>Current Diabetes Reviews</i> , 2023, 19, .	1.3	1
2218	The effect of saffron (<i>Crocus sativus</i> L.) on glycemia, lipid profile, and antioxidant status in patients with type 2 diabetes mellitus: A randomized placebo-controlled trial. <i>Phytotherapy Research</i> , 2023, 37, 388-398.	5.8	5
2219	Treatment of Type 2 Diabetes with Biphasic Insulin Analogues. <i>European Medical Journal Diabetes</i> , 0, , 74-83.	4.0	5
2220	Effectiveness and safety of hydrogen inhalation as an adjunct treatment in Chinese type 2 diabetes patients: A retrospective, observational, double-arm, real-life clinical study. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	3
2221	Effects on glycemic control by combination therapy of gliclazide-metformin and insulin in type 2 diabetes mellitus patients. , 2023, 2, 51.		0
2222	Heart rate variability in different sleep stages is associated with metabolic function and glycemic control in type 2 diabetes mellitus. <i>Frontiers in Physiology</i> , 0, 14, .	2.8	2
2223	Investigating the Effect of Thyroid Hormones on Diabetic Nephropathy in Type 2 Diabetic Patients Referred to Ahvaz Hospitals in 2017. <i>Gene, Cell and Tissue</i> , 2023, In Press, .	0.2	0
2224	Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model. <i>Chinese Medical Journal</i> , 2023, 136, 102-104.	2.3	1
2225	Cyb5r3-based mechanism and reversal of secondary failure to sulfonylurea in diabetes. <i>Science Translational Medicine</i> , 2023, 15, .	12.4	4
2226	The Role of Gut Microbiota in High-Fat-Diet-Induced Diabetes: Lessons from Animal Models and Humans. <i>Nutrients</i> , 2023, 15, 922.	4.1	5
2227	Effects of different regimens of insulin on body mass index commonly used in type 2 diabetes mellitus. , 2022, 1, 22.		0
2228	Effects of marine phenolics on diabetes, obesity, and metabolic syndrome. , 2023, , 431-472.		0
2229	Artemisia abrotanum and Symphytum officinale Polyphenolic Compounds-Rich Extracts with Potential Application in Diabetes Management. <i>Metabolites</i> , 2023, 13, 354.	2.9	4

#	ARTICLE	IF	CITATIONS
2230	The modifier effect of physical activity, body mass index, and age on the association of metformin and chronic back pain: A cross-sectional analysis of 21,899 participants from the UK Biobank. PLoS ONE, 2023, 18, e0282205.	2.5	0
2231	Safety and efficacy of anti-hyperglycemic agents in patients with type 2 diabetes mellitus (T2DM): Protocol for an overview of systematic reviews based on network meta-analysis. PLoS ONE, 2023, 18, e0282143.	2.5	0
2232	Design expert software assisted development and evaluation of empagliflozin and sitagliptin combination tablet with improved in-vivo anti-diabetic activities. Heliyon, 2023, 9, e14259.	3.2	0
2233	Basal insulin titration algorithms in patients with type 2 diabetes: the simplest is the best (?). MÄÄ¼narodnj EndokrinologÄ¼nj Ä¼urnal, 2023, 19, 72-78.	0.4	0
2234	Current Strategies of New Drugs for Diabetes Management. Frontiers in Clinical Drug Research Diabetes and Obesity, 2023, , 22-47.	0.1	0
2235	Update on Medical Management of Diabetes. Orthopedic Clinics of North America, 2023, , .	1.2	0
2236	Adherence to the therapeutic guidelines recommendations among the people with type 2 diabetes mellitus and obesity, frailty, or recent diagnosis, attended in primary health care centers in Spain: A cross-sectional study. Frontiers in Medicine, 0, 10, .	2.6	0
2237	How does HbA1c predict mortality and readmission in patients with heart failure? A protocol for systematic review and meta-analysis. Systematic Reviews, 2023, 12, .	5.3	0
2238	Risk of Lactic Acidosis in Hospitalized Diabetic Patients Prescribed Biguanides in Japan: A Retrospective Total-Population Cohort Study. International Journal of Environmental Research and Public Health, 2023, 20, 5300.	2.6	0
2239	Diabetes and Heart Failure. , 2023, , 177-204.		0
2240	Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects. Translational and Clinical Pharmacology, 2023, 31, 59.	0.9	1
2241	Weight loss to disrupt type 2 diabetes. Diabetology International, 0, , .	1.4	0
2242	Versatile Solid Modifications of Multicomponent Pharmaceutical Salts: Novel Metforminâ€œRhein Salts Based on Advantage Complementary Strategy Design. Pharmaceutics, 2023, 15, 1196.	4.5	4
2243	Berry Dietary Interventions in Metabolic Syndrome: New Insights. Nutrients, 2023, 15, 1906.	4.1	2
2246	Cognitive protection of incretinâ€œbased therapies in patients with typeâ€œ2 diabetes mellitus: A systematic review and metaâ€œanalysis based on clinical studies. Journal of Diabetes Investigation, 2023, 14, 864-873.	2.4	4
2247	Design and development of a piezoelectric driven micropump integrated with hollow microneedles for precise insulin delivery. Journal of Micromechanics and Microengineering, 2023, 33, 075003.	2.6	3
2248	Regulation of biological processes by intrinsically chiral engineered materials. Nature Reviews Materials, 2023, 8, 403-413.	48.7	12
2249	DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature. Frontiers in Molecular Biosciences, 0, 10, .	3.5	10

#	ARTICLE	IF	CITATIONS
2250	An Update on the Molecular and Cellular Basis of Pharmacotherapy in Type 2 Diabetes Mellitus. International Journal of Molecular Sciences, 2023, 24, 9328.	4.1	6
2251	Diabetes Management in the United States. , 2023, , 309-328.		0
2252	The â€œOldâ€•Oral Antidiabetics. , 2023, , 551-563.		0
2253	Metformin attenuates diabetes-induced osteopenia in rats is associated with down-regulation of the RAGE-JAK2-STAT1 signal axis. Journal of Orthopaedic Translation, 2023, 40, 37-48.	3.9	0
2254	Duration and effectiveness of glucose-lowering regimens in the real world management of diabetes: Data from the Australian EXTEND45 Linked Cohort Study. Endocrine and Metabolic Science, 2023, 12, 100135.	1.6	0
2255	Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering. BMJ Open Diabetes Research and Care, 2023, 11, e003270.	2.8	2
2256	Genetics of diabetes. World Journal of Diabetes, 0, 14, 656-679.	3.5	1
2257	Chronic Metformin Administration Does Not Alter Carotid Sinus Nerve Activity in Control Rats. Advances in Experimental Medicine and Biology, 2023, , 203-208.	1.6	0
2258	Polymorphism in epigenetic regulating genes in relation to periodontitis, number of teeth, and levels of highâ€•sensitivity Câ€•reactive protein and glycated hemoglobin: The TromsÃ, Study 2015â€•2016. Journal of Periodontology, 2023, 94, 1324-1337.	3.4	2
2259	The Potential Benefits of Drug-Repositioning in Muscular Dystrophies. , 0, , .		0
2260	Novel RP-HPLC Method Development and Validation of Metformin HCl and Repaglinide in bulk and Tablet dosage form. International Journal of Pharmaceutical and Phytopharmacological Research, 2023, 13, 7-12.	0.2	0
2261	Tailoring the Treatment of Type 2 Diabetes Mellitus to the Individual. Contemporary Cardiology, 2023, , 1043-1070.	0.1	0
2262	High glucose promotes the progression of colorectal cancer by activating the BMP4 signaling and inhibited by glucagon-like peptide-1 receptor agonist. BMC Cancer, 2023, 23, .	2.6	1
2263	Development, Feasibility, Impact and Acceptability of a Community Pharmacy-Based Diabetes Care Plan in a Lowâ€•Middle-Income Country. Pharmacy (Basel, Switzerland), 2023, 11, 109.	1.6	0
2264	Topic Modeling Analysis of Diabetes-Related Health Information during the Coronavirus Disease Pandemic. Healthcare (Switzerland), 2023, 11, 1871.	2.0	1
2265	Paradigm Shift in Management of Hyperglycemia in Patients with Type 2 Diabetes: Glucocentric versus Organ Protection. Journal of Korean Diabetes, 2023, 24, 59-65.	0.3	0
2266	Use of complementary and alternative medicine among persons with diabetes at Mzuzu Central Hospital in Malawi: A cross-sectional study. Advances in Integrative Medicine, 2023, 10, 101-106.	0.9	1
2267	A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus. Pharmacoeconomics, 2023, 41, 1469-1514.	3.3	1

#	ARTICLE	IF	CITATIONS
2268	Recent advancements on novel approaches of insulin delivery. <i>Medicine in Novel Technology and Devices</i> , 2023, 19, 100253.	1.6	4
2270	Evaluation of a digital tool supporting therapeutic decision making for the personalized management of patients with type 2 diabetes not treated with insulin: a pilot study. <i>Diabetes Research and Clinical Practice</i> , 2023, , 110836.	2.8	0
2271	Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis. <i>Annals of Medicine</i> , 2023, 55, .	3.8	4
2272	Antidiabetic effects of polyherbal mixture made of <i>Centaurium erythraea</i> , <i>Cichorium intybus</i> and <i>Potentilla erecta</i> . <i>Journal of Ethnopharmacology</i> , 2024, 319, 117032.	4.1	1
2273	Nanotherapeutic approaches for managing phospholipase-mediated neurodegenerative and metabolic diseases. , 2023, , 129-157.		0
2274	Factors associated with therapeutic inertia in individuals with type 2 diabetes mellitus started on basal insulin. <i>Diabetes Research and Clinical Practice</i> , 2023, 203, 110888.	2.8	0
2276	Clinical Inertia: A Wider Perspective and Proposed Classification Criteria. <i>Indian Journal of Endocrinology and Metabolism</i> , 2023, 27, 296-300.	0.4	0
2277	Medicinal Plants for the Treatment of Type 2 Diabetes. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2023, , 114-132.	0.1	0
2278	Metabolic control and incidence of hypoglycaemia, hospitalisation and complications among Saudi patients with type 2 diabetes initiating second-line therapy: an analysis of the Saudi Arabia data from the DISCOVER Observational Study programme. <i>BMJ Open</i> , 2023, 13, e063586.	1.9	0
2279	Box Behnken optimization of cubosomes for enhancing the anticancer activity of metformin: Design, characterization, and in-vitro cell proliferation assay on MDA-MB-231 breast and LOVO colon cancer cell lines. <i>International Journal of Pharmaceutics: X</i> , 2023, 6, 100208.	1.6	0
2280	Boxâ€œBehnken design-assisted optimization of RP-HPLC method for the estimation of evogliptin tartrate by analytical quality by design. <i>Future Journal of Pharmaceutical Sciences</i> , 2023, 9, .	2.8	0
2281	How Effective are Gliflozins as DPP-4 Inhibitors? A Computational Study. <i>Theoretical Foundations of Chemical Engineering</i> , 2023, 57, 403-410.	0.7	3
2282	Development of stability indicating liquid chromatographic method for estimation of novel antiâ€œdiabetic drug Evogliptin. <i>Separation Science Plus</i> , 2023, 6, .	0.6	0
2283	Management of type 2 diabetes: Self-management education and clinical findings. , 2023, 14, 135-142.		0
2284	An update on the role of antihyperglycemic agents in diabetoporosis. , 2023, 14, 117-125.		0
2285	Efficacy and safety of cetagliptin as monotherapy in patients with type 2 diabetes: A randomized, doubleâ€œblind, placeboâ€œcontrolled phase 3 trial. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 3671-3681.	4.4	0
2286	Pharmacotherapy in patients with vasomotor disorders. <i>IJC Heart and Vasculature</i> , 2023, 48, 101267.	1.1	0
2287	Elucidation of anti-hyperglycemic activity of <i>Psidium guajava</i> L. leaves extract on streptozotocinâ€œinduced neonatal diabetic Long-Evans rats. <i>Journal of Ayurveda and Integrative Medicine</i> , 2023, 14, 100776.	1.7	0

#	ARTICLE	IF	CITATIONS
2288	Comparative efficacy and safety of sodium-glucose cotransporter 2 inhibitors for renal outcomes in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. Renal Failure, 2023, 45, .	2.1	0
2289	Real-World Hemoglobin A1c Changes, Prescribing Provider Types, and Medication Dose Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide. Advances in Therapy, 2023, 40, 5102-5114.	2.9	1
2290	<sc><i>Syzygium cumini</i></sc> ameliorates high fat diet induced glucose intolerance, insulin resistance, weight gain, hepatic injury and nephrotoxicity through modulation of <sc>PTP1B</sc> and <sc>PPAR1</sc> signaling. Environmental Toxicology, 2024, 39, 1086-1098.	4.0	1
2291	Insights Into Metformin XR Pharmacotherapy Knowledge Among Community Pharmacists: A Cross-Sectional Study. Clinical Medicine Insights: Endocrinology and Diabetes, 2023, 16, .	1.9	0
2292	Dapagliflozin Improved Cardiac Function and Structure in Diabetic Patients with Preserved Ejection Fraction: Results of a Single Centre, Observational Prospective Study. Journal of Clinical Medicine, 2023, 12, 6698.	2.4	1
2293	Efficacy and safety of tirzepatide, dual GLP-1/GIP-receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetology and Metabolic Syndrome, 2023, 15, .	2.7	2
2294	Hardware design for blood glucose control based on the Sorensen diabetic patient model using a robust evolving cloud-based controller. Computer Methods in Biomechanics and Biomedical Engineering, 0, , 1-22.	1.6	0
2295	The economic value of insulin glargine 300â€‰U/mL (Gla-300) in people â‰¥18 years of age with type 2 diabetes mellitus: a value-based economic model from a U.S. payer perspective. Journal of Medical Economics, 2023, 26, 1469-1478.	2.1	0
2296	Effects of green coffee aqueous extract supplementation on glycemic indices, lipid profile, CRP, and malondialdehyde in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Frontiers in Nutrition, 0, 10, .	3.7	0
2297	Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial. Beni-Suef University Journal of Basic and Applied Sciences, 2023, 12, .	2.0	0
2298	Prevalence of Hepatitis B and Hepatitis C Viral Infections and Their Associated Factors among Diabetic Patients Visiting Debre Tabor Referral Hospital, Northwest Ethiopia, 2021: A Cross-Sectional Study. Canadian Journal of Gastroenterology and Hepatology, 2023, 2023, 1-7.	1.9	0
2299	Risk Factors for and Risk of Peripheral Artery Disease in Swedish Individuals With Type 2 Diabetes: A Nationwide Register-Based Study. Diabetes Care, 0, , .	8.6	0
2300	Pathophysiology-Oriented Treatment of Type 2 Diabetes: 10 Case Reports. , 0, , .		0
2301	A Randomized, Double-Blind, Parallel-Group Phase-III Trial Investigating the Glycemic Efficacy and Safety Profile of Fixed-Dose Combination Dapagliflozin and Linagliptin Over Linagliptin Monotherapy in Patients with Inadequately Controlled Type-2 Diabetes with Metformin. Diabetes Therapy, 0, , .	2.5	0
2302	Glucagon in health and diabetes. , 2023, 14, S34-S41.		0
2303	Bioequivalence assessment of two formulations of empagliflozin in healthy adult subjects. , 0, 2, 19.		0
2304	Intestinal glucose excretion: A potential mechanism for glycemic control. Metabolism: Clinical and Experimental, 2024, 152, 155743.	3.4	0
2305	Health locus of control, personality and social support in treatment adherence among diabetic patients. Journal of Psychology in Africa, 2023, 33, 618-624.	0.6	0

#	ARTICLE	IF	CITATIONS
2306	6. Glycemic Goals and Hypoglycemia: <i>Standards of Care in Diabetes"2024</i>. Diabetes Care, 2024, 47, S111-S125.	8.6	9
2307	The Principles of Insulin Management of Type 2 Diabetes Mellitus. Journal of Diabetes Mellitus, 2023, 13, 284-299.	0.3	0
2308	Patient and Physician Perspectives on the Use of a Connected Ecosystem for Diabetes Management: International Cross-Sectional Observational Study. JMIR Formative Research, 0, 7, e47145.	1.4	0
2309	Nutritional Strategies for the Management of Type 2 Diabetes Mellitus: A Narrative Review. Nutrients, 2023, 15, 5096.	4.1	3
2310	Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study. Diabetologia, 2024, 67, 483-493.	6.3	0
2311	Plasma proteome profiling reveals the therapeutic effects of the PPAR pan-agonist chiglitazar on insulin sensitivity, lipid metabolism, and inflammation in type 2 diabetes. Scientific Reports, 2024, 14, .	3.3	0
2312	 Investigating Semaglutide in Adult Patients on Body Weight Compared with Other GLP-1 Drugs. International Journal of Pharmaceutical Research and Allied Sciences, 2023, 12, 95-103.	0.9	0
2313	Living with diabetes. , 2024, , 337-357.		0
2314	A machine learning-based algorithm to identify U-500R insulin candidates among adults with type 2 diabetes mellitus in US retrospective databases. Current Medical Research and Opinion, 2024, 40, 367-375.	1.9	0
2315	Fixed-Dose Combination Formulations in Solid Oral Drug Therapy: Advantages, Limitations, and Design Features. Pharmaceutics, 2024, 16, 178.	4.5	0
2316	Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial. Diabetes, Obesity and Metabolism, 2024, 26, 1714-1722.	4.4	0
2317	Cyb5r3 activation rescues secondary failure to sulfonylurea but not β^2 -cell dedifferentiation. PLoS ONE, 2024, 19, e0297555.	2.5	0
2318	The efficacy of combining adjuvants with non–surgical periodontal therapy in individuals with type 2 diabetes: A Bayesian network meta–analysis. Journal of Clinical Periodontology, 2024, 51, 610-630.	4.9	0
2319	Suboptimal control and failure to intensify therapy for South Africans with type 2 diabetes: an audit of diabetes management at primary health care facilities. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2024, 29, 37-42.	0.2	0
2320	The effects of transcription factor 7-like 2 rs7903146 and paired box 4 rs2233580 variants associated with type 2 diabetes on the therapeutic efficacy of hypoglycemic agents. Heliyon, 2024, 10, e27047.	3.2	0
2321	From data to insights. , 2024, , 97-123.		0
2322	Chitosan as a promising materials for the construction of nanocarriers for diabetic retinopathy: an updated review. Journal of Biological Engineering, 2024, 18, .	4.7	0
2323	Real-World Study on Effectiveness of Insulin Glargine U300 After Oral Antidiabetic Drug Failure in Patients with Type 2 Diabetes in the Gulf Region. Diabetes Therapy, 2024, 15, 691-704.	2.5	0

#	ARTICLE	IF	CITATIONS
2324	Efficacy and safety of basal insulins in people with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials. <i>Frontiers in Endocrinology</i> , 0, 15, .	3.5	0
2325	Type 2 diabetes patients requiring empagliflozin in Southeast of Iran: Frequency and guideline adherence (2022â€“2023). <i>Hipertension Y Riesgo Vascular</i> , 2024, 41, 87-94.	0.6	0
2326	The Reasons for the Low Uptake of New Antidiabetic Drugs with Cardiovascular Effectsâ€”A Family Doctor Perspective. <i>Journal of Clinical Medicine</i> , 2024, 13, 1617.	2.4	0